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Abstract 
KLF1 is a three-fingered C2H2 transcription factor essential for the differentiation of 
definitive erythroid cells. KLF1 regulates the expression of many genes involved in this 
process and loss of Klf1 results in perinatal death due to anaemia and severe -thalassaemia 
in mice. The three C2H2 zinc-fingers of KLF1 are interconnected by two linker peptides. The 
first linker that connects the first and second zinc finger of KLF1 contains the conserved 
TGEKP sequence. The second linker connects the second and third zinc fingers and sequence 
TGHRP is more variant. 
In human patients, there have been multiple mutations identified in the 2nd linker of KLF1. 
These mutations result in non-spherocytic haemolytic anaemia (NSHA) with microcytosis, 
and high foetal haemoglobin. While we understand pathology resulting from KLF1 
mutations in these patients, very little is known about the precise molecular function of the 
2nd linker mutation, and in general, linker mutations across all C2H2 proteins. 
C2H2 zinc fingers are the largest class of DNA-binding proteins in the mammalian genome. 
They are characterized by the presence of two anti-parallel -sheets and an -helix (-
fold). Two cysteine and two histidine residues in the -fold coordinate a zinc molecule 
and are highly conserved across the family giving the zinc fingers their identity. Additionally, 
the -helix is directly involved in DNA contact through 3 amino acid residues at positions -1, 
+3 and +6 relative to the start of the helix. The linker peptide between each finger allows 
flexibility so that the -helix of each zinc-finger can contact DNA, while providing additional 
stability to these interactions through forming hydrogen bonds with the preceding -helix. 
This mechanism is known as c-capping and closes the ‘frayed’ c-terminus end of the -helix 
upon contacting DNA. 
Our laboratory recently identified the mommeD45 mutation from a mouse ENU 
mutagenesis screen for modifiers of an alpha-globin transgene. The mutation results in a 
transversion of the histidine to an arginine (H350R) residue in the second linker of KLF1. The 
mutation appears relatively benign in the heterozygous state. However homozygous D45 
mice develop a mild anemic phenotype, including splenomegaly and microcytosis. 
To generate a model of NSHA in mice, like that observed in human patients, I crossed the 
mommeD45 mouse to a Klf1 heterozygous loss of function mouse to produce compound 
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heterozygous offspring (Klf1H350R/-). The mice suffer the same haemolytic, microcytic anemia 
observed in humans and have significantly enlarged spleens due to erythroid hyperplasia. 
However, the mice did not show signs of thalassaemia unlike the complete loss of function 
of Klf1. Interestingly, compound heterozygous mice had normal expression levels of the -
globin gene, which is a known direct target KLF1. I performed RNAseq and identified 1786 
KLF1-dependant genes of which only 168 genes were sensitive to the H350R mutation. 
Using gene ontology I found the genes were enriched for membrane localization, membrane 
function and transmembrane proteins. 
Using ChIP-seq I identified the genomic binding profile for KLF1 (1144 total sites) and 
H350R-KLF1 (490 total sites). I found evidence of binding by H350R-KLF1 to many KLF1 
occupied sites (372 wildtype sites were occupied by H350R-KLF1), but on the whole, most 
sites of KLF1 occupancy (772) did not reach significance in the KLF1H350Rdataset. 
Furthermore, the loss of binding was not due to a change in sequence specificity, but due to 
a global reduction in DNA-binding affinity across all KLF1 bound sites by KLF1H350R. This 
reduced binding affinity was validated through EMSA and FP binding assays. My data 
suggests the mutation results in a global reduction in DNA-binding affinity that is not due to 
an alteration in DNA sequence specificity. 
The loss of binding by KLF1H350R correlates with the loss of expression of some of the genes 
identified from the RNA-seq such as Slc1a5 and Slc43a1. However, we observed a significant 
loss of KLF1 target gene expression at many loci that appear to be transcriptionally sensitive 
to KLF1 DNA-binding affinity. In this way, the mutation leads to a selective hypomorphic 
effect on KLF1 target gene expression. In order to comprehensively understand the KLF1 
function in erythropoiesis we sought to investigate the proteins that interact with KLF1 to 
drive normal erythropoiesis.  
We studied the protein interactions of KLF1 by performing co-immunoprecipitation coupled 
with mass spectrometry. We identified a list of candidate proteins that interacted with KLF1; 
in particular proteins that are involved in the formation of paraspeckles of the nucleus such 
as NONO and SFPQ.  
C2H2 zinc fingers make up one of the largest families of DNA binding proteins in the 
mammalian genome. However our understanding of how mutations in the linker peptides 
can alter DNA binding affinity and the function of C2H2 zinc fingers remains unclear. Here 
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we begin to understand how in vivo changes to the linker sequence may change the 
function and DNA binding affinity of C2H2 zinc finger proteins. This project has 
demonstrated how mutations occurring in the second linker of Klf1 can have severe 
consequences for the function of a critical transcription factor, leading to heritable human 
disease.  
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1.1 Haematopoiesis 
The multipotent haematopoietic stem cell (HSC) is able to generate all haematopoietic cells 
in a process called haematopoiesis.1 The HSC is a highly specialized stem cell that resides in 
many tissues throughout development (Figure 1.1). The first HSCs arise from haemogenic 
endothelial (HE) cells in the ventral mesoderm; HE emergence demarcates the first step of 
HSC generation.2,3 In mice, the first blood progenitor cells seed the yolk sac around 7.5 days 
post coitium (DPC) and then later in development, the HE gives rise to adult HSCs that seed 
the aorta-gonad-mesonephros (AGM) region of the embryo between 9.5 -10.5DPC.3-5 HSCs 
bud from the HE into the circulation and seed the foetal liver between 11.5DPC to 14.5DPC, 
before the establishment of the bone marrow niche.3 When the bone marrow niche has 
developed, the HSCs relocate there where they reside throughout life.3 
1.1.1 Megakaryocyte erythrocyte progenitor 
The classical view of haematopoietic differentiation proposes cell development occurs in a 
linear fashion resulting from increasingly lineage restricted progenitors.1-3 Specific cell 
lineages become defined through the choices made at each progenitor stage as the HSC 
differentiates.6 An example is the bipotent Megakaryocyte-erythroid progenitor (MEP).2,3,7-10 
As the name suggests this cell is able to differentiate into megakaryocytes (MK) which 
develop into platelets or into committed erythroid precursors which become enucleated red 
blood cells.8-16  
1.1.1.1 Megakaryopoiesis 
Megakaryocytes (MK) are large multinucleated cells that reside in the bone marrow and 
release platelets into circulation by extending long processes into the sinusoidal blood 
vessels. Megakaryopoiesis is the process of differentiation of MKs from the MEP. As MKs 
mature they increase in size due to the expansion of cytoplasmic content and cytoskeletal 
proteins.  
A major regulatory pathway involved in differentiating MEPs into MKs is the cytokine 
thrombopoietin (TPO) and its receptor C-MPL.7,8,11,14,17-19 The C-MPL receptor is found 
primarily on MKs and platelets. Due to an autoregulatory loop, plasma TPO concentrations 
are inversely proportional to platelet number.13,18,20 Elimination of either TPO or c-MPL 
results in thrombocytopenia, due to reduced MK progenitors and mature MKs.18 The 
binding of TPO to its receptor leads to activation of multiple cytoplasmic signalling pathways 
that result in the expansion of MKs and increased release of platelets. 
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Endomitosis is a process dependant on TPO and is unique to megakaryocytes.13 This process 
involves cycles of DNA replication without cell division; i.e. increasing DNA content within a 
single cell.21 It has been observed that MKs can have as much as 128n DNA content in a 
single lobulated nucleus. The precise regulation of endomitosis is poorly understood. This 
accumulation of DNA content is subsequently followed by pro-platelet production, which 
become platelets as they bud from the MK.13-16,21 The hypothesis behind the immense 
ploidy levels of MKs is so that it can support the high demand of RNA and protein synthesis 
which is packaged into granules and ultimately platelets.21 There are various types of 
granules such as lysosomes, dense granules and α-granules, which play major roles in 
platelet function such as haemostasis, thrombosis and inflammation.13  
Approximately 1011 platelets are produced by MKs on a daily basis in a process called 
thrombopoiesis.13 Platelets are highly specialized cells that circulate in the blood and 
function to minimize bleeding after blood vessel injury.1,13,15 Too many platelets, or 
thrombocytosis, can result in venous or arterial vessel occlusion and thus, heart attacks 
and/or strokes. Conversely too few, thrombocytopenia, can result in haemorrhaging.1,13,15 
Differentiation of MKs into platelets is a complex process that requires fine control of 
transcriptional programs. In addition to cytokine signalling, transcriptional regulation by 
specific transcription factors such as Fli1 are critical in MK and platelet 
differentiation.7,13,16,19,22-25 
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Figure 1.1 Ontogeny of developmental haematopoiesis in mice 
Developmental haematopoiesis begins from the mesoderm. The mesoderm gives rise to the 
primitive wave of erythropoiesis and haemogenic endothelium (HE) which in turn gives rise 
to erythroid-myeloid progenitors (EMP) and haematopoietic stem cells (HSC). The EMP 
produces erythroid cells which first seed the foetal liver but it can also give rise to 
Megakaryocytes (MK) and macrophages. Once the foetal liver has been established, the HSC 
buds from the HE in the aorta-gonad-mesonephros (AGM) region and seeds the foetal liver 
around 11.5DPC.  
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1.1.1.2 Erythropoiesis 
The erythrocyte or red blood cell, like the megakaryocyte, begins differentiation from the 
MEP.7-10 The process of progenitor cells developing into mature erythrocytes is known as 
erythropoiesis.1,6 Similar to MKs, there are major cytokine signals that interplay with 
transcription factors to generate a mature red blood cell. The major cytokine signalling 
pathway is erythropoietin (Epo) and its receptor (EpoR).26-28 Deletion of Epo or EpoR in mice 
results in severe anaemia and death by 13.5DPC which is due to failure of terminal erythroid 
differentiation.26,27,29 
In terminal erythroid differentiation, cells are transcriptionally regulated to develop into 
erythroid burst forming units (BFU-e) and then erythroid colony forming units (CFU-e).4,5,30-
35 During this stage of erythroid development these progenitors proliferate and expand at 
an extremely high rate. After approximately 4-5 cell cycle events, all CFU-es synchronously 
differentiate into pro-erythroblast and then sequentially into basophilic erythroblasts, 
polychromatic erythroblasts and orthochromatic erythroblasts.4,5,30-35 The cells then 
asymmetrically divide which extrudes the nucleus to form a reticulocyte, which retain 
ribosomal RNA for ongoing translation. The reticulocytes continue to generate haemoglobin 
for 1-2 days in circulation then extrude their RNA to become mature red blood cells.4,5,30-35  
1.1.1.3 Developmental erythropoiesis 
Erythropoiesis occurs in different stages and organs throughout embryonic development. 
Traditionally, there are two defined waves of erythropoiesis.4,5,30-32,35 The first wave, or 
primitive wave, begins at 7.5DPC within the blood islands of the yolk sac (Figure 1.1). 
Primitive erythrocytes transiently expand in the yolk sac and differentiate when they begin 
to circulate in the bloodstream with the onset of cardiac contractions.3 A defining feature of 
primitive erythrocytes is the presence of a nucleus and expression of embryonic globins; 
both are not present in the definitive wave.3-5,30-32,35 
The definitive wave has classically been attributed to erythropoiesis in the developing foetal 
liver which occurs from 11.5DPC and onwards throughout life.4,5,30-32,35 Definitive 
erythropoiesis begins with the BFU-e which develops into a mature enucleated erythrocyte. 
Although these two waves appear to be well defined and compartmentalized, we now know 
that there is a third transient wave of erythropoiesis and megakaryopoiesis (Figure 1).2,3 
The erythro-myeloid progenitor (EMP) begins in the yolk sac emerging around 8.25DPC from 
HSCs derived from the HE.3-5,30,31 During the transition to definitive erythropoiesis, around 
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9.5DPC, the EMP gives rise to the first BFU-es (Figure 1.1). These BFU-es are the first 
definitive erythroid cells in circulation and seed the foetal liver by 10.5DPC.3 The initial 
colonization of the foetal liver by EMPs and BFU-e precedes the presence of defined HSCs in 
the foetal liver. Due to the similarities between EMPs and HSCs in the foetal liver, it is 
currently unknown when the transition from EMP derived erythroid cells to HSC derived 
erythroid cells occurs.3 However the transcriptional mechanisms that are critical to primitive 
and definitive erythropoiesis are very similar and also likely to regulate the same 
mechanisms in the EMP.  
1.1.2 Transcriptional Control in MEP lineage determination 
Transcription factors are proteins that bind and recognize sequences in DNA known as 
motifs. They introduce specificity to gene regulation and transcription by allowing 
recruitment of other regulating co-factors and RNA polymerase. 
Megakaryocytic and erythroid differentiation share a common progenitor, the MEP. It is 
unsurprising to find similar transcription factors between the two different lineages. These 
transcription factors include Gata1, Fog1, Nfe-2 and Tal1.24,25,36-41 Although there are shared 
transcription factors, it is likely that their target genes are specifically driven by lineage 
restricted transcription factors. Fli1 and Klf1 are unique and lineage restricted transcription 
factors that drive megakaryocytic and erythroid differentiation, respectively.19,42-46  
1.1.2.1 Transcriptional control in Megakaryopoiesis 
The megakaryocyte is unique among the blood cell types owing to the unusual processes of 
endomitosis, accumulation of extensive internal membranes, and dynamic organisation of 
the cytoskeleton that are required for the physiological production of platelets. The 
transcription factors GATA1, Friend of GATA1 (FOG1/ZFPM1), NF-E2 and FLI1 are critical 
regulators of gene expression during megakaryopoiesis.15,16,19,21,24,25,38,47 
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Figure 1.2 Opposing forces of Klf1 and Fli1 drive differentiation of their respective lineages 
The megakaryocytic-erythroid progenitor (MEP) is a bipotent cell that gives rise to two 
unique cell lineages, platelets and red blood cells. Thrombopoietin (TPO) with its receptor c -
MPL and Friend leukaemia virus integration factor 1 (Fli1) are critical for megakaryopoiesis. 
Deletion of either of these genes results in thrombocytopenia due to a lack of mature 
platelets produced. The alternative differentiation pathway from MEPs is erythropoiesis, the 
production of red blood cells (erythrocytes). The cytokine EPO and its receptor (EpoR) are 
tightly involved in regulating erythropoiesis. The transcription factor KLF1 is critical in 
maintaining red blood cell lineage and deletion of EpoR or KLF1 results in embryonic death 
due to anaemia.  
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GATA1 and FOG1 
The GATA1 transcription factor and its co-activator FOG1 are essential for 
megakaryopoiesis; loss of GATA1 or FOG1 leads to decreased platelet counts and abnormal 
platelet morphology, and a complete loss of megakaryocyte progenitors respectively.48,49 
These two transcription factors also have a critical role in erythropoiesis and will be 
discussed in greater detail below. 
NF-E2 
The basic-leucine zipper transcription factor NF-E2 was initially of great interest in the field 
of molecular haematology due to its ability to bind the β-globin locus control region (LCR) to 
influence globin gene transcription. Gene knockout studies in mice revealed a further critical 
role for NF-E2 in platelet production, whereby the loss of NF-E2 prevented the production 
and release of platelets from megakaryocytes and led to premature death of neonates due 
to haemorrhaging.24  
FLI1 
Friend leukemia virus integration 1, Fli1, belongs to a large family of ETS transcription 
factors.19 FLI1 is not only clinically significant for its role in megakaryopoiesis, but also for its 
role in the development of Ewing sarcoma tumours caused by chromosomal translocations 
involving itself and the EWS gene. The role of FLI1 in megakaryopoiesis has been 
demonstrated in knockout mice whereby there is an increase in megakaryocyte progenitor 
cells coincident with a defect in megakaryocyte maturation. 
FLI1 is responsible for the transcriptional activation of a number of megakaryocyte genes, so 
it is not surprising that loss of the chromosomal region encoding FLI1 in humans is strongly 
associated with thrombocytopenia (lack of platelets). FLI1 acts in tandem with another 
family member GABPA and as the megakaryocyte (MK) mature, the ratio of FLI1 to GABPA 
increases. While GABPA activates genes for early MK development, FLI1 activates genes 
required for both early and mature MK differentiation.13,19  
1.1.2.2 Transcriptional Control in Erythropoiesis 
GATA1 
GATA1 consists of two zinc fingers in the C-terminal domain that binds to specific DNA 
sequences and the N-terminal domain that stabilises DNA binding events and interacts with 
other proteins. The promoter and regulatory region of many erythroid genes contains the 
5’(A/T)GATA(
A/G)3’ motif recognised by GATA1. GATA1 plays significant roles in both 
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primitive and definitive erythropoiesis. Deletion of Gata1 in mice results in embryonic death 
due to aberrant primitive erythropoiesis.50 However, GATA1 is also involved in definitive 
erythropoiesis where it works in concert with a range of protein partners and transcription 
factors. Similar to primitive erythropoiesis, definitive erythropoiesis requires the 
transcription factors (TFs) GATA1, FOG-1, NF-E2, and the TAL1-LMO2-LBD1-E2A 
complex.51,52 In addition MYB, BCL11A and KLF1, are specific to definitive 
erythropoiesis.44,45,53,54 The diversity of interacting proteins allows GATA1 to repress or 
activate transcription of specific target genes.55,56 
NF-E2 
In the erythroid lineage, NF-E2 is activated by GATA1.57 It is essential for -globin expression 
and interacts with CBP to activate transcription.58,59 In addition to globin expression, NF-E2 
is a key regulatory molecule controlling pathways of haem and globin synthesis, leading to 
balanced production of the components of haemoglobin.60,61  
TAL1 
TAL1 or SCL is a basic helix-loop-helix (bHLH) transcription factor.48 SCL binds to E-Box cis-
regulatory sequences (5’CANNTG3’) and is able to interact with other transcription factors 
such as GATA1 by forming a complex with LMO2.62,63 Gene ablation of SCL in mice results in 
embryonic death around 9.5DPC due to failed primitive erythropoiesis, similar to loss of 
Gata1.48 Indeed throughout erythropoiesis, TAL1 forms a complex with a similar basic helix-
loop-helix transcription factor, E2A.52 The LIM domain containing co-factors, LMO2 and 
LDB1 are then recruited and together with GATA1, binds to an E-box-GATA motif with 
specific spacing between the individual motifs.63,64 There is now evidence to suggest that 
KLF1 also participates in this transcriptional complex.65  
LMO2 and pentad complex formation 
The LIM domain containing protein (LMO2) acts as a critical bridge protein in transcriptional 
complexes formed during erythropoiesis.66,67 LMO2 is particularly important in combining 
together the DNA binding transcription factors GATA1 and TAL1. Studies into LMO2 loss of 
function have demonstrated critical roles in erythroid differentiation.67 LMO2 null embryos 
are similar to TAL1 and GATA1 loss of function and die at 10.5DPC due to failed primitive 
erythropoiesis.67 This is unsurprising due to the transcriptional complexes formed by GATA1, 
TAL1, and LMO2. Further studies of LMO2 null embryonic stem cells (ESC) also revealed 
roles in definitive erythropoiesis; whereby LMO2 null ESC were unable to generate mature 
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erythrocytes.68 Recent studies have added the Lim Domain Binding protein (LDB1), which 
can homo-dimerize, to this transcriptional complex.69,70 This pentad of proteins (i.e. TAL1, 
GATA1, E2A, LDB1 and LMO2) is likely to be critical in defining erythroid specific 
chromosome architecture.51,55,62,68-73 The likely mechanism is TAL1, GATA1 and E2A binds 
the DNA and LMO2 complexes with the three transcription factors.62 LDB1 is then able to 
bind to LMO2 and can dimerize with another LDB1 protein which is bound to the same 
complex elsewhere in the genome.52,66,74 The -globin LCR is an example where many of 
these transcription factors and proteins co-localize on DNA.75-77 Recent studies have found 
significant overlap of KLF1-occupied sites with GATA1 and TAL1-occupied sites in the 
genome.65 There is also a distinct spacing between their respective motifs at co-localized 
sites.65 This would suggest that KLF1 may play a role in directing the pentad complex in an 
erythroid specific manner. 
1.1.2.3 Opposing transcriptional regulation determines MEP fate 
Common transcription factors can be found in both erythropoiesis and megakaryopoiesis. 
These include GATA1, GATA2, FOG1, SCL/TAL1 and NF-E2. However transcription factors 
that are critically required for one pathway or the other are seen to be restricted specifically 
to their respective lineages. FLI1 is found in megakaryopoiesis but never found in 
erythropoiesis; conversely, KLF1 is restricted to erythropoiesis. 
In the MEP, expression of both FLI1 and KLF1 is observed.78,79 Current models of MEP 
differentiation into the two lineages propose a mutual antagonistic mechanism between 
FLI1 and KLF1. Starck et al. proposed a mechanism based on biochemical assays utilizing 
tagged protein isolation to suggest direct interaction between KLF1, FLI1 and GATA1.80 They 
concluded that KLF1 and FLI1 compete for the attention of GATA1. In addition to this, they 
reported functional antagonism between KLF1 and FLI1 by using a reporter that is repressed 
by FLI1 when transfected into mouse erythroleukaemia cells; they showed by increasing 
KLF1 levels the reporter activity in these cells also increased. The authors also show that 
FLI1 is able to repress KLF1 activity. In cells with exogenous KLF1 expression, increasing the 
levels of FLI1 reduced the activity of the reporter. 
The evidence for the KLF1-FLI1 interaction is further suggested by the repressive function of 
KLF1. Siatecka and colleagues examined a particular post translational modification of KLF1, 
sumoylation at lysine 74 (K74).81 This modification is proposed to enable KLF1 to interact 
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with a transcriptional repressive complex known as NuRD. The authors show mutation of 
K74 results in the production of more megakaryocytes compared to the wildtype.  
These studies address the issues in a biochemical fashion with circumstantial evidence these 
interactions occur in vivo. An issue is the biochemical studies performed in both papers use 
artificial constructs in an immortalized cancerous cell line and fail to reflect the observed 
results in primary cells. An experiment such as isolating primary MK progenitors, 
erythrocyte progenitors and bipotent MEPs to determine the SUMO levels of KLF1 in each 
population could be a starting point in addressing this issue. 
In vivo loss of KLF1 leads to an increase in megakaryocyte differentiation and platelet 
production.82 Frontelo, et al. performed micro-arrays on KLF1 null (Klf1-/-) and wildtype 
(Klf1+/+) fetal livers and observed an increase in certain genes such as Fli1 and other platelet 
related genes (i.e c-Mpl). This could perhaps be due an increase in platelets caused by the 
loss of KLF1 and subsequent lack of erythroid cells. This would skew the cell proportion 
which would result in an enrichment of gene expression for platelets and progenitors cells. 
Tallack and Perkins showed by FACS that single Klf1-/- erythroid cells express CD41 at the 
surface; i.e. there is lineage infidelity in the absence of KLF1.83 We have yet to clearly define 
the role of KLF1 directly in the megakaryocytic erythroid progenitor. Whether KLF1 inhibits 
megakaryopoiesis, drives erythropoiesis or does both simultaneously is yet unknown.  
1.1.3 Hereditary Anaemia 
Haematopoietic disorders that fall under the classification of anaemia can result from the 
disturbance of a vast array of cellular processes.84-87 Anaemia can arise from disruptions to 
processes such as haemoglobin synthesis, either by interfering with haem synthesis or 
globin protein function; defects in the maturation of erythroid cells, leading to an increase 
of circulating immature erythrocytes; or defects in the erythroid membrane or erythroid 
enzyme function leading to a shortened lifespan, membrane fragility and reduced transport 
of critical molecules.85-90 
A common theme among many red cell disorders is the perturbation of critical cytoskeletal 
and membrane proteins.85-88,90 Erythrocytes undergo tremendous stress on their 
membranes as they undergo cellular deformation during passages through capillaries. 
Erythrocytes that are unable to maintain a flexible and strong membrane become 
sequestered in the spleen, where they are phagocytozed and destroyed. This results in 
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shortened erythrocyte life spans, splenomegaly and haemolytic anaemia. In fact 
transcriptional regulation of many erythroid membrane genes can be attributed to 
KLF1.65,91,92 KLF1 has been shown to regulate Dematin, Ermap, Ankyrin, Slc2a4, Band4.1/4.2, 
Band 3 and Darc.61,65,91,92 This thesis also further elucidates the roles of KLF1 in activating 
transcription of genes critical not only to the integrity of the membrane but also membrane 
associated transporters.  
1.1.3.1 KLF1 mutations perturb erythropoiesis and cause anaemia.  
Recent reports have identified many mutations in KLF1 resulting in highly varied 
phenotypes.93-102 Heterozygous loss of function (LOF) mutations results in benign, 
asymptomatic phenotypes, such as the In(Lu) blood group phenotype. In humans, Lutheran 
(Lu) is a direct KLF1 target gene and is sensitive to KLF1 gene dosage. This is usually 
unnoticed until a blood cross match is required. Haploinsufficiency of KLF1 can also lead to 
Hereditary Persistence of Foetal Haemoglobin (HPFH), which results from incomplete 
haemoglobin switching and is generally a benign phenotype. 
A recent report revealed that in thalassaemia endemic regions the prevalence of KLF1 
mutations was as high as 1 in 80 people.101,103 Given the frequency of KLF1 mutations in the 
population and that many KLF1 mutations in heterozygous state results in benign 
phenotypes, it would not be surprising to find unexplained cases of hereditary anaemia 
resulting from co-inheritance of KLF1 mutations. 
Indeed in the last three years, two independent reports of severe nonspherocytic 
haemolytic anaemia (NSHA) with disturbed erythroid morphologies and HPFH were found to 
be a result of compound heterozygosity of KLF1 mutations.96,100 Mutations identified from 
all patients revealed two different point mutations within the DNA binding domain of KLF1 
(P338S and G334R) and a loss of function allele, whether it was loss of direct DNA contact 
(A298P) or major deletions within the protein itself (G176RfsX179). Furthermore, a recent 
study described the second known case of hydrops fetalis with severe neonatal NSHA with 
HPFH and lowered haemoglobin due to KLF1 mutations.97 The mutations identified from the 
patient revealed compound heterozygosity for a novel second linker mutation (P338T) and 
an insertion which likely results in the loss of a functional protein. 
What is most remarkable is the discovery of a human patient that carried two loss of 
function alleles for KLF1.104 This patient had hydrops fetalis similar to the aforementioned 
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patient but was also jaundiced with hepatosplenomegaly, and marked erythroblastosis. It is 
possible that this case is unique, as complete loss of KLF1 results in pre-natal death in mice. 
However, studies of and pre/peri-natal death do not take into consideration KLF1 
mutations, which may be far more prevalent than previously thought. 
1.1.3.2 The mommeD45 (H350R) linker mutation and other mutations in mice 
Recently our group undertook experiments to determine the molecular mechanisms behind 
some of these mutations (Figure 1.3). We have studied the E339D (Nan; for neonatal 
anaemia) mutation in mouse which is equivalent in position to the E325 in humans.95,105,106 
In human patients the E325 residue is mutated into a lysine (E325K) which results in severe 
anaemia even in the presence of a wildtype allele. 
The Nan mouse mutation was generated as part of an ENU (1-Ethyl-1-nitrosourea) 
mutagenesis screen.106 Nan heterozygous mice survive through development and birth but 
suffer neonatal anaemia and hereditary spherocytosis.106 Nan homozygous mice die 
between 11.5 and 12.5DPC of a severe failure in haematopoiesis with no other overt, non-
erythroid defects. We found that the E339D mutation altered the binding specificity of KLF1 
resulting in loss of KLF1 binding at critical erythroid genes and the phenotype exacerbated 
by ectopic activation of non-erythroid genes.95 
In another study our collaborators used an ENU mutagenesis screen to find epigenetic 
regulators of variegated (GFP) transgene expression in erythrocytes.107 They used this 
system to find a number of important epigenetic regulators of gene expression. In 
collaboration with them, we discovered a novel mutation which increases the variegated 
GFP expression and identified the mutation as a transversion of the central histidine in the 
second linker of KLF1 to an arginine (H350R). The mutation was originally designated 
mommeD45 for modifiers of murine metastable epi-alleles (momme) mutation D45, but for 
simplicity we will be referring to the mutation as H350R throughout this thesis.  
We found that the mutation lead to a hypomorphic allele of KLF1 and animals homozygous 
for the mutation had mild compensated anaemia.107 Interestingly homozygous H350R 
animals did not have altered -globin expression unlike the KLF1 loss of function alleles. This 
suggests the mutation is not just a simple loss of function hypomorph. However, the 
mechanisms underlying the selective hypomorphic phenotype is not understood and will be 
the focus of this thesis.  
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Figure 1.3 Point mutations identified in human and mouse KLF1 and the possible alteration to KLF1 function 
Alignment of human and mouse KLF1 with DNA binding residues (dashed blue lines) 
highlighted for each zinc finger (grey). Below are identified point mutations from human 
patients which either disrupt DNA contact or Zinc (Zn2+) binding (blue) or reside in the 
linkers and have the potential to disrupt the c-capping mechanism (black). This mechanism 
closes the fray at the end of the -helix and stabilizes DNA binding. Known mouse 
mutations are listed below. This thesis focuses on the H350R mutation in the second linker 
of murine KLF1 and nearby variants in linker 2.  
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1.2 Erythroid Krüppel-Like Factor 
Krüppel-Like Factor 1 (KLF1) also known as erythroid Krüppel -Like factor (eKLF) is a 
transcription factor essential for red blood cell development.44,45,108 KLF1 was discovered in 
1993 by Ira Miller and James Bieker using a subtractive hybridisation screen to identify 
genes expressed uniquely in a mouse erythroleukaemia (MEL) cell line compared to a mouse 
macrophage cell line (J774).42 They found that the protein sequence encoded from this 
cDNA is highly homologous to the Drosophila melanogaster gap gene Krüppel and was thus 
named erythroid Krüppel-Like factor. Throughout development the expression of Klf1 is 
restricted to cells that become committed to the erythroid lineage.108 
In mice, complete loss of Klf1 results in embryonic death by 14.5DPC due to severe -
thalassaemia and lack of definitive erythropoiesis (Figure 1.4A). 43-45,91 Since its initial 
discovery, KLF1 has been shown to bind to both the human and murine adult β-globin gene 
promoter and activate the transcription of the β-globin gene.45,109-111 
KLF1 has been extensively studied due its role in a process known as globin switching. 
Globin switching is the process during development where the globin components that 
make up haemoglobin in circulating blood cells switch from embryonic (ζ† and ε), to foetal 
(α and γ) and then to adult (α and β).43,46,65,75-77,92,110,112,113 It is believed that globin switching 
facilitates improved oxygen delivery from the placenta to the growing embryo. An 
attempted rescue of the Klf1 null phenotype by a -globin transgene proved ineffective, 
suggesting additional roles for KLF1 in erythropoiesis.45  
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Figure 1.4 KLF1 is critical for erythropoiesis and is involved in all aspects of red blood cell function 
(A) Klf1 null mouse embryos are pale and smaller than their wildtype counter parts. The Klf1 
null embryo lacks definitive erythropoiesis and dies by 14.5DPC. KLF1 coordinates nearly all 
aspects of red cell differentiation and function. Image is courtesy of Dr. Michael Tallack. (B) 
Klf1 has been shown to regulated genes involved in red cell membrane structure and 
integrity (Dematin), cell survival (Bcl-X), haem synthesis (Alas2), cell cycling (E2f2), iron 
procurement (Slc25a37), and globin chain synthesis (-globin). Image Adapted from Tallack 
et al, 2010.   
Chapter 1 – Literature Review 
18 
 
1.2.1 Gene Regulation 
Recent studies incorporating next generation sequencing have revealed that KLF1 
coordinates nearly all aspects of red blood cell development by regulating the transcription 
of critical erythroid genes.43,46,65,91,114-118. I contributed to some of this work during my 
honours year and first 6 months of my PhD (Tallack, 2012). KLF1-regulated genes are 
involved in a variety of biological processes mostly directed at driving cells towards terminal 
erythroid differentiation. These genes fall into categories such as survival (Bcl-x46), cell 
cycling (E2f2114,116), essential cytoskeletal and membrane integrity (Dematin, Ermap91) as 
well as erythroid specific functions such as haem synthesis (Alad), iron procurement (Tfrc) 
and globin chain production (Hbb-b1) (Figure 1.4B).65,117  
1.2.1.1 Regulation of Cell cycle and Cell turnover in erythropoiesis 
KLF1 directly activates the expression of many genes involved in the cell cycle and apoptosis. 
The earliest evidence for KLF1 regulating the cell cycle came from studies in the K1-ER cell 
line (an immortalised Klf1-/- cell line containing a KLF1 transgene fused to the estrogen 
receptor).43 Activation of KLF1 (by addition of tamoxifen) inhibited the growth of these cells, 
promoting differentiation and haemoglobinisation.43 Later studies revealed the direct 
activation of cell cycles genes by KLF1.43,114,115 KLF1 directly activates cell cycle genes such as 
E2f2, E2f4, p18INK4c/Cdkn2c, p21WAF/CIP1 and Pim1.65,114,115,117 
The cell cycle is critical for erythropoiesis and is controlled by KLF1 through these genes. 
High turnover is required for the early stages during expansion of burst forming units – 
erythroid (BFU-e) and colony forming units – erythroid (CFU-e). Tight control and inhibition 
of the cell cycle during later stages of erythropoiesis is also critical for correct erythropoiesis. 
KLF1 directly activates p18 and p27 which are involved in exiting the cell cycle.115,119,120 Cell 
cycle inhibition is an important mechanism for enucleation where asymmetric division 
extrudes the nucleus. Inhibiting the cell cycle also allows for the cytoskeletal and membrane 
structures to develop.  
1.2.1.2 Erythroid membrane and cytoskeletal regulation 
Erythrocyte membrane disorders are one of the most commonly inherited human 
pathologies.121,122 It was first noted that Klf1-/- erythrocytes had a “wrinkled and deformed 
appearance” and an “aberrant folding of the cell membrane” resulting from a disordered 
membrane and cytoskeletal structure.91,92 Recent studies have shown that KLF1 directly 
controls the expression of genes critical for the cytoskeletal architecture as well as cell 
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surface protein. These genes include Band4.1/4.2, and Ankyrin as well as membrane genes 
Band3, Slc43a1, Slc2a4, and Transferrin receptor (Tfrc).65,91,123 Transcriptome analysis of the 
first described KLF1-/- human revealed significantly reduced expression of many membrane 
and cytoskeletal genes.104 There are also humans with mutations of KLF1 which display 
haemolysis due to fragile membranes and structure, as well as abnormal size and increased 
foetal haemoglobin (hereditary persistence of foetal haemoglobin).98  
1.2.1.3 Haem synthesis  
KLF1 controls expression of genes involved in haem biosynthesis, haem transport and iron 
procurement. KLF1 directly activates genes involved in globin chain production such as Hba-
b1, Hba-a1, Hba-a2 and Ahsp.43,45,54,65 KLF1 has been shown to transcribe genes involved in 
haem synthesis and transport such as Alad, Alas2, Urod and Abcg2,65,124 as well as genes 
involved in iron transport which include, transferrin receptor (Tfrc), Slc25a37 (Mitoferrin) 
and Steap3.65,91,92 KLF1 is also involved in an important process during developmental 
erythropoiesis known as globin switching.  
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Figure 1.5 The -globin LCR is bound by various erythroid transcription factors that alter its 3-dimensional structure 
(A) The -globin LCR was first defined by the 5 distinct DNaseI hypersensitive sites (HS). 
ChIPseq experiments have shown that many erythroid transcription factors (GATA1, TAL1 
and KLF1) and adaptor proteins (LDB1, LMO2) co-localize in the same genomic regions as 
the HS. Data for KLF1 (Tallack et al, 2010), GATA1 (Cheng et al, 2009), SCL/TAL1 (Kassouf et 
al, 2010), LDB1 and LMO2 (Soler et al, 2010), H3K4me1 and DNase1 (Ren Lab) was visualized 
on the UCSC genome browser (B) In the absence of KLF1 the globin LCR primarily drives the 
expression of embryonic globin. The pentad of transcription factors can bind the LCR which 
causes a conformational change in the DNA. This brings the LCR closer to the -globin 
promoter and drives the expression of -globin. 
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1.2.1.4 Globin Switching 
Embryonic and foetal globins are expressed until the onset of definitive erythropoiesis when 
adult globins are expressed. The embryonic globin genes are silenced and expression of 
adult globin begins during the switch from primitive to definitive erythropoiesis. This 
process is known as globin switching. 
Enhancer and promoter binding by KLF1 directly coordinates globin switching throughout 
embryonic development and the activation of adult globin genes (Hbb-b1, Hba-a1, and Hba-
a2).54,65,117,118,125 The -globin genes span approximately ~50 kilobases (Kb) and consist of 
embryonic, foetal and adult globin genes as well as a regulatory region known as the -
globin locus control region (LCR). LCRs are areas in the genome that have the ability to 
drastically enhance the expression of linked genes in a tissue specific and copy-number 
dependant manner.112,126,127 They are similar to an enhancer or cluster of enhancers (also 
known as super-enhancers).75,76,127 The -globin-LCR was the first to be discovered and 
spans 16Kb (Figure 1.5A).128 The LCR was first defined by DNAseI hypersensitivity assays, 
where 5 “hyperpsensitive sites” (HS1-5) were found upstream of the -globin gene.128 
KLF1 binds directly to the -globin promoter as well at HS1, HS2 and HS4 (Figure 1.5A). The 
enhancer activity of the globin LCR on -globin transcription is driven by several 
transcription factors binding to the HS regions which cause a conformation change in the 
organization of the genomic DNA. Many KLF1 occupied sites (OS) are co-occupied by other 
important erythroid transcription factors such as GATA1, TAL1, LMO2 and LDB1 (Figure 
1.5A). The co-occupancy of these transcription factors suggests co-regulation of -globin by 
these factors as well as a possible role looping Distal DNA elements, the LCR, to the 
promoter (Figure 1.5B). 
1.2.2 KLF1 interacting proteins 
Studies to find proteins that form physical and functional interactions with KLF1 have 
proven difficult. Nonetheless, there have been a number of studies that have shown post-
translational modifications (PTM) on KLF1 and potential interacting proteins. In general 
most protein interactions identified to date increase the transcriptional output of KLF1’s 
target genes with some exceptions.59,124,129-145 
GATA1 and KLF1 functionally associate on DNA leading to a synergistic increase in 
transcription.129 Physical association between KLF1 and GATA1 has also been shown through 
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GATA1 pull down and detection of KLF1 by Western blot analysis.129 Interestingly another 
member of the KLF family, SP1, can functionally and physically interact with GATA1.138 
Specific deletions of different domains in SP1 have shown that the domain required for 
physical interaction is located in the C-terminal region containing the three C2H2-ZFs; this 
region is highly conserved across all KLF and SP proteins.138 It was shown that the ZFs of SP1 
was required to synergistically activate transcription when co-operating with GATA1. 
Further evidence has shown that the acidic residues in the linkers of SP1 form electrostatic 
interactions with the basic residues near the first zinc finger of GATA1.138 Mutations of the 
acidic residues in the linkers of SP1 ameliorated the interaction with GATA1. Thus, it is 
possible the DNA binding domain of KLF1 is responsible for interactions with GATA1.138 
Studies in the -globin LCR have shown that KLF1 stabilizes the occupancy of GATA1 as well 
as other transcription factors, TAL1 and NFE-2, to the hypersensitivity sites.59,144 Increasing 
the transcription of -globin gene is also observed when KLF1 recruits the histone 
chaperone, HIRA.143 Unsurprisingly, deletion of all three KLF1 zinc fingers resulted in a loss 
of interaction between KLF1 and HIRA. KLF1 zinc fingers can also interact with TATA-binding 
protein associated factor 9 (TAF9), increasing -globin transcription through interactions 
with core transcriptional machinery.141,143  
These studies show evidence of physical interactions through pull-down assays and 
immunoblotting with various deletions in the protein. Potentially, the loss of KLF1 or the 
loss of the zinc fingers in KLF1 results in lack of DNA binding and thus physical association of 
KLF1 with these proteins. Alternatively the deletions could result in aberrant folding and 
altered tertiary protein structures in KLF1. However, what is clear from these studies, is the 
ability of KLF1 to functionally interact with these proteins to increase gene 
transcription.59,129,130,132,133,139,141,143,144 
The proteins that interact with the zinc fingers of KLF1 may also interact with other KLF/SP 
family members due to the high conservation of their DNA binding domains. Therefore, 
protein interactions unique to KLF1 and potentially other activating KLFs (e.g. KLF2 and 
KLF4) would likely occur in the N-terminal domain.132 
TAD2 of KLF1 has been shown to interact with the p62 subunit of TFIIH.141 Interactions with 
TAF9 and p62 may assist KLF1 in forming a stable conformation with core machinery.141 In 
addition to core machinery, KLF1 also interacts with remodelling factors such as BAF47 
(Ini1), BAF155 (Smarcc1), BAF170 (Smarcc2) and strongly with BRG1 (Smarca4) which are all 
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components of the SWI/SNF complex.130,131,135,141 It is possible that KLF1 is recruiting the 
SWI/SNF complex to maintain erythroid specific enhancers controlling critical erythroid 
genes.59,135,141,144,145 
KLF1 has been shown to interact with chromatin modifying proteins p300 and CREB binding 
protein (CBP).132 CBP has been demonstrated to acetylate KLF1 at two resides near the C-
terminal end of the protein, the Lysine at amino acid 288 (K288) and Lysine at 302 (K302). 
K288 is only found in KLF1, KLF2 and KLF4 and the K302 is conserved across all KLF/SP 
members. Acetylation of these residues does not ameliorate the ability of KLF1 to bind DNA. 
Mutation of K288 results in loss of acetylation at this residue and concomitant loss of 
synergistic upregulation of transcription by p300. However, alterations to K302 did not 
result in the same phenomenon.146 This suggests that the acetylation and synergistic 
increase in transcription is a trait of activating KLFs (KLF1, 2 and 4), although this has yet to 
be confirmed for KLF2 and KLF4. 
Specific amino acid residues in TAD1 of KLF1 are known to undergo various PTMs, 
suggesting other unique protein interactions in the N-terminal domain. Within TAD1, there 
are two PEST (proline, glutamic acid, serine and threonine rich) sequences (PEST1 - 50-70aa 
and PEST2- 74-89aa) determined by the algorithm PEST-FIND (Figure 1.6 A&B).140,146 These 
sequences are typical of proteins with short half-lives and hypothesized to target the 
protein for degradation. Absence of either PEST sequence led to a longer half-life of the 
KLF1 protein.146 
The majority of known PTMs of KLF1 are found within either PEST1 or PEST2. Specifically 
phosphorylation of Serine at residue 68 by PKC is required for timed import of KLF1 into 
the nucleus.142 The phosphorylation of S68 dissociates KLF1 from a cytoplasmic Ankyrin 
protein, Friend of EKLF (FOE), which then allows translocation of KLF1 into the nucleus.142 
Furthermore, a phosphatase known as PPM1B has also been shown to interact with the 
PEST1 sequence in KLF1.140. siRNA knockdown of PPM1B resulted in a general loss in 
transcription of KLF1 target genes due to lower levels of KLF1 protein. It could be possible 
that PPM1B plays a protective role in stabilizing KLF1 protein and inhibiting its destruction. 
Indeed, KLF1 has been demonstrated to interact with the 26S proteasome which is 
responsible for turnover of proteins. The lysine (K74) in PEST2 has been noted as a potential 
lysine receptor site for ubiquitination.134 Mutation of this lysine to an arginine decreased 
overall ubiquitination of KLF1 but suggested there were other lysine acceptor sites. It is 
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likely that ubiquitination of K74 and other lysine residues in KLF1 are required for targeted 
degradation of KLF1.  
Additionally the K74 residue in KLF1 can also be sumoylated by protein inhibitor of activated 
STAT 1 (PIAS1).145 It is believed that sumoylation of K74 allows KLF1 to interact with Mi- 
component of the NuRD repressive complex; unlike other PTMs that serve to increase the 
stability or transcriptional activity of KLF1. 
In addition to PIAS1, there is evidence to suggest that N and C-terminal domains of KLF1 
physically interact with PIAS3.145 PIAS3 acts as a co-repressor for KLF1, independent of 
sumoylation, in a promoter dependent manner. However PIAS3 does not inhibit KLF1 
binding, instead represses genes through the SAP domain.145 Other co-repressors that 
interact with KLF1 include Sin3A and HDAC1.147,148  
However, it is thought that KLF1 is unlikely to play a direct role in repression of gene 
expression in vivo.65 Rather, studies into the genome occupancy of KLF1 have shown it acts 
primarily as an activator of gene transcription.65 However, these studies fail to delineate 
roles in committed erythroid cells versus bipotent megakaryocytic erythroid progenitors 
(MEPs). It may be possible repression of gene transcription by PIAS1 and PIAS3 is required 
for appropriate differentiation of megakaryocytes from the MEP. 
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Figure 1.6 Structure of KLF1 
(A) The structure of KLF1 can be broadly defined into the N-terminal transactivation domain 
and the C-terminal DNA binding domain. The N-terminal domain contains two 
transactivation domains (TADs) which are required to interact with cofactors such as p300. 
In the first TAD (TAD1) there are two PEST sequences. PEST sequences are motifs which 
generally target the protein for degradation. (B) Within the PEST domain the serine in PEST1 
(S68) can be phosphorylated which allows nuclear import of KLF1. Lysine in PEST2 (K74) can 
undergo ubiquitination or sumoylation. Towards the C-terminal domain the nuclear 
localization signal (NLS) is found containing many basic resides. The DNA binding domain is 
adjacent to the NLS and contains three C2H2 zinc fingers which are interspersed by two 
linker peptides, TGEKP and TGHRP.  
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1.2.3 Structure and Function of KLF1 and the KLF/SP family 
There are 17 Krüppel-like factors (KLF) and 9 Specificity Proteins (SP) encoded in the 
mammalian genome, all of which are characterized by a conserved DNA binding domain 
consisting of 3 C2H2 zinc fingers (Figure 1.7). The ZFs of the KLF/SP proteins are connected 
by highly conserved linker sequence. The canonical linker peptide sequence, TGEKP, is 
present in nearly all KLF/SP zinc fingers (Figure 1.8). However some variations do occur. For 
example, the second linker of KLF1 has changes in the +3 and +4 residues relative to the 
threonine (TGHRP). This variant linker peptide is also present in KLF2 and KLF4; both 
primarily activate gene expression and are similar to KLF1 by sequence (Figure 1.8, green). 
Because KLF/SP proteins have similar DNA binding domains and DNA contact residues they 
recognize the same DNA sequences (a motif known as a ‘CACCC’ motif) which are found in 
many tissue specific promoters and enhancers including those in the globin genes.45,149 
While the DNA-binding domains are almost identical between members of the KLF/SP family 
their N-terminal domains are highly variable and are responsible for recruiting different 
cofactors and thereby repressing or activating target genes. Thus, the KLF family of proteins 
can be grouped into different clades according to their N-terminal domains.150-152 KLFs 
belonging to the ‘activation’ clade such as KLF1, KLF2, and KLF4 primarily activate target 
genes by recruiting cofactors such as p300 and CBP. Alternatively KLF3, KLF8, and KLF12 
belong to the repressor clade and recruit cofactors such as C-terminal binding proteins 
(CtBP1, CtBP2) which inhibit transcription.153,154 Our group has shown that KLF1 and KLF3 
can directly compete to fine tune transcription of genes required for erythropoiesis.155 
In the case of KLF1, recruitment of co-factors occurs through the proline-rich N-terminal 
transactivation domain (1-275aa in mice, Figure 1.6A).156 The proline-rich transactivation 
region contains two redundant transactivation domains (TADs) which are necessary for 
interaction with other proteins i.e. p300.132-134,146 The first TAD includes aa 20-124 (TAD1).157 
The second TAD includes aa 140-225 (TAD2).157 The nuclear localisation signal (NLS) consists 
of highly conserved basic residues prior to the Zinc-finger domain (260-271aa), but all three 
zinc fingers are necessary for efficient nuclear localisation.156 
The KLF1 DNA-binding domain contains 88 amino acids spanning 276-358aa in mice. The 
three C2H2 zinc fingers of KLF1 bind specifically at ‘CACCC’ motifs in many erythroid gene 
promoters and enhancers. KLF1 binds the CCA CAC CCT sequence found at -90 in the β-
globin gene promoter and binds less well to variations of the motif found in β-thalassaemia 
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patients.149 The CACCC motif bound by KLF1 was further refined with de novo motif 
discovery and motif enrichment from KLF1 ChIPseq experiments.95,155,158 The refined motif 
revealed that KLF1 could bind to the sequence 5’CC(A/C) C(
A/G)C CCN 3’. 
Nearby to the CACCC motif in the genome there are consistently over represented motifs 
for GATA, and GATA1 ChIPseq experiments show co-localization of GATA1 with KLF1.65 In 
addition, another transcription factor, TAL1, co-localizes with KLF1. We also find evidence of 
NFY as well as NRF1 motifs nearby CACCC sites, suggesting that these other proteins may 
interact with KLF1 while bound to DNA.65,95,155  
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Figure 1.7 Conservation of Cysteines, Histidines and +44 aspartic acid residue in KLF/SP proteins 
Sequence alignment of murine KLF/SP factors highlighting the conserved Cysteine and 
Histidine resides (shaded). In addition it was recently found that all KLF/SP have a highly 
conserved aspartic acid residue at position +44 from the start of the DNA binding domain 
(shaded). Linker peptides all have a highly conserved glycine in position +2 from the start of 
the linker and the +5 is always a proline (dark grey). The +1 threonine is nearly always 
present with the exception of a Serine in SP6.  
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Figure 1.8 KLF/SP family members all contain 3 C2H2 zinc fingers with similar linkers 
Murine KLF/SP proteins of mouse aligned and grouped by conservation of their sequence 
using the Clustal Omega program. Distinct clades can be observed for KLFs in particular 
KLF1/2/4 (green) as well as KLF 3/8/12 which form activating and repressive clades, 
respectively. KLF/SP have three zinc fingers which are highly conserved and are interspaced 
by linker peptides. Many of the KLF/SP family proteins have the canonical TGEKP linker and 
slight variations on their second linker.  
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1.3 C2H2 Zinc finger transcription factors 
Transcription factors (TF) are proteins that generally consist of a DNA binding domain (DBD) 
and a regulatory domain. In general the DBD recognizes factor specific sequences in the 
DNA known as ‘motifs’. The regulatory domain interacts with other proteins, or co-factors, 
that cooperate with the transcription factor to control the expression of genes. TFs bind 
throughout the genome, primarily at enhancers and promoters, and regulate activation or 
repression of target gene expression. 
C2H2 type zinc finger proteins (ZFP) are one of the largest class of DNA binding proteins in 
the mammalian genome.159-161 There are over 700 C2H2 ZFPs characterized in the human 
genome and 500 in the mouse.159-161 These highly conserved ZFPs are characterized by their 
DNA binding domain which consists of multiple C2H2 zinc fingers often found in tandem, 
ranging from 2 through to 35 C2H2-ZF in tandem.159 
The structure of an individual C2H2-ZF consists of two anti-parallel -sheets forming a -
hairpin and followed by an -helix which makes direct contact with DNA.162 There are two 
conserved cysteines in the -hairpin and two conserved histidines in the -helix which 
coordinate a zinc molecule.163-165 The zinc finger structure is stabilized by the zinc molecule. 
The α-helix of each finger makes contact in the major groove of DNA mediated through -1, 
+3 and +6 amino acid residues of the finger (relative to the start of the α-helix) (Figure 1.9A). 
164-169  
Highly conserved linker peptides connect tandem C2H2 zinc fingers (Figure 1.9B). The linker 
peptides connect the -helix of the preceding ZF to the first -sheet of the following ZF. The 
canonical linker consists of 5 amino acids; Threonine, Glycine, Glutamic Acid, Lysine and 
Proline (TGEKP). The TGEKP linker can be found throughout all C2H2 zinc fingers, in at least 
1 or more linkers between the ZFs.159 Linker peptides rarely deviate from this sequence with 
only slight variations in the +1 to +3 residues.159 The high conservation of the amino acid 
sequence in the linkers mean they are more than just spacer elements for the modular 
C2H2-ZFs. In fact, the canonical linker plays an important role in the regulation of ZF DNA 
binding affinities.164,165,167,168,170-179 
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Figure 1.9 Schematic of C2H2 Zinc fingers and their linkers 
(A) C2H2 zinc finger structure depicting the two -sheets forming a -hairpin connected to 
the -helix. The -1, +3 and +6 residues relative to the start of the -helix makes direct 
contact with the DNA. The Cysteine and Histidine residues are highlighted and coordinate 
the zinc ion which stabilizes the structure. (B) A Schematic model of KLF4 bound to DNA 
showing the linker peptides between each zinc finger (PDB 5KE6). The DNA binding domain 
of KLF4 is nearly identical to that of KLF1 and KLF2. The Threonine in each linker extends the 
helix and the glycine in linker 1 and possible histidine in linker 2 form hydrogen bonds and 
closes the c-terminal fray of the helix.  
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The canonical linker is able to extend the preceding -helix and stabilize the helical 
structure via conformational change.163,164,168,180 This mechanism is known as c-capping. The 
first two residues (threonine and glycine) in the linker form hydrogen bonds to residues in 
the -helix and the 3rd residue (glutamic acid) forms a hydrogen bond with the threonine 
thus sealing the frayed end at the c-terminus of the -helix. The lysine in the 4th position has 
been shown to make 2 water mediated contacts with the phosphate backbone of DNA.164,168 
This is likely to be the trigger for the C-capping mechanism to occur as this highly ordered 
structure is only observed when the protein is crystallized when bound to DNA. This could 
explain why the linker peptides have a flexible or chaotic structure when C2H2 ZFPs are 
crystallized in the absence of DNA.163,167,180,181 
The threonine in the canonical linker peptide can also be phosphorylated which reduces the 
DNA binding affinity of C2H2 ZFPs.173-179 In vitro studies of recombinant C2H2 zinc fingers 
with phosphorylated linker peptides also show reduced DNA binding affinity when 
compared to un-phosphorylated ZFs.178 Additionally, when C2H2 ZFPs, such as SP1 and 
IKZF1, are isolated from mitotic extracts they show reduced DNA binding affinity compared 
to their non-mitotic extracts.179 
The phosphorylated threonine is only observed during mitosis where faithful segregation of 
sister chromatids requires the evacuation of DNA bound proteins.176 Recently it has been 
identified that a mitotic kinase, TOPK, is critical for the phosphorylation of the canonical 
linker.175 Cdk1 is another mitotic kinase that is implicated in the phosphorylation of the 
canonical linker.174 Expression of TOPK and Cdk1 is highly restricted to mitosis and in vitro 
experiments have shown the abilities of both these proteins to phosphorylate the canonical 
linker. Although it has yet to be directly observed, it is likely the phosphorylation of the 
threonine would disrupt the formation of the c-cap and thus reduce DNA binding affinity of 
C2H2 ZFPs. 
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1.4 Hypothesis and Aims 
KLF1 is a master regulator of erythroid differentiation and controls the expression of many 
genes involved in this process. KLF1 belongs to the largest class of DNA binding proteins 
known as C2H2 zinc fingers. It has been shown to control the expression of genes that are 
involved in cell cycle regulation in erythroid cells such as E2f2 and E2f4; haem and globin 
synthesis such as Alas2, -globin; and cytoskeletal and membrane structure such as Epb4.9, 
Slc2a4 and Band4.1/4.2. Complete loss of Klf1 is embryonically lethal in mice with death 
occurring around 14.5DPC due to severely perturbed erythropoiesis and -thalassaemia.  
Mutations in KLF1 cause a range of erythroid phenotypes, from benign phenotypes such as 
hereditary persistence of foetal haemoglobin (HPFH), to more severe phenotypes such as 
congenital dyserythropoietic anaemia (CDA), non-spherocytic haemolytic anaemia (NSHA) 
and hydrops fetalis. KLF1 mutations that result in a hypomorphic allele are common 
although loss of function mutations are the most prevalent type of mutation found in 
humans. 
The hypomorphic mutations are mainly found within the DNA binding domain of KLF1. 
These mutations are generally point mutations of particular amino acid residues that are 
likely to directly disrupt zinc ion binding, DNA contact or the functon of the linkers. Nearly 
all patients with compound heterozygous KLF1 mutations carry a hypomorphic allele and a 
loss of function allele.  
The linkers of many different C2H2 zinc finger transcription factors have been studied 
thoroughly. They may provide an insight into the mechanism of KLF1 linkers and why these 
mutations in the linker domain are hypomorphic. The linker peptides between C2H2 zinc 
fingers generally confer an increase in DNA binding affinity by a mechanism known as c-
capping; which occurs when the linker peptide forms hydrogen bonds with the preceding 
alpha helix thus extending and stabilizing the helical structure and closing the frayed end. 
Recently, two patients were described with compound heterozygous mutations of KLF1 
causing severe NSHA with microcytosis and HPFH. Both patients inherited a loss-of-function 
allele and a point mutation in the second linker domain of KLF1. The mechanism of the 
hypomorphic nature of the linker mutations were unable to be thoroughly characterized.  
Our group recently identified a novel mutation within the second linker of mouse KLF1. The 
mutation resulted in transversion of the central histidine at position 350 to an arginine 
(H350R). Mice homozygous for the linker mutation have a mild compensated anaemia but 
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have normal -globin gene expression. Perturbations in erythropoiesis in these mice would 
likely result from the mutation. However, it does not explain the normal -globin gene 
expression. 
In order to understand the function of KLF1 linkers and the possible mechanism of how 
mutation in them result in a hypomorphic function, we sought to create a mouse model of 
NSHA. 
I hypothesized: 
“The H350R mutation in Klf1 will result in perturbed erythropoiesis due to the 
disruption of its DNA binding ability.” 
 
In order to test this hypothesis I developed the following aims: 
1. Establish and characterize a mouse model to replicate human NSHA using the H350R 
mutation. 
2. Identify how the H350R mutation affects KLF1 binding across the genome. 
 
Another important aspect of KLF1 function is its direct interactions with proteins that affect 
KLF1’s transcriptional output throughout erythropoiesis. There are many studies into 
specific protein interactions with KLF1 which commonly result in an increase of KLF1 target 
gene transcription. However some interactions are known to repress gene transcription. 
While it may be possible that the repressive functions of KLF1 occur at the MEP stage where 
lineage determination occurs, a comprehensive analysis of all potential protein interactions 
has yet to be established. 
In this thesis I begin to explore potential protein interactions with KLF1. 
In order to study the protein interactions with KLF1 the following objectives were 
developed. 
1. Optimize co-immunoprecipitation method for tandem mass-spectrometry 
compatability 
2. Optimize LC methods and MS/MS proteomics 
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Chapter 2  General Methods 
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2.1 Animal Husbandry and Tissue collection 
All animal procedures were reviewed and approved by the University of Queensland animal 
ethics committee. 
2.1.1 Animal Husbandry 
2.1.1.1 KLF1 homozygous null mice and mommeD45 homozygous mice 
The bedding of male animals was placed into the cage of females 3 days prior to pairing. 
Female animals were weighed before the bedding change, prior to pairing and 14 days after 
observation of vaginal plug. Klf1 heterozygous null mice (Klf1+/-) were interbred and 
pregnant females were sacrificed at 14.5Days Post Coitum (DPC).45 The mommeD45 
heterozygous mice (Klf1+/D45) and homozygous mice (Klf1D45/D45), when available, were bred 
with the same strategy to obtain homozygous embryos.107  
2.1.1.2 Klf1 null and mommeD45 compound heterozygous 
MommeD45 homozygous and heterozygous (Klf1D45/D45 and Klf1+/D45) mice were interbred 
with Klf1 null heterozygous (Klf1+/-) mice.45. Heterozygous crosses were used to generate 
offspring for phenotyping assays (Klf1+/- x Klf1+/D45). Klf1D45/D45 mice were interbred with 
Klf1+/- mice to generate compound heterozygote mice (Klf1D45/-). Klf1D45/- mice were then 
back crossed to Klf1+/- to generate null embryos from one litter. The embryos were collected 
and foetal livers removed for RNA sequencing. Animals and embryos were genotyped 
through the AEGRC genotyping facility, University of Queensland. 
2.1.2 Animal Procedures 
2.1.2.1 Embryo Collection 
Pregnant female mice were sacrificed at 14.5DPC. An incision was made in the lower 
abdominal region to expose the uterine horns. The uterine horns were cut longitudinally to 
free the embryos from any maternal tissue. Using a curved forcep, embryos were removed 
from the uterine horns. Embryos were washed twice in 1x phosphate buffered saline (PBS) 
and transferred into a 24 well dish with 2ml of PBS supplemented with 5%FCS (PBS/5%FCS). 
2.1.2.2 Foetal Liver microdissection 
Embryos were dissected on a Nikon microdissection scope (SMZ1500). Embryos were 
euthanized by disconnecting the central nervous system before dissection. Using watch 
maker forceps (Size 4 and 5), incisions were made in the abdominal region of the embryo. 
The foetal Liver was extracted and washed in PBS. Any residual tissue (e.g. kidneys and 
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intestines) was removed. Foetal Livers were placed in 1.5mL Eppendorf tubes (Eppendorf) 
with 1mL of PBS/5%FCS and homogenized with a 23g needle (Nipro) followed by a 25g 
needle (Nipro). Homogenized foetal livers were pelleted for 5min at 500g in 4C with an 
Eppendorf centrifuge (5424R). The supernatant was removed after spinning and pellets 
were resuspended in either TRIzol (Thermofisher 15596018) for RNA extraction or in PBS.  
Foetal Liver samples for RNA-seq were generated from a cross between compound 
heterozygous (Klf1D45/-) and Klf1+/- mice. Pregnant females were sacrificed 14 days after 
gestation and the foetal livers from the embryos were collected. Homozygous mommeD45 
were interbred and sacrificed for embryos at 14.5dpc for ChIP experiments; wildtype age 
matched embryos were used as a control. Foetal livers were dissociated with a 23G needle 
followed by dissociated with a 25G needle. 
2.1.2.3 Blood Collection 
75µL of Peripheral blood was collected into ACD (150µL) at 2 weeks and 6 weeks after birth. 
Animals were first anaesthetized with ketamine/xylazine. Blood was then collected by retro-
orbital bleeding with a heparin coated tube (FisherScientific).  
2.1.2.4 Spleen and Bone marrow collection 
Animals were sacrificed at 6 weeks of age to collect the spleen and bone marrow. Animals 
were anaesthetized and weighed before surgical procedures. An incision was made in the 
lower abdominal region in to remove the spleen. Spleens were removed with watchmaker 
forceps and residual adipose tissue was removed. The spleens were then washed with PBS 
and placed in PBS/5%FCS in 1.5mL Eppendorf tubes. Femurs were removed from the hip to 
harvest the bone marrow. The caps of the femurs were removed and a 23G needle with 1mL 
PBS/5%FCS was used to flush the bone marrow.  
2.2 Histology and Haematological Evaluation 
2.2.1 Haematoxylin and Eosin staining 
Isolated mouse spleens were fixed in 4%PFA overnight at 4oC. Spleens were then 
dehydrated in 70% ethanol (Etoh) and embedded in paraffin. Spleens were sectioned to 
4µm thickness (Leica RM2125) and placed on slides (Menzel-Glasser). Slides were de-waxed 
with three washes with xylene for four minutes (min) followed by three washes in 100% 
ethanol. Slides were then rehydrated with one 90% ethanol and 70% ethanol washes for 
4min and left in deionized water for 5min. Slides were then stained with haematoxylin 
(Sigma) for one minute, washed in water for 5min and stained with eosin (Sigma) for one 
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minute. Slides were then washed twice with 95% Etoh for 20s and 100% Etoh. Slides were 
then prepared for mounting by washing three times in xylene for 5min before sealing the 
specimens with cyto-seal 60 (ProSciTech) and a coverslip (Menzel-Glasser).  
2.2.2 May Grünwuld Giemsa and Haematological evaluation 
Blood films were prepared with 10µL of peripheral blood from two week old mice and 
stained with May- Grünwuld-Giemsa. Peripheral blood from six week old mice was collected 
and analysed with the Cell-DYN sapphire (Abbott diagnostics). 
2.3 Bacterial and Tissue culture 
2.3.1 Cell culturing Procedures 
2.3.1.1 J2E, K1 and K1ER cell lines 
K1 and K1ER cells were previously created in the lab by Elise, and Melissa (Coghill et al, 
2001). J2E cells were obtained from the Klinken lab (Busfield et al, 1992). Cells were 
maintained in DMEM culture media (Thermofisher 11995073) supplemented with 10% FCS 
(thermofisher 10099141), 5mM L-Glutamine (thermofisher 25030081) or Glutamax 
(Thermofisher 35050061), 100U penicillin/streptomycin (Thermofisher 15140122). K1 and 
K1ER Cells were maintained at a density of approximately 100-200cells/mL and grown to 
1x106cells/mL for experimentation. Cells were quantified by diluting cells 1:2 in trypan blue 
(Thermofisher 15250061) and analysed on the Biorad TC20 cell counter. 
2.3.1.2 K1 and K1ER induction 
K1 and K1ER (Clone A, C and D) cells were grown to 1x106cells/mL. Cells were counted on 
the Biorad TC20 cell counter and cultures with a viability of over 80% were used. Cells were 
induced with 10mM of Tamoxifen (Sigma) or an equal volume of 100% Ethanol (Etoh) as 
control. Cells were harvested after 3hours (hr) of induction. Cells were used for ChIPseq and 
co-immunoprecipitation of KLF1 
2.3.2 Bacterial Culture Procedures 
2.3.2.1 DH5 culture and transformation 
50µL of DH5a cells were transformed with 1µL of plasmid (Appendix 8.4). Bacteria were 
incubated on Ice for 10min before heatshocking at 42oC for 90 seconds and then on ice for 
90 seconds. 1mL of LB media was added and the bacteria were incubated at 37oC for 1hr 
before plating on LB agar plates supplemented with 100ug of Ampicillin. Individual colonies 
were picked and grown in 10mL (miniprep) or 50mL (midiprep) of LB media supplemented 
with 100ug of Ampicillin. 
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2.3.2.2 BL21 Bacterial culture and induction 
50µL of Bl21 Cells were transformed with 1µL of pGEX-6p-1 containing GST fusion to the zinc 
finger domain of Klf1 (table). pGEX-4T1 was used as a GST only control. Bacteria were 
incubated on ice with plasmid for 15min then heat shocked at 42oC for 2min and then on ice 
for another 2min. 1mL of fresh LB media was added and the bacteria were incubated at 
37oC for 1hr before plating on LB agar plates supplemented with Ampicillin (100ug final 
concentration). Individual colonies were picked the following day and grown overnight in 
5mL cultures containing LB broth, Ampicillin (100ug final concentration), and 
chloramphenicol (50ug final concentration). The cultures were then pooled into a total of 
250mL LB broth supplemented with Ampicillin and Chloramphenicol. The density of bacteria 
was measured on the spectrophotometer (Beckman Coulter DU800) until OD600=0.4 – 0.6 
and were then placed in a 16oC shaker for 1hr with addition of ZnCl2 (50µM final 
concentration). Bacteria were then induced with IPTG (1mM) and incubated at 16oC 
overnight. Bacteria were collected in 50mL aliquots and pelleted at maximum speed, 4oC for 
10min on the Eppendorf centrifuge (5424R).  
2.4 Molecular Biology 
2.4.1 Molecular extractions 
2.4.1.1 RNA extraction 
TRIzol reagent was used for RNA extraction following manufacturer’s protocol with minor 
alterations. Foetal liver cells were homogenized in 1mL of TRIzol reagent frozen at -80oC 
overnight. 250µL of chloroform (Sigma) was then added to the homogenized tissue in 1mL 
of Trizol. The mixture was shaken and incubated for 3min at RT. The samples were then 
spun for 12,000G for 15min at 4oC in an Eppendorf centrifuge. The aqueous phase was 
moved into a new tube and 10ug of glycogen was added. 0.5mL of 100% isopropanol 
(Sigma) was added to the aqueous mixture and incubated at RT for 10min. The samples 
were then spun at 12,000G for 10min at 4oC. The Supernatant was removed and 1mL of 75% 
Etoh was added. The mixture was then spun at 7,500G for 5min at 4oC. The supernatant was 
removed and the pellet was left to dry on ice. Once the Etoh had dried the RNA was 
resuspended in 50µL of RNase/DNase free water (Thermofisher 10977015). RNA was 
quantified using the nanodrop1000 (Thermofisher). RNA was quantified and qualified using 
the Agilent 2100 Bioanalyzer with the RNA pico kit (Agilent 5067-1512) for RNA sequencing.  
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2.4.1.2 Recombinant protein purification 
50mL of induced BL21 bacteria was lysed on ice with chilled lysis buffer containing lysozyme 
(Thermofisher 89833) for 30min. After lysis, 50µL of 100x Protease Inhibitors (Roche 
11836170001) and 5µL of 0.1M PMSF (Sigma) was added then vortexed, following this 25µL 
of 1M dithiothreitol (DTT, Sigma) and 100µL of 10% NP-40 (Igepal ca-630, Sigma) was added 
and vortexed. 800µL of 5M NaCl was added to the samples and incubated for 5min on ice. 
200µL of 5%PEI was added and vortexed. The samples were then spun at 21,000G for 15min 
at 4oC and the supernatant was moved into a new tube. 40µL of 10mg/mL BSA (NEB) was 
added to the supernatant and incubated on ice for 5min. 5mL of lysis buffer with 500ug/ml 
lysozyme, 5mM DTT, 0.2% NP-40, 200µM PMSF and 1X Protease inhibitors was added to the 
supernatant and mixed. The mixture was then spun at 21,000G for 15min at 4oC and the 
supernatant move into a 50mL falcon tube. 100µL of washed Sepharose 4B (glutathione, GE 
Health) was prepared per 50mL of induced bacterial pellet. Sepharose 4B beads were spun 
for 3min at 500g and the supernatant removed. The beads were washed twice with 1mL of 
PBS for 5min with rotation and resuspended in 1mL of wash buffer I. The beads were then 
incubated with the supernatant in the 50mL falcon tube for 1hr at RT. The mixture was then 
spun at 500g for 10min at RT. The beads were washed 3x in 10mL of wash buffer I and then 
3x in 10mL of wash buffer II by rotating at RT for 5min then collecting the beads by 
centrifugation at 500g for 5min at RT. The beads were then resuspended with equilibration 
buffer and transferred into a 1.5mL eppendorf tube. The beads were equilibrated with 
rotation for 5min and then spun for 500g for 5 min at RT. The beads were then incubated in 
800µL of chilled elution buffer and proteins were eluted overnight in 4oC with rotation.  
2.4.1.3 KLF1 Co-Immunoprecipitation 
2x107 K1 and K1ER cells were induced with tamoxifen. After 3 hours of induction cells were 
lysed in 200µL or 1mL of CoIP buffer with 1x Protease Inhibitors. The cell pellet was 
homogenized with a pipette tip and incubated on ice for 20min. The lysates were then spun 
at max speed for 10min at 4oC. The supernatant was collected and frozen at -30oC.  J2E cells 
were harvested and lysed in the same way. 200µL of whole cell lysate was pre-cleared with 
20µL of 50/50 Protein A Sepharose beads in PBS (Thermofisher). In conjunction, 30µL of 
anti-KLF1 antibody (KLF1)45 was bound to 125µL of Protein A Sepharose beads in 800µL of 
CoIP buffer. Pre-clearing and pre-binding was performed at 4oC, overnight with rotation. 
Pre-bound antibody was washed 3 times with CoIP buffer supplemented with protease 
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inhibitors and resuspended in 800µL of CoIP buffer. Pre-cleared lysate was added to the 
antibody-Sepharose and incubated overnight at 4oC with rotation. Antibody bound protein 
complexes were washed 3 times with CoIP buffer (with protease inhibitors). Protein 
complexes were eluted by incubating the beads in 30µL of elution buffer at 95oC for 5min. 
The elution process was repeated for a total of 2 elutions.  
2.4.2 Molecular detection 
2.4.2.1 q-RTPCR 
Reverse transcription of 2ug of RNA was performed to produce complementary DNA (cDNA) 
with SuperscriptIII (Thermofisher) as directed by the manufacturer’s protocol. The cDNA 
was then used for quantitative-reverse transcriptase polymerase chain reaction (q-RTPCR) 
analysis. A final reaction volume of 10µL was used. Individual reactions consisted of 5µL of 
2x SYBR mix (Thermofisher 4309155), 0.1µL of 10µM forward primer and reverse primer 
(Appendix 8.2), 1µL of cDNA and 2.8µL of RNase/DNase free H2O. Reactions were set up in a 
384 well plate (Thermofisher 4309849) and read on the Vii7 thermocycler (Applied 
Biosciences). Cycling conditions for the thermocycler were set up with a dissociation step at 
50oC for 2 min and 95oC for 10min, then 40 cycles of amplification at 95oC for 15s and 60oC 
for 1min, followed by melt curve analysis by dissociating at 95oC for 15s, 60oC for 1min and 
95oC for 15s. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as the 
house keeping gene and was normalized using the equation Percentage of housekeeping=2-
(Ct(gene)-Ct(housekeeping). Primers were designed to amplify across intron/exon boundaries. The 
data was exported from the Vii7 software to Excel (Microsoft) and analysed. Graphs were 
created using Graphpad 5 (Prism).  
2.4.2.2 ChIP-qPCR 
DNA extracted from ChIP experiments (section 2.5.2) was diluted 1/10 and used for 
quantitative PCR analysis. Reactions volumes and thermocycler settings were the same as 
described in section 2.4.2.1 with genomic ChIP DNA used instead of cDNA. ChIP samples 
were normalised to the input samples which were DNA extracted prior to 
immunoprecipitation from pre-cleared whole cell extract. The equation used to normalize 
ChIP samples to input is Percentage of input=100/2(Ct(ChIP)-Ct(Input) Samples were analysed in 
Excel (Microsoft) and graphed in Graphpad 5 (Prism).  
2.4.2.3 Tris, Ascetic acid and EDTA gel DNA electrophoresis 
DNA gels were set with 0.7%, 1% or 2% agarose in Tris, acetate, EDTA (TAE) buffer. Each well 
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was loaded with 6µL of sample mix which consists of 5µL of sample and 1µL of 6x loading 
dye (NEB). Gels were run at 90V-100V for 40-50min. Ethidium Bromide staining solution 
(Sigma) was made mixing 60µL EtBr stock into 100mL of TAE buffer. Gels were stained for 
15min at RT with light shaking and visualized on the Vilbur Fluorescence Gel dock. 
2.4.2.4 Commassie stain and Western Blotting 
Commassie gels were run with 5µL of protein with 5µL of 2x Loading buffer and made up to 
20µL with RNase/DNase free H2O. The protein mixture was denatured at 70C for 10min 
before loading into a pre-cast SDS-PAGE gel (Thermofisher) and run for 35min at 200V. The 
gel was visualized on the Vilbur Luomat.  
2.4.2.5 Mass Spectrometry 
Proteins were prepared as described in 1.4.1.3. 10µL of eluted protein was first boiled at 
95oC for 5min and resuspended to 100µL in ultrapure H2O. The protein was then digested 
with 0.2ug of trypsin (Sigma T6567) overnight at 37oC with low agitation (400rpm). The 
digest was stopped by adding in 5µL of 10% Trifluoretic Acid (TFA, Sigma) and spun at 
13000g for 10min to remove particulates. 95µL of each sample was then transferred 
individual wells of a 96 well dish. Samples were filtered through a c18 tip (Thermofisher) by 
first activating the filter in a solution of 80% Acetonitrile (ACN), equilibrating in 0.5% TFA 
and then binding the sample peptides to the column. Elution of peptides was done by 
washing in 0.5% TFA and eluting with 80% Acetonitrile. Samples were then dried by spinning 
in a heated vacuum centrifuge (SAVANT SPD1010) for 1hr at 45oC. Samples were 
resuspended with 10µL of 0.05% TFA and spun at maximum speed for 10min to remove 
particulates. 9µL of sample was transferred to a 96 well Eppendorf plate and 4µL of sample 
was analysed on the Orbitrap-Q-Exactive plus(Thermofisher). Analysis cycles included a 
Quality check (with BSA) and blank (0.05% TFA solution) before sample analysis and at the 
end of the cycle, as well as a blank between each sample. Samples were run with a 90min 
gradient (appendix 8.5), blank and BSA samples were run with 28min gradients (appendix 
8.5). 
2.4.3 PCR and Cloning  
2.4.3.1 PCR mutagenesis 
PCR mutagenesis was done to introduce the G349R and T348A mutations into the zinc 
fingers of Klf1. pBabe-EKmER (Appendix 8.4) was used as the template DNA. Primers were 
designed to amplify the full length of the EKmER insert with BamHI and EcoRI restriction site 
Chapter 2 – General Methods 
45 
 
over hangs (BamFw EcoRv). PCR mutagenesis primers targeting the second linker of Klf1 
were designed in both forward and reverse directions for both the G349R (G349RFw, 
G349RRv) and T348A (T348AFw, T348ARv) mutations. PCR mutagenesis was performed in 
50µL volumes by mixing 26.6µL of H2O 20µL of 2xKapa Polymerase mix (KAPA Biosystems) 
and 1µL pBabe-EKmER (200ng/µL) template with 1.2µL 10µM of BamFw or EcoRv primers 
with their respective mutagenesis primers (i.e G349RRv or G349RFw respectively). Samples 
were then incubated in an Eppendorf thermocycler at 95oC for 3min, followed by 15 cycles 
of 98oC at 20s, 60oC at 30s and 72oC at 1.5min with a final elongation step at 72oC for 5min. 
Samples were then run on a 0.7% TAE gel and bands at 1Kb were purified with the Qiagen 
Gel purification kit following manufacturers protocol (Qiagen 28706). A second round of PCR 
was performed after gel purification of either the forward amplified or reverse amplified 
templates (i.e BamFw+G349RRv, EcoRv+G349RFw). PCR was performed in 50µL reactions by 
mixing 25.6µL of H2O, 20µL of 2xKapa mix, 1µL each of the two DNA templates containing 
the mutation and 1.2µL each of BamFw and EcoRv primers. PCR was by incubating at 95oC 
for 3min, followed by 1 cycle of 98oC for 20s, 60oC for 1min, 72oC for 1.5min followed by 15 
cycles of 98oC for 20s 60oC for 30s and 72oC for 1.5min with a final elongation at 72oC for 5 
min. PCR products were then ran on a 0.7% gel and bands at 2Kb were Gel purified as 
before. 
2.4.3.2 pGEX-6p-1 cloning 
1ug of Purified PCR products from section 2.4.3.2 were digested with high fidelity restriction 
enzymes EcoRI and BamHI to create overhangs and purified using the Qiagen PCR cleanup 
kit (Qiagen 28106). The same enzymes were also used to linearize 10ug of pGEX-6p-1 
plasmid. Linear plasmid was purified by gel extraction as previously described. Ligations 
were performed at volumetric ratios of 1µL Vector with 3µL of insert. Ligations were set up 
in 20µL volumes by mixing 13µL of H2O, 1µL of T4 ligase (NEB), 1µL of linearized pGEX-6p-1 
with 3µL of digested template. Ligation samples were incubated at 16oC overnight and heat 
inactivated at 65oC for 5min. 10µL of Ligated product was then used to transform 50µL of 
DH5 competent E. Coli as described in section 2.3.1.3. Colonies were selected and grown 
overnight in 5 mL LB broth supplemented with ampicillin (100ug/mL) and colonies which 
expanded were then chosen for plasmid extraction with the Qiagen miniprep kit (Qiagen 
27106). Samples were then quantified on the nanodrop 1000 and sequenced with the 
pGEX_3_primer. 
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2.4.4 Flow Cytometry 
2.4.4.1 Flow Cytometric Analysis 
Flow cytometric analysis was performed on blood, spleen and bone marrow collected from 
mice 6 weeks after birth. The combination of antibodies and their dilutions used is provided 
in the Appendix 8.3. Samples were harvested as described in section 2.1.2.3 and 2.1.2.4. 
Samples were then washed twice with 2%FCS/PBS before preparation for staining. Samples 
were counted and 1x106 cells were aliquot into a well of a 96 well plate (Sarstedt) or bullet 
tubes (QSP 845-Q). Cells were then pelleted at 500g for 5min at 4oC. Antibodies were mixed 
into a master mix panel (appendix 8.3) and 100µL of the master mix was used to resuspend 
the cells. Samples were then stained for 30min on ice. The cells were then spun at 500g for 
5 min at 4oC and resuspended in 400µL of 2%FCS/PBS. Samples were then run on the LSRII 
(BD) or Fortessa flow cytometer (BD). The data and cytometry plots were analysed and 
generated on FlowJo 9. 
2.4.4.2 Fluorescence-activated cell sorting (FACS) 
Samples were harvested as described in section 2.1.2.1 and stained as described in section 
2.4.4.1. Antibody panels for sorting can be found in the appendix 8.3. Minor changes were 
made as compared to section 2.4.4.1. The entire foetal liver was stained (at a density of 
1x106 cells/mL) as opposed to 1x106 total cells and sorting was performed on the Astrios 
(Beckman Coulter) or ARIA cell sorted (BD). 
2.4.5 Binding affinity assays 
Annealing Fluorescent Probes 
Oligonucleotide sequences (appendix 8.2) were diluted from 100µM stock to 10µM. Probes 
were annealed by mixing 40µL of 10µM forward and 40µL of 10µM reverse primer pairs 
with 20µL of 5xTE buffer. Annealing was performed in an Eppendorf thermocycler by 
heating to 98oC for 3min and slowly cooling at 1oC per minute until the temperature 
reached 25oC and was further incubated for 3min at 25oC. Annealed probes were then 
further diluted to 20nM in IDTE when used in FP assays.  
Fluorescent Polarization assay 
KLF1 zinc finger constructs were purified as described in section 2.4.1.2. Fluorescent 
Polarization assays were performed in black 384 well plates (Sarstedt 94.6130.384) and 
polarization was read on the PHERAstar FS (BMG Labtech). Each well contained a 20µL 
reaction by mixing 2µL of 20nM probe with 18µL of Protein at various concentrations. 
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Proteins were serially diluted 1/2 with elution buffer and 18µL of each dilution was added 
into individual wells. 2µL of 20nM probe was added to all wells and the reaction incubated 
for 10min at RT. After incubation the plate was read immediately on the PHERAstar for 6 
cycles with approximately 6 minutes for each cycle. Raw Fluorescent Polarization values 
were normalized to the GST control and percentage of binding was calculated by comparing 
to the maximal protein concentration.  
2.5 Next Generation Sequencing Techniques 
2.5.1 mRNA sequencing 
RNA from Klf1+/-, Klf1D45/- and Klf1-/- foetal livers were extracted using the TRIzol as described 
in section 2.4.1.1. RNA samples were measured on the Agilent Bioanalyzer (Agilent 
Technologies) and RNA with a RNA Integrity Number (RIN) of 9 or more were used. RNA 
samples were first depleted of globin RNA by filtering through the mouse GLOBINclearTM kit 
(Thermofisher AM1981) following the manufacturer’s protocol. DynaBeads mRNA DIRECT 
kit (Thermofisher 61011) was then used to enrich mRNA transcripts from the Globin 
depleted RNA. cDNA libraries were prepared from the mRNA using the Ion total RNA-seq Kit 
v2 (ThermoFisher 4479789) following the manufacturer’s protocol. The cDNA libraries were 
sequenced on the Ion Proton (Thermofisher) using the Ion P1 Hi-Q sequencing kit following 
the manufacturer’s protocol (Thermofisher A26433). Sequenced reads were mapped with 
bowtie2 and unmapped reads from bowtie were mapped with TMAP. We then used CuffDiff 
to analyse differential gene expression between the three different genotypes.  
Detailed bioinformatic analyses of sequencing reads can be found in section 2.6.1.2. 
2.5.2 Foetal Liver Chromatin Immunoprecipitation with next generation sequencing 
Chromatin Immunoprecipitation (ChIP) was performed with Klf1 on foetal liver samples 
from both wildtype and homozygous mommeD45 mutants.45 We pooled 2 foetal livers for 
each genotype totalling approximately 8x107 cells each at the library preparation step. 
However each foetal liver was processed independently for ChIP. We fixed each foetal liver 
individually at a 1x106 cells/mL with fresh 1% Para-Formaldehyde in PBS (PFA) at RT for 10 
minutes and quenched with Glycine (0.125M F.C). Following fixation, each foetal liver 
sample was washed twice with PBS and snap frozen in dry ice/ethanol. 50x Protease 
Inhibitors was used in all buffers from this point onwards. Each foetal liver was then lysed 
with 1mL of cell lysis buffer for 10 minutes on ice. The samples were then spun at 500g for 5 
min at 4oC. Supernatant was removed and replaced with 900µL of nuclear lysis buffer and 
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further lysed in ice for 10min. Each Sample was then split into 6x 150µL aliquots and placed 
into Diagenode bioruptor tubes (Diagenode C30010016). A further 150µL of nuclear lysis 
buffer was added to each tube. Each Foetal liver was then sonicated on the Diagenode 
Bioruptor Pico for 4cycles (3x 300) and 8 cycles (3x 300) of 30s on and 30s off. Sonicated 
chromatin was pooled into 15mL falcon tubes (FisherScientific) respective of their genotype 
and number of cycles thus generating two samples from each foetal liver, 4 cycles and 8 
cycles. Each tube was washed with 1mL of IP dilution buffer and pooled with their 
respective sonication cycles in the 15mL falcon tubes. Thus in the falcon tubes 900µL of 
nuclear lysis buffer was diluted with 3mL of IP dilution buffer, totalling approximately 4mL. 
Each 4mL sonicated chromatin was pre-cleared with 100µL of a 50:50 Protein A Sepharose 
bead (GE Health) mixture in PBS. At the same time 30µL of KLF1 was added to 1mL of PBS 
and pre-bound with 125µL of a 50:50 Protein A Sepharose bead PBS mixture. The pre-
binding reaction was made for each sample, thus a total of 2 reactions were made for each 
foetal liver (4cycles and 8 cycles each foetal liver). Pre-clearing and pre-binding were 
processed overnight at 4oC on a rotary spinner (BMG Labtech). The following day pre-
cleared chromatin was spun at 500g for 5 minutes at 4oC and the supernatant moved to a 
new 15mL falcon tube. 200µL of chromatin was moved into a ‘lobind’ Eppendorf tube as the 
“Input” sample, this sample is the total unenriched chromatin. Pre-bound antibodies were 
spun at 500g for 5 min at 4oC and the supernatant removed. The pre-bound antibodies were 
then washed with fresh PBS. The wash was repeated and after the second wash pre-bound 
antibody was resuspended in 1mL of IP dilution buffer. 1mL of Pre-bound antibody was 
mixed with ~4mL of pre-cleared chromatin and was immunoprecipitated (IP) overnight at 
4oC on a rotary spinner. After the IP reaction samples were spun at 500g for 5min at 4oC and 
the supernatant was removed. The beads were resuspended in 700µL of wash buffer one 
and transferred into Spin-X columns (Co-star). The columns were then spun for 1000g for 
5min at 4oC and the flow through removed. The original tubes were washed with another 
700µL of wash buffer one and transferred into the spin-x columns and spun again. After 
washing and transferring the beads into Spin-X columns, 700µL high salt buffer was used to 
wash the beads. High salt buffer was added directly to the beads to resuspend them without 
contacting the pipette tip. Columns were spun as described and the flow through removed, 
the high salt buffer wash was repeated for a total of two washes. 700µL of wash buffer two 
was then added directly onto the beads and spun as described. After wash buffer two beads 
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were washed twice with TE buffer. Elution buffer was made fresh and incubated to 65oC 
before use. 125µL of heated elution buffer was added directly to the beads and the columns 
incubated at 65oC for 15min. After incubation the columns were spun at 5000g for 5 min at 
RT and the flowthrough collected into lobind Eppendorf tubes. The elution was performed 
twice for a total of 250µL of elution. 10µL 5M NaCl and 1µL of 10mg/mL RNaseA was added 
to the elution and incubated at 37oC for 4-5 hours. After RNaseA incubation 3µL of 20mg/mL 
Proteinase K was added to the reaction and incubated at 45oC for an hour and then 
overnight at 65oC.  
ChIP and Input DNA was recovered by adding 250µL of a 25:24:1 phenol:chloroform:iso-
amyl alchol mixture (sigma) and shaking the mixture until homogenous. The mixture was 
then spun at 16,000g for 5min at 4oC. The aqueous layer was moved into a new lobind 
Eppendorf tube and another 250µL of the phenol:chloroform mixture was added and 
process as before. The aqueous layer was moved into a new tube and 250µL of chloroform 
(Sigma) was added and mixed until homogenous. The tube was spun again at 16,000g for 5 
min at 4oC and the aqueous layer moved into a new tube. 100% ethanol was incubated in 
ice and 1mL of cold ethanol was added along with 2µL of 10mg/ml Glycogen (Roche). The 
mixture was incubated at -80oC for 1 hour to precipitate the DNA, then the samples were 
spun at maximum speed for 15min at 4oC in an Eppendorf centrifuge (5424R). The ethanol 
was removed and the pellet was dried on ice. After the ethanol had dried the pellet was 
resuspended in 50µL of ultrapure H2O. 5µL of input and ChIP was used to quantify by ChIP-
qPCR as described in section 2.4.2.2. 
Foetal liver samples were pooled for sequencing library synthesis. Thus for wild-type and 
mommeD45 samples 2 foetal livers with 2 different sonication cycles were pooled (total of 4 
samples each genotype). A total of 180µL of DNA was used for ChIP library synethsis 
whereas 10ng was used for the Input libraries. Libraries were created with the NEBNext 
ChIP-seq Library prep reagent set (NEB#6200) and multiplex barcodes were used from the 
NEBNext Multiplex oligo for illumina (NEB#E7335). Libraries were synthesized following the 
manufacturer’s protocol. After library synthesis libraries were purified with Ampure beads 
(Beckman A32782) by using a 1.8x volumetric ratio of beads to library. Following purification 
libraries were size selected by using 0.55x volumetric ratio followed by a 0.65x bead 
purification. Purified libraries were then PCR amplified with the NEBNext ChIP-seq library 
prep kit and purified with 0.9x volumetric ratio of Ampure beads to library. A 1/20 dilution 
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was analysed on the agilent bioanalyzer with the DNA1000 kit (Agilent Technologies). 
Libraries were size selected between 150-500bp before sequencing on the NextSeq500 
(Illumina) with the NextSeq High output 75 cycle kit with paired end configuration. Briefly, 
data were mapped with Bowtie2 was used to map the reads to the mouse genome, a 
blacklist was used to filter out repetitive and difficult to map regions with the globin gene 
LCR re-introduced, and Picard tools was used to remove duplicates.182 The MACS2 was used 
to identify peaks and MEME Suite was used to perform de novo motif discovery. The bio-
informatic analysis pipeline is detailed in section 2.6.1. 
2.5.3 K1ER ChIPseq 
K1ER (Clone C) were used to ChIPseq KLF1 after induction with Tamoxifen. This was used as 
a standard for the NanoChIPseq and polyA ChIPseq protocols. ChIP was performed as 
describe in section 2.5.2 with modifications as follows. 
 1x107 cells were used after induction as described in section 2.3.1.2.  
 1mL of nuclear lysis buffer was used to lyse the nuclear pellet and split into 500µL 
aliquots in 15mL falcon tubes. 
 Sonication was performed with a Diagenode Bioruptor with 5, 10 and 15 cycles of 
30s on/off cycles. 
The wash steps and elution were performed as previously described with spin-x columns. 
Samples were aliquot from one ChIP sample for NanoChIPSeq, polyA ChIPseq and ChIPseq 
standard. We had 5million cells for the ChIP samples as 5 million were used as the serum 
control. The ChIP samples were diluted 1/10 for the nanoChIPseq protocol and 1/20 for the 
polyA ChIPseq protocol.  
Library synthesis was performed on ChIP samples with 5x106 cells using the Ion Xpress Plus 
Fragment Library Kit (Thermofisher Scientific #4471269) with the Ion ChIPseq Library prep 
protocol (Thermofisher Scientific publication 44773623, Revision B). Libraries were 
quantified using the Ion Library TaqMan Quantitation Kit (Thermofisher Scientific # 
4468802) following manufacturer’s protocol. ChIP and Input libraries were multiplexed and 
sequenced using the Ion P1 Hi-Q sequencing kit following the manufacturer’s protocol 
(Thermofisher A26433).  
2.5.4 NanoChIPseq 
Our NanoChIPseq protocol was developed based on the protocol from Adli and Bernstein, 
2011.183 Pre-cleared chromatin was prepared from K1ER C cells as described in section 2.5.3 
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and 1/10 of the total K1ERC ChIP sample (250µL of 5mL chromatin sample, approximately 
500,000 cells) was prepared for NanoChIPseq. 
We incubated 3µL of Klf1 with 250µL of IP sample overnight with rotation at 4oC. After 
incubation we washed 40µL of protein A sepharose beads in 1mL of ChIP dilution buffer 
(CDB, appendix 8.6) and spun the samples at 1000g for 30s at 4oC. The supernatant was 
discarded and the beads resuspended in 50µL of CDB. The beads were then added to the 
chromatin-antibody mixture and incubated for 5hrs with rotation at 4oC. After incubation 
the entire sample was placed in a Spin-X column and spun at 1000g for 30s at 4oC. The flow-
through was discarded and 700µL of low salt buffer (appendix 8.6) was added and spun. The 
flow-through was removed and the low salt buffer wash repeated. After the second low salt 
wash 700µL of Lithium Chloride buffer (LiCl buffer) was used to wash the beads. The LiCl 
wash was performed twice. Following this TE buffer was used to wash the beads twice. All 
wash buffers contained Protease Inhibitors. After all washes were performed columns were 
moved into lobind Eppendorf tubes for elution. Elution buffer was pre-warmed to 65oC and 
125µL was added directly onto the beads in the column. The elution mixture was then 
incubated at 65oC for 15min and then spun at 5000g for 1min at RT. A total of 250µL of 
elution was collected. We then layered the top of the elution with 300µL of mineral oil 
(Sigma) to prevent evaporation and performed reverse cross-linking by incubating the 
samples at 65°C overnight. After reverse crosslinking, 250µL of Proteinase K buffer (ProK 
Buffer, appendix 8.6) was added to the sample without disturbing the mineral oil layer. The 
samples were then incubated at 37oC for 4 hours. After incubation 500µL of 
Phenol:chloroform:isoamyl alcohol was added and mixed until homogenous. The samples 
were then spun at 16,000g for 10min at RT. The aqueous layer of the mixture was removed 
into a new lobind Eppendorf tube. 1mL of 100 Etoh, 40µL of 3M Sodium Acetate pH5.2 and 
1µL of 20mg/mL glycogen was added and samples were incubated at -80oC overnight to 
precipitate the DNA. Following the incubation tubes were spun at 22,000g for 20min at 4oC 
the next day. The supernatant was removed and ice cold 70% Etoh was added to wash the 
pellet. The samples were then spun again for 22,000g for 10min at 4oC. The Supernatant 
was removed and the samples were air-dried on ice. After the ethanol had evaporated the 
DNA was resuspended in 30µL of Ultrapure H2O. 1µL of RNaseA was added to the sample 
and incubated at 37oC for 30min. Samples were then vacuum concentrated to 7µL and 2µL 
of 5x sequenase buffer (Thermofisher) and 1µL of 4µM primer 1 (appendix 8.2) was added 
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(MixA). At the same time a second mixture (MixB) was prepared containing 1µL of 5x 
Sequenase buffer, 1.5µL of 3mM dNTP, 0.75µL of 0.1M DTT, 1.5µL of 10mg/ml BSA, 0.3µL of 
sequenase enzyme (Thermofisher). MixA was incubated at 98oC for 2min and rapidly cooled 
to 8oC and further incubated for 1min at 8oC in a thermocycler. The samples were removed 
and spun before adding 5.05µL of MixB on ice. The samples were then incubated at 8oC for 
2min, 16oC for 1min, 22oC for 1min, 28oC for 1min, 36oC for 30s 36.5oC for 1min and lastly 
37oC for 8min. After this first cycle, 1.2µL of sequenase enzyme mixture containing 0.3µL of 
sequenase enzyme and 0.9µL of 5x buffer was added to each sample. The samples were 
cycled three more times with the same cycling conditions (8oC 2min, etc.) with addition of 
1.2µL of sequenase enzyme mixture at the beginning of each cycle. After 4 cycles 3µL of 
ExoSapIP (Thermofisher) was added and incubated at 37oC for 15min and heat inactivated at 
80oC for 15min. The samples were then diluted by adding 40µL of ultrapure H2O. 15µL of 
sample was used in a PCR reaction by mixing with 10µL of 5X GC reaction buffer (NEB), 2µL 
of 10mM dNTP, 1µL of 10µM Primer 2 (appendix 8.2), 1µL of 100% DMSO, 2µL of H2O and 
1µL of PHUsion Polymerase (NEB). Two PCR reactions were mixed for each sample and 
cycled at 15x and 30x cycles. The PCR cycling conditions were set at 98oC for 2min followed 
by 15 or 30 cycles of 98oC for 10s, 50oC for 30s, 60oC for 30s and 72oC for 20s followed by a 
final elongation at 72oC for 1min. Samples were then qualified by ChIP-qPCR for the AHSP 
promoter and E2F2 enhancer binding sites.  
2.5.5 polyA ChIPseq Library preparation for Ion Torrent 
We developed polyA ChIPseq by combining two published protocols Capture and 
Amplification by Tailing and Switching (CATS) and Peregrine.184,185 ChIPed DNA from the 
K1ERC ChIP (section 2.5.3) was diluted 1/20 to replicate low cell number conditions and 
made up to 16µL. Input samples were diluted to 16ng in 16µL (1ng/µL). The ChIP and input 
DNA samples were incubated at 95oC for 5 min. After denaturing the DNA the samples were 
placed immediately on ice and 2µL of 10x Terminal Transferase buffer was added (NEB 
M0315L). The mixture was then heated at 95oC for 2 min and then placed on ice. 0.5µL of T4 
PNK (NEB M0201L) was added and incubated at 37oC for 5min. After adding phosphate to 
the 5’ end of the DNA sample 2µL of 0.1mM dATP and 0.5µL of Terminal Transferase (NEB 
M0315L) was added to the mixture and incubated at 37oC for 15min. The samples were then 
incubated at 70oC for 20min to inactivate the reaction. The DNA was then purified with 
Ampure beads at a volumetric ration of 30µL beads to 20µL sample (1.5x beads). Samples 
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were eluted with 12µL of H2O into PCR tubes and vacuum concentrated to 7µL. 
1µL of 2nM poly-dT primer was added to the ChIP samples and to the input samples 1µL of 
2µM was added. 1µL of 5x RT buffer (Takara #639537) was added to the mixture and 
incubated at 72oC for 2 min followed by 42oC for 2 min. Smartscribe mix consisting of 2µL of 
10mM dNTP, 0.5µL of 20mM DTT, 4µL of 5x RT buffer, RNase Inhibitors and 2µL of 
SMARTscribe reverse transcriptase was added to each sample. The mixture was then 
incubated at 42oC for 15min. After incubation 2µL of 10µM switching templates (with 
sequencing barcodes) were added to the mixture and incubated at 42oC for 2 hours. The 
reaction was terminated by incubating at 70oC for 10min. 
All 20µL of mixture was used for PCR with PHUsion polyermase (NEB #M0530S) as per the 
manufacturer’s protocol. 2xKAPA-HiFi polyermase mix was also used however cycling 
conditions needed to be optimized for the high efficacy of KAPA. PCR was performed with 
primers specific for the switching primer and poly-dT primer and PCR cycled at 94oC for 
2min followed by two cycles of 94oC for 30s, 55oC for 30s, 72oC for 30s followed by 22 cycles 
of 94oC for 30s, 62oC for 30s 72oC for 30s and a final elongation at 72oC for 5min.  
2.6 Computational Analysis of sequencing data 
2.6.1 Bioinformatics 
All Bioinformatic analysis was performed on the high performance computing (HPC) cluster 
located at the Translational Research Institute (TRI) running Red Hat Enterprise Linux 6 with 
the Portable Batch Scheduler 12 (PBS). All BASH scripts can be found in the appendix 8.7.  
2.6.1.1 Mapping and processing of Illumina PE sequencing data 
Base calling of sequencing reads was performed on the NextSeq500 with Real-time Analysis 
(RTAv2). Sequencing reads with an average Phred Score less than 30 were removed before 
aligning the data to the mouse genome. Reads were aligned to the mouse reference 
genome (version mm9) using Bowtie2 with default parameters (appendix 8.7) and filtered 
through a blacklist and whitelist (re-introducing  and -globin regions). Reads were sorted 
with SAMtools (http://samtools.sourceforge.net/). 
Duplicate reads were then removed using the MarkDuplicates function of Picard tools 
(https://broadinstitute.github.io/picard/) with default parameters (appendix 8.7).  
FastA files for the ChIPseq peak regions were extracted with an inhouse PERL script for 
annotation of ChIPseq Peaks (unpublished work Fellrunner by KR Gillinder).  
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2.6.1.2 Mapping and processing of Ion Proton Sequencing data 
Reads were aligned to the mouse reference genome (mm9) using Tophat2 
(http://ccb.jhu.edu/software/tophat/index.shtml) to perform spliced alignment using 
default parameters with additional options: -g 3 and –library-type fr-firststrand. Unaligned 
reads from tophat2 were then mapped with TMAP (Ion Torrent) with tmap map4 and –o 1 
options.186 Mapped reads from tophat and TMAP were sorted and combined into one file 
with SAMTools (appendix 8.7).  
2.6.1.3 Analysis of sequencing data 
Model-based Analysis of ChIPseq (MACS) 2 
MACS2 was used to identify regions of read enrichment from the ChIPseq sequencing reads 
(https://github.com/taoliu/MACS).187 ChIP samples were analysed for enrichment relative to 
the input sample. MACS2 was run with the callpeak module using default parameters with 
additional options: -g mm, --call-summits, -B (appendix 8.7). 
MEME suite analysis 
MEME was used to analyse the motif under the regions in wildtype and H350R ChIPseq 
experiments.188 MEME was run with fasta files from wildtype and H350R chipseq 
experiments with –DNA, -mod zoops, -nmotifs 5, -minw 8, -maxw10 –revcomp, -maxsize 
300000 options. FASTA files were created with a 50bp flank on either side of the summit 
(total 101bp). CENTRIMO was used to discover the relative enrichment of motifs in a set of 
FASTA files. CENTRIMO was run with the website interface (http://meme-
suite.org/tools/centrimo) with the discovered CACC motif and 250bp flank on either side of 
the summit (501bp total).  
CuffDiff  
Cuffdiff was used to identify differential gene expression across the three genotypes.186 
cuffdiff was run with basic parameters using all three genotypes and their biological 
replicates. BASH scripts for cuffdiff can be found in the appendix 8.7.  
UCSC Visualization 
UCSC wiggle tracks were created for RNAseq and ChIPseq experiments. RNAseq wiggle 
tracks were created by consolidating the reads across biological replicates into one file and 
creating a track for each genotype. Combined reads were then processed and converted 
into wiggle tracks using an inhouse PERL script (unpublished work Trailblazer by KR 
Gillinder). ChIPseq reads were normalized to their respective input files by using the MACS2 
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bdgcmp module with –m subtract –p 1.0 options. Normalized files were processed in 
relation to the chromosome size with BEDtools (http://bedtools.readthedocs.io/en/latest/) 
and then converted into bigwig files with bedGraphToBigWig 
(https://www.encodeproject.org/software/bedgraphtobigwig/). 
2.6.2 Software for Data Visualization and Statistical Analysis 
1. Spectrum Mill 
Spectrum Mill (Agilent) was used to analyse mass spectrometry data collected from the Q-
Exactive. Peptide sequences generated from spectra were matched against the mouse 
proteome (Swissprot June 27, 2018 update).  
2. Proteome Discoverer 2.2 
Proteome discoverer was used to analyse the quality of the mass spectrometry data.  
3. R software 
Heatmaps were generated using Rstudio with the ggplots2 package (ver. 0.98.1103). All 
Packages and code can be found in the appendix 8.7.  
4. GraphPad Prism 5 
Statistical Analysis was performed on Graphpad Prism (ver.5.01). All graphs were created 
with Prism where possible with the exception of heatmaps and Read density plots. 
5. EAseq 
Read Density plots were created using the EAseq program. Where available BAM files were 
used as read input and BED region files were used to analyse the reads in each region.189 
6. Flow Jo  
Flow Jo versions 9 and 10 were used to analyse data from flow cytometers and create 
graphs of flow cytometry plots. 
7. Adobe Illustrator CS6 
Illustrator was used to create diagrams and final figures.  
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3.1 Introduction 
Healthy human adults produce nearly 2x1012 red blood cells (RBC, erythrocytes) per day 
through a coordinated process known as erythropoiesis.1,190,191 This process involves RBC 
differentiation from multipotent haematopoietic stem cells (HSC). One model of 
haematopoiesis involves hierarchical differentiation where the cell becomes more restricted 
to one lineage upon cell division, firstly giving rise to a bipotent progenitor, called the 
megakaryocytic erythroid progenitor (MEP), which in turn gives rise to the first committed 
erythroid precursor, the erythroid burst forming unit (BFU-E). The BFU-E becomes a mature 
red blood cell through successive cell divisions, stepwise differentiation (which expands the 
cells capacity for erythroid function) and ultimately extrusion of its nuclear content.29,192,193 
The maturation of the RBC requires different processes, such as cell cycling, membrane 
formation, haemoglobin synthesis and iron uptake, to be tightly coordinated and well timed. 
Control of cellular proliferation is critical during early erythropoiesis as BFU-Es and CFU-Es 
rapidly expand.29,192,193 Proliferation is then restricted as the cells begin the process of 
terminal erythroid differentiation.114,115,119,120 The differentiating cells, within 3 to 4 
divisions, increase iron uptake, and synthesize haem and globin which is assembled into 
haemoglobin.29,192,193 Enucleation, a unique feature of erythropoiesis, occurs at the end of 
differentiation where the red blood cell undergoes membrane and cytoskeletal 
restructuring and in a final asymmetric cell division extrudes the nucleus.192,193 Erythrocytes 
must also overcome the extreme forces that are applied to the red cell membrane during 
transport through arteries, veins and capillaries. This requires a membrane that is easily 
deformable but maintains its structural integrity.84,86,90 The special red blood cell membrane 
assembly and composition allows it to negotiate through the vasculature.121-123 Disruption of 
these processes leads to aberrant erythropoiesis and anaemia.85,88,89,194 
Anaemias due to red cell intrinsic disruptions are typically due to underlying genetic 
abnormalities, with many having monogenic aetiology.89 An example of this is Diamond-
Blackfan anaemia which is caused by mutations that disrupt ribosomal proteins.195 
Anaemias arising from other altered RBC intrinsic proteins can be categorized broadly into 
those due to disruption of enzymatic functions, altered membrane assembly and 
haemoglobinopathies.87,122,196 The two most common enzyme deficiencies are Glucose-6-
phosphate dehydrogenase deficiency and pyruvate kinase deficiency. These enzymes belong 
to the glycolytic pathway which is critical for the RBC not just in energy generation but also 
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for removal of oxidative species. Incorrect membrane assembly or lack of membrane 
components can lead to changes in the cell size and shape, and haemolysis.85,87,88,122,194 The 
most common membrane deficiencies are in ankyrin, and spectrin. These cause hereditary 
spherocytosis and elliptocytosis.  
Mutations within the globin genes cause thalassaemia, which is also a haemolytic 
disorder.45,149,197 These monogenic diseases are due to mutations found in the alpha () or 
beta () globin genes.198,199 Mutations within the complex regulatory region of both  and  
globin LCRs can also cause thalassaemia via distant effects on globin gene expression. 
Sickle-cell-disease (SCD) is another disease contributing to anaemia that also falls under the 
category of haemoglobinopathies. In SCD a specific mutation in the -globin gene leads to 
an amino acid change which causes polymerization of -globin chains in low oxygen 
environments and the cells to deform into a crescent or sickle like shape.200,201 The “sickling” 
of RBCs causes capillary obstruction and organ damage from micro-infarction that 
characterises SCD. 202,203 
In this chapter I have developed a mouse model of hereditary anaemia which focuses on 
disrupting an intrinsic factor to red cell function and development; i.e. the master regulator 
of red blood cell function and development, erythroid Krüppel-like factor (EKLF) (see 
introduction). All KLFs and the related Specificity Proteins (SP) are characterized by their 
common C-terminal DNA binding domain (DBD). The DBD consists of three tandem C2H2 
zinc fingers, which make direct contact with the DNA, and are interspersed by two 
conserved linker peptides.152,204,205 The highly conserved zinc fingers, like other C2H2 zinc 
fingers, make direct contact with DNA through specific residues in the alpha helix.204,206-208 
The linker peptides of the KLF/SP family also share high sequence homology within the 3 
C2H2 zinc fingered family as well as broadly across all C2H2 zinc fingers. In nearly all KLF/SP 
proteins the first linker has the canonical linker peptide sequence, TGEKP. This linker 
peptide is found in nearly all C2H2 zinc finger proteins and has been shown to regulate the 
DNA binding affinity of these proteins.162,164,165,168,172,173,175,178-180,209 Because of the 
similarities in the DBD, all KLFs and SPs recognize very similar DNA sequences which are 
known as CACCC motifs.  
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KLF1 binds specific CACCC motifs and acts primarily as an activator of gene transcription. 
The ‘CACCC’ motif bound by KLF1 has been refined to 5’ CC(A/C) C(
A/G)C CCN 3’. This motif is 
found in the promoters of many critical erythroid genes such as β-globin.95,116,149 
The first linker of KLF1 follows the canonical sequence (TGEKP) found in nearly all C2H2 zinc 
fingers and increases the strength of C2H2 zinc finger binding to DNA. The residues that 
impart strength to DNA binding are threonine and glycine. 46-49,58-60 The second linker 
(TGHRP) follows the same canonical sequence with minor deviations in the 3rd and 4th 
residue; this linker is also found in KLF2 and KLF4. The change in the 3rd and 4th positions is 
not well understood but the function of the second linker in KLF1 is also likely to increase 
DNA binding strength.163-165,167-169,172 
KLF1 knockout mice die in utero shortly after 14.5DPC due to severely reduced -globin 
expression and dysfunctional definitive erythropoiesis.44,45,108,149 Use of next generation 
sequencing techniques such as RNA-seq and ChIP-seq have revealed additional roles for 
KLF1 beyond globin gene control (see introduction).65,91,92,116 In fact, nearly all aspects of red 
blood cell function are directly controlled by KLF1, typically through transcriptional 
activation; these include cell cycling, haem synthesis, cytoskeletal and membrane 
regulation, and iron uptake.46,91,92,110,111,114,115,118,124 
In humans, many different KLF1 mutations have been identified which result in a wide range 
of red cell phenotypes.93,96-100,102,104,105,210-212 Heterozygous loss of KLF1 can cause a benign 
phenotype known as hereditary persistence of fetal haemoglobin (HPFH).210 However, a 
dominant mutation found within the second zinc finger of KLF1 (E325K) can cause 
congenital dyserythropoetic anaemia (CDA).105 This is due to perturbations in the ZF-DNA 
interface of KLF1 which changes the DNA sequence specificity and leads to ectopic 
activation of gene transcription.95,106,213 
Most KLF1 mutations identified within the DBD are point mutations that lead to a 
hypomorphic allele of KLF1. That is they have a benign phenotype and only manifest as 
disease when co-inherited with other KLF1 mutations or a loss-of-function (LoF) 
allele.93,94,99,101,103,210,212 These mutations, when co-inherited with LoF mutatiosn, cause 
hydrops fetalis and non-spherocytic haemolytic anaemia (NSHA) with microcytosis and 
elevated fetal haemoglobin (HbF).96,97,100,103,104 In two cases of NSHA, a loss-of-function 
allele was identified along with mutations within the DBD region of KLF1.96,100 Specifically 
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the mutations were within the linker peptide (linker 2) between the second and third zinc 
fingers.96,100 Interestingly, many mutations of human KLF1 are clustered within linker 2. 
We have previously identified a novel mutation within linker 2 of murine Klf1 in mice known 
as mommeD45.107 The mutation results in a transversion of the central histidine to an 
arginine (H350R). In the homozygous state, mice have compensated anaemia with mild 
microcytosis, increased reticulocytes and decreased haemoglobin levels. However, normal  
and  globin expression was observed, suggesting the mutation still retains, in some 
contexts, normal function of KLF1. In contrast, homozygous loss of Klf1 results in embryonic 
death by 14.5DPC and lack of -globin gene transcription.  
Mice heterozygous for the H350R mutation (Klf1+/H350R) were bred with Klf1 loss of function 
heterozygotes (Klf1+/-). We were able to obtain offspring that were compound heterozygous 
(Klf1H350R/-) with single heterozygous (Klf1H350R/+ and Klf1+/-) and wildtype (Klf1+/+) genotypes 
in single litters. In this thesis I show severe non-spherocytic haemolytic anaemia in Klf1H350R/- 
mice, similar to human patients with compound KLF1 mutations. In order to study this 
phenotype at the molecular level I performed RNA sequencing on 14.5DPC foetal livers from 
Klf1+/-, Klf1H350R/- and Klf1-/- mice. In order to understand how the H350R mutation might 
affect KLF1 binding across the genome I performed ChIPseq for KLF1 in 14.5DPC foetal livers 
from wildtype (Klf1+/+) and H350R homozygous (Klf1H350R/H350R) mice (chapter 4). 
In this chapter using the Klf1H350R/- mutant mouse I aim to:  
1. Replicate the NSHA disease phenotype observed in humans.  
2. Study how the second linker of KLF1 contributes to its function. 
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Figure 3.1 Experimental design for generating and characterizing Klf1
H350/- 
mice 
Animals were bred in accordance to the diagram. mRNAseq samples were generated by 
crossing compound heterozygous Klf1H350R/- and single heterozygous Klf1+/-mice. ChIPseq 
samples were generated from f2 mice with single heterozygous genotypes Klf1H350R/+.  
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3.2 Results 
In order to generate a mouse model of NSHA, I bred heterozygous (Klf1+/H350R) mice with 
Klf1 loss of function heterozygous mice (Klf1+/-) (Figure 3.1). This is because the H350R 
mutation in the homozygous state produced offspring with mild compensated anaemia with 
no difference in the canonical KLF1 controlled gene, -globin. So I bred the H350R mice onto 
a Klf1 null background. This breeding strategy should also model NSHA with similar genetics 
to those found in human patients with compound KLF1 mutations.  
Offspring from these crosses were born at expected Mendelian ratios (Table 3.1). I noted 
that some mice were pale and jaundiced compared to other littermates and genotyping 
confirmed these mice to be compound heterozygous for the H350R mutation and loss of 
function Klf1 allele. 
3.2.1 Klf1H350R/- animals have abnormal red cell morphology and perturbed haematology 
I collected blood from mice at two weeks of age and visualized the blood by staining with 
May-Grunwuld Giemsa stain (Figure 1.2). There were no overt differences between the 
single heterozygous animals (Klf1+/-, Klf1+/H350R) compared to the wildtype (Klf1+/+). However 
I observed extreme morphological perturbations in the compound heterozygous mice 
(Klf1H350R/-); there were cells exhibiting anisocytosis and poikilocytosis as well as an increase 
in circulating reticulocytes and nucleated red cells. 
Haematology parameters were analysed using a Cell-DYN Sapphire (Abbott Diagnostics). Hb, 
MCV, MCH, HCT and reticulocyte parameters in simple heterozygous animals (+/- and 
H350R/+) did not deviate from the wildtype. Homozygous H350R mutants exhibited no 
significant difference from the wildtype littermates. However, the compound heterozygous 
red blood cells had significantly smaller size (mean corpuscular volume, MCV), and 
haemoglobin content (MCH).   
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Table 3.1 Klf1
+/-
 crosses with Klf1
H350R/+
 produce offspring at expected mendelian ratios 
Litter Number +/+ +/H350R +/- H350R/- X2 
1 2 2 2 5  
 
P<0.005 
 
2 6 2 4 0 
3 6 1 2  3 
Total 14 5 8 8 35 
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Figure 3.2 Klf1
H350R/-
 animals have severe haemolytic anaemia with abnormal red cells 
Blood films from blood collected at 2 weeks after birth stained with May-Grunwuld-Giemsa. 
The single heterozygous (Klf1+/H350R and Klf1+/-) mice showed no differences in cell 
morphology when compared to that of the wildtype (Klf1+/+) mice. There were severe 
morphological abnormalities in the compound heterozygous (Klf1H350R/-) animals such as red 
cell deformities (red arrows), smaller cell sizes (red arrows) and circulating nucleated red 
blood cells (white arrow). Images were taken on the Olympus BX50 with a DP26 camera 
using the cellSens standard software.  
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There was a significant increase in reticulocytes and decrease in haemoglobin, HCT, MCV, 
and MCH in Klf1H350R/- mice compared to all other genotypes (Figure 3.3). Haematological 
evaluation and the blood films showed that the compound heterozygous mice models non-
spherocytic haemolytic anaemia that is found human patients.96,100  
3.2.2 Klf1H350R/- animals have abrogated bone marrow erythropoiesis 
I used flow cytometry to determine the differentiation state of red blood cells in the bone 
marrow and in the circulation (Figure 3.4). We are able to stratify erythroid differentiation 
based on surface expression of CD71 and TER119. Cells which express CD71 are immature 
red cells (the polychromatic and chromatic stages of erythroid development), whereas cells 
that only express TER119 are mature RBCs. Double positive cells are in transit between 
these two states. I found that terminal erythroid differentiation in the bone marrow was 
impaired in compound heterozygous mice indicated by the marked reduction of single 
positive TER119 cells (Figure3.4). In the circulation I found an increase in immature red cells 
(CD71+ and TER119+) in the compound heterozygous animals, corroborating the findings of 
increased numbers of circulating reticulocytes.  
3.2.3 Klf1H350R/- animals have splenomegaly due to extra-medullary erythropoiesis 
When RBCs fail to mature correctly the spleen compensates by becoming a secondary site 
of RBC production. I observed a significantly enlarged spleen in compound heterozygous 
animals compared to littermates of either single heterozygotes and wildtype genotypes. 
There was expansion of red pulp in compound heterozygous animals, suggesting an increase 
in red blood cell production (Figure 3.5). I used flow cytometry for CD71 and TER119 to 
identify the differentiation stage of red blood cells, and B220 and CD3 to identify cells of the 
white pulp (i.e. B and T cells, respectively).214 There was a significant enrichment of CD71 
positive red blood cells in the spleen of compound heterozygous mice, confirming that 
extra-medullary erythropoiesis was occurring to compensate for the lack of bone marrow 
derived red blood cells.  
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Figure 3.3 Severe microcytic hypochromic anaemia in Klf1
H350R/-
 adult mice. 
The Klf1H350R/- animals have significantly lower mean corpuscular volume (MCV), 
haemoglobin, mean corpuscular haemoglobin (MCH) and haematocrit. There was a 
significant increase in circulating reticulocytes. All parameters were severely perturbed in 
Klf1H350R/- mice than their H350R homozygous counterparts. Blood was collected from two-
week old mice. Statistical significance was calculated using a one-way ANOVA with Tukey 
post-hoc test (***, P<0.005. mean±SD.) 
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Figure 3.4 Mature erythroid cells are reduced in all haematological compartments 
Flow cytometric analysis of CD71 (transferring receptor) conjugated to phycoerythrin (PE) 
and TER119 (mature erythrocyte antigen) conjugated to PE-Cy7.214 1x106 cells from blood, 
bone marrow and spleen were stained and analysed on a LSR2 (BD). There is an increase in 
TER119 and CD71 double positive cells and a respective decrease in TER119 single positive 
cells in all three tissues from Klf1H350R/- mice. Tissues were collected from 8-week old mice.  
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Figure 3.5 Splenomegaly and extra-medullary erythropoiesis is observed in Klf1
H350R/-
 mice 
There is an expansion of red pulp in the spleen of Klf1H350R/-. Formaldehyde-fixed, paraffin-
embedded spleens were sectioned at 4uM thickness and stained with haematoxylin and 
eosin. Images were taken on the OlympusBX50 with a DP26 camera using the cellSens 
standard software. There is a significant increase in spleen weight of Klf1H350R/- when 
compared to all genotypes (***, P<0.005. mean±SD). There is an increase in immature 
erythroid cells (as indicated by CD71 positive erythroid cells) in Klf1H350R/- mice. Relative cell 
proportions were determined with flow cytometric analysis on 1x106 cells using B220 (B-
cells), CD3e (T-cells), CD71 (positive and negative staining denote immature and mature 
cells, respectively) and TER119 (erythroid cells).   
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3.2.4 A subset of Klf1 dependent genes are sensitive to the H350R mutation 
I performed mRNA sequencing to identify the changes in gene expression due to the H350R 
mutation in Klf1. I first crossed Klf1H350R/- animals with Klf1-/- to generate Klf1+/-, Klf1H350R/- 
and Klf1-/- 14.5DPC embryos (Figure3.1). I then selected only female embryos based on Y 
chromosome PCR as to avoid gene expression changes based on sex differences.  
3.2.5 High quality RNA and libraries can be generated from compound heterozygous and 
null embryos 
I extracted RNA from livers homogenized in TRIzol, and measured the total RNA on the 
Agilent Bioanalyzer. I was able to obtain high quality RNA as measured by the RNA Integrity 
Number (RIN). The RIN value is a measure of RNA quality by using ribosomal RNA 
measurements as a standard. The RIN generally reflects the amount of RNA degradation 
that may occur in a sample, with higher RIN values (Max. 10) indicating less degradation. All 
samples had a RIN higher than 8, except for the Klf1+/- in the 3rd biological replicate. Due to 
sample limitations (female only embryos of the correct genotype in one litter) and quantity 
this sample was further processed by clearing globin mRNA and enriching the remaining 
mRNA transcripts. Sequencing libraries were successfully synthesized from all processed 
RNA. The size (fragment size between 50-1000bp) and quality (low amount of fragments 
between 50-160bp) of libraries as measured by the bioanalyzer shows that all libraries were 
optimal for Ion Proton sequencing (Figure 3.7). I then performed a Pearson correlation on 
each biological replicate for each genotype. I found little to no variance between biological 
replicates of each genotype; all comparisons had a Spearman coefficient of >0.95. 
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Figure 3.6 High quality RNA for sequencing was obtained from all genotypes 
Agilent Bioanalyzer 2100 traces showing quality (expressed as RIN score) and relative 
quantity (expressed as Fluourescent Units; FU) of total RNA isolated from embryonic (e13.5) 
fetal liver cells. 
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Figure 3.7 High quality and size appropriate RNAseq libraries for Ion Proton 
Agilent Bioanalyzer 2100 traces of cDNA libraries showing quantity (Fluorescent units; FU) of 
DNA libraries with respect to DNA length. Libraries were quantified for fragment sizes 
between 50-1000bp (Green dotted lines) and 50-160bp (Blue dotted lines).  
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Figure 3.8 Ion Proton Sequencing of multiplex libraries show good quality reads and depth 
Sequencing metrics generated from Ion Suite software v3.0 (Thermofisher Scientific). Ion 
proton sequencing of replicate libraries show consistent loading of Ion sphere particles (ISP) 
onto sequencing chips (left). Total read depth (middle) and sequenced fragment sizes (right) 
was consistent across all replicates.   
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Table 3.2 Uniquely mapped reads across all replicates and genotypes 
 
Klf1+/- Klf1H350R/- Klf1-/- 
Replicate 1 1.24E+07 9.34E+06 1.52E+07 
Replicate 2 1.84E+07 8.14E+06 1.48E+07 
Replicate 3 1.24E+07 2.02E+07 2.02E+07 
Average reads per genotype 1.44E+07 1.26E+07 1.67E+07 
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Figure 3.9 Low variance across biological replicates of the same genotype 
Pearson correlation of gene FPKM values between biological replicates. 
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3.2.6 The H350R mutation does not affect lineage fidelity and the expression of -globin 
and other known Klf1 target genes. 
I initially analysed expression of canonical KLF1 target genes  globin, E2f2, E2f4, Alas2 and 
Dusp1 (Figure 3.11). I found intermediate or normal levels of expression by normalised 
FPKM of most of these in Klf1H350R/- samples compared with Klf1+/- samples (Figure 3.11). I 
validated expression of these genes by q-RTPCR. The expression levels of all of these genes 
were significantly different (P<0.005) when comparing the Klf1+/- and the Klf1-/- mice as 
expected. Although there was a trend towards mildly reduced expression, there was no 
significant differences for any of these 4 genes between the Klf1H350R/- and Klf1+/-mice. This 
suggests that the H350R retains some normal or near normal KLF1 functions at these gene 
enhancers and/or promoters. 
I then performed q-RTPCR for the transcription factors Fli1, Gata1, Gata2 that correlate 
broadly with megakaryocytic, erythroid and stem cell lineages, respectively. In Klf1-/- foetal 
liver (FL) there is upregulation of Gata2 and Fli1 compared with Klf1+/- FL. This is consistent 
with a block in erythroid differentiation or shift towards megakaryocytic transcriptome, as 
previously published.83 This was not seen in the Klf1H350R/- mice.  
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Figure 3.10 Classical Klf1 target genes show dosage dependent response to the H350R mutation 
UCSC visualization of KLF1 target genes showing read density as a histogram (wiggle track). 
Exons are represented in dark blue boxes and introns are the dashed lines between. The 
wiggle track is coloured grey (reverse strand) or black (forward strand). Klf1H350R/- mice have 
a lower level of coverage for all four genes compared to Klf1+/- mice, but higher than the 
Klf1-/-mice. 
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Figure 3.11 The H350R allele is hypomorphic with respect to expression of classic KLF1-target genes 
Bar graph of fragments per kilobase of transcript per million reads (FPKM) values extracted 
from RNA-seq data for KLF1 target genes (Hbb-b1, Dusp1, E2f4, and E2f2). FPKM is a 
normalized measure of read enrichment and thus expression of genes. Klf1H350R/- mice had 
intermediate expression levels of classical KLF1 genes (Hbb-b1, Dusp1, E2f2 and E2f4) 
compared to Klf1+/- and Klf1-/- mice. Statistical significance was calculated using a one-way 
ANOVA with Tukey post-hoc test (*, P<0.05, mean±SD. N=3). 
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Figure 3.12 The H350R mutation exhibits selective hypomorphic response even in the compound heterozygous state but 
does not alter expression of lineage specific transcription factors 
KLF1 target genes were validated by qRT-PCR. There was no significant difference between 
Klf1H350R/- mice and Klf1+/- mice for Hbb-b1, E2f4, Alas2, Dusp1 and E2f2. However, there is a 
downward trend in expression in the Klf1H350R/- samples. Expression of lineage specific 
transcription factors were also validated by qRT-PCR. There was no significant difference in 
the expression of lineage specific transcription factors Gata1, Gata2 and Fli1 between 
Klf1H350R/- and Klf1+/-. Statistical significance was calculated using a one-way ANOVA with 
Tukey post-hoc test (***, P<0.005. mean±SD. N=3). 
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3.2.7 Klf1 dependant genes have a dosage response to the H350R mutation 
I used CuffDiff to analyse the differentially expressed genes (DEGs) between each genotype. 
I found 1786 genes differentially expressed between the Klf1+/- and Klf1-/- foetal liver but 
only 228 genes between the Klf1+/- and the Klf1H350R/- foetal liver. 
I found that the fold change of expression of specific genes between Klf1H350R/- and Klf1+/- 
mice varied greatly and was independent of the absolute expression levels (Figure 3.14).  
I then compared the two gene lists and found just 168 genes were dependant on KLF1 
(down in Klf1-/- vs Klf1+/-) and sensitive to the H350R mutation (down in Klf1H350R/- vs Klf1+/-); 
i.e. “shared”. I also identified a list of 1618 genes that were KLF1 dependant but not 
sensitive to the H350R mutation (“Het only”), as well as just 60 unique genes that were not 
Klf1-dependant but sensitive to the mutation (“H350R only”). Individual interrogation of 
these 60 genes revealed inconsistent but generally low FPKM across biological replicates; 
this would suggest that the FPKM of these genes were likely to be noise.  
I then compiled the genes into two bins (Het only and Shared) and undertook hierarchical 
clustering (Figure 3.15). I found that in both lists the H350R mutation caused an 
intermediate expression level of genes sensitive to the H350R mutation (168) as well as 
genes that were found in the Klf1+/- list only (1618). So, many of the 1618 genes not found 
to be differentially expressed between Klf1+/- and Klf1H350R/- are actually slightly responsive 
to the H350R allele. The expression of these 1618 genes in the KlfH350R/- RNA-seq may have 
just missed significance cut-off. This is visible in the volcano plot where the majority of the 
1618 genes have a relative expression level between 1 and 0.5 in Klf1H350R/- with respect to 
Klf1+/- mice (Figure 3.14). 
Chapter 3 – A novel mouse model of non-spherocytic haemolytic anaemia 
83 
 
 
Figure 3.13 There is an overlap of 168 genes that are sensitive to the mutation and are Klf1 dependant 
Differentially expressed genes identified by cuffdiff. 1786 genes were identified with 
significant expression differences between Klf1+/- mice and Klf1-/- mice (Klf1-dependent 
genes). There are 228 genes sensitive to the H350R mutation when comparing Klf1+/- to 
Klf1H350R/- mice (H350R sensitive genes). There were 168 genes found in common between 
the two gene lists. 
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Figure 3.14 A small proportion of KLF1-dependent genes show sensitivity to the H350R mutation 
Volcano plot showing expression of all KLF1 dependent (1786) genes ranked by FPKM and 
relative fold change between Klf1H350R/- and Klf1+/-. Positive fold change indicates an 
increased expression in the Klf1H350R/- samples (Red arrow), whereas the negative fold 
change indicates a decreased expression (Blue arrow) in the Klf1H350R/- samples.  
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Figure 3.15 Gene expression of Klf1
H350R/-
 appears to be in between Klf1
-/-
 and Klf1
+/- 
Heatmap density plots with unassisted clustering of genes sets from two categories; “Het 
only” (1618) and “Shared” (168) (defined by the overlap in figure 3.13). The compound 
heterozygous (H350R) samples consistently showed expression levels between the loss of 
function (Klf1-/-) and heterozygous (Klf1+/-).  
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3.2.8 H350R mutation exhibits selective hypomorphism of Klf1 dependant membrane 
associated genes 
I analysed the 168 genes that were found in the shared bin and used gene ontology analysis 
to gain insight into the possible functions.215 I found by functional annotation from DAVID 
(version 6.7) that these genes mainly localized to the membrane or were important to 
membrane function. The genes used for DAVID clustered into membrane (cellular 
compartment), intrinsic to membrane (cellular component), integral to membrane (cellular 
component), transmembrane region (SP_PIR_keywords, UP_SEQ_feature), Glycoslyation 
site (UP_SEQ_feature), glycoprotein (SP_PIR_keywords), topological domains: cytomplasmic 
and extracellular (UP_SEQ_feature). Further interrogation into the cellular component by 
gene ontology found that the genes were integral to membrane, intrinsic to membrane, 
membrane part or membrane. I validated a selection of membrane genes Slc1a5, Slc2a4, 
Slc2a1, Slc43a1, Dematin and Ermap by qRT-PCR (Figure 3.17). I also validated other genes 
from the shared list: Tspo2, Rgcc and Fn3k. I found that the Klf1H350R/- mice had expression 
levels similar to the Klf1-/- mice in all validated membrane genes except for Ermap. This 
contrasts starkly with classical published KLF1-dependent genes such as -globin. The loss of 
expression of membrane genes likely explains the membrane abnormalities present in the 
blood films of the Klf1H350R/- mouse. I also found that the Klf1H350R/- mice had reduced 
expression of Rgcc and Fn3k to levels similar to the Klf1-/-mice. In short, the transcriptome in 
Klf1H350R/- erythroid cells mirrors the phenotype of NSHA.  
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Figure 3.16 Gene ontology analysis reveals H350R sensitive genes show localization and function in the membrane 
Gene ontology analysis with DAVID6.7 on the shared gene set (168).   
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Figure 3.17 Loss of Several membrane transporters and cytoskeletal genes in Klf1
H350R/-
 foetal liver 
qRT-PCR validation of membrane and transporter genes found in the “shared genes list” 
(168 genes). There is significant decrease in the expression of all tested genes in the 
Klf1H350R/- mice when compared to the Klf1+/- mice. The only exceptions were Tspo2 and 
Ermap which did not have any significant differences between Klf1+/- and Klf1H350R/-. 
Statistical significance was calculated using a one-way ANOVA with Tukey post-hoc test (***, 
P<0.005. mean±SD. n=3).  
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3.3 Discussion 
In this chapter I established a mouse model of non-spherocytic haemolytic anaemia (NSHA) 
and characterized the molecular mechanisms underpinning this mouse model. I did this by 
breeding heterozygous animals carrying a loss of function allele (Klf1+/-) with heterozygous 
animals carrying a mutation (Klf1+/H350R) in the second linker of KLF1 and creating compound 
heterozygous offspring (Klf1H350R/-).  
I found destruction of red cells in the compound heterozygous mice and mildly impaired 
differentiation erythroid progenitor bone marrow. Consistent with impaired erythropoiesis I 
found significantly enlarged spleens in compound heterozygous animals from a 
compensated expansion of the red pulp due to extra-medullary erythropoiesis. All together 
our data suggest that a mutation in the second linker of Klf1 between zinc finger 2 and 3 
results in a hypomorphic allele which becomes more pronounced when inherited with a loss 
of function allele.44,45,65 This is consistent with human patients suffering from NSHA who 
carry loss of function and linker mutations.96,100,107  
The prevalence of KLF1 mutations in the human population is not well understood. In 
geographical boundaries such as Sardinia and Southern China there is a high incidence of 
KLF1 mutations across the population.101,103 In Southern China, ~1:80 people are 
heterozygous for a damaging KLF1 mutation. Most of these mutations in the heterozygous 
state exhibit a benign phenotype and go undetected throughout life. However, co-
inheritance of two loss of function KLF1 alleles will cause in utero death or hydrops 
fetalis.44,45,96,97,100,104-106 Thus, it is likely that co-inheritance of two mutant copies of KLF1 will 
cause NSHA in these geographical areas where the parents do not exhibit any disease 
phenotype. Given the prevalence of these mutations in these regions, I would expect to find 
many patients with inherited anaemia due to KLF1 mutations. However, in the literature this 
is not the case. This could be due to the lack of investigation into of the underlying 
mechanisms of the anaemia in these counties. As next generation sequencing becomes 
more readily available to health services it is likely we will begin to see an increase in KLF1 
mutations causing inherited anaemias.  
I then interrogated the molecular mechanisms underpinning our mouse model of NSHA. 
Because KLF1 is a transcription factor I performed mRNA sequencing (mRNAseq) in foetal 
livers of 14.5DPC embryos. I chose embryos so that I could compare to the KLF1 null 
genotype; as these mice die after 14.5DPC. Our samples were restricted to female embryos 
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of Klf1+/-, Klf1H350R/- and Klf1-/- genotypes to ensure as little variance in the transcriptome as 
possible and selected only a change in 1 allele to better gauge the H350R mutation by 
having a consistent null allele. 
I used Cuffdiff to determine KLF1-dependent genes by comparing Klf1+/- and Klf1-/- and 
H350R-sensitive genes by comparing the Klf1+/- and Klf1H350R/-. I found that a small subset of 
KLF1-dependant genes were sensitive to the H350R mutation. Interestingly, I observed that 
not all KLF1-dependant genes were differentially expressed or had reduced expression due 
to the H350R mutation. -globin was not differentially expressed both by mRNAseq and q-
RTPCR. This observation is also true for other established KLF1 target genes such as E2f2, 
E2f4, Alas2 and Dusp1.43,46,65,91,92,110,114-116,118 
It is also interesting to note that I did not find any change in lineage specific transcription 
factors such as Gata1, Gata2 and Fli1 in the Klf1H350R/- mice. This suggests that the H350R 
mutation is able to retain sufficient function to commit progenitor cells to the erythroid 
lineage and therefore there is no lineage infidelity unlike the complete KLF1 loss of 
function.83 This is further evidence that the hypomorphic allele is not just a simple loss of 
function allele. 
I then performed gene ontology analysis with DAVID6.7 on the set of genes that were 
H350R-sensitive and KLF1-dependant. I found by functional annotation the genes were 
primarily associated with membrane localization, membrane function or transmembrane 
proteins. This was a surprise. 
I validated the membrane target genes by q-RTPCR. I confirmed that genes such as Slc2a4, 
Slc2a1, Slc1a5, Slc43a1 and Dematin were differentially expressed between the Klf1+/- and 
Klf1H350R/-. It is likely that the dysregulation of the genes involved in critical erythrocyte 
membrane function is causing the NSHA. Many of these genes are involved in transporting 
amino acids through the cell membrane as well as maintaining integral membrane 
function.216-219 The dysregulation of membrane genes correlates with the dramatic 
morphological changes I observed in the blood films, such as destruction of red cells, small 
cell size and volume as well as inconsistent membrane shape and structure.85-88,90,220  
Despite the destruction of the red blood cells, there is no defect in expression of -globin, 
E2f2, E2F4, Dusp1. As previously described, the H350R homozygotes (two copies of KLF1) 
retain near normal function of KLF1 and thus RBC function. This must be because there is 
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sufficient expression of these critical genes. This is further evidence that the H350R allele is 
hypomorphic rather than null with respect to regulation of these genes.   
In this chapter I describe a novel mouse model of NSHA that phenocopies human patients 
and characterize the underlying molecular changes that causes the disease phenotype. 
Classical KLF1 target genes such as -globin, E2f2, E2f4, Alas2 and Dusp1 remain unchanged 
in the NSHA mice but genes integral to the membrane such as Slc2a4, Slc2a1, Slc1a5, 
Slc43a1 and Dematin, were significantly affected. 
A remaining puzzle is why some genes are sensitive to the H350R mutation and some are 
not. In the next chapter, I attempted to address the mechanism by using chromatin 
immunoprecipitation with Next generation sequencing (ChIPseq) in Klf1H350R/H350R vs Klf1+/+ 
erythroid cells. 
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Chapter 4  Global loss of DNA binding affinity in 
vivo is caused by the H350R in KLF1 
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4.1 Introduction 
C2H2 zinc finger proteins (ZFP) are the largest family of DNA binding proteins in the 
mammalian genome.160,161 An individual C2H2 zinc finger consists of a  fold which 
contains a -hairpin (two anti-parallel sheets) and an -helix. In this structure there are 2 
highly conserved cysteine and histidine residues that coordinate a zinc ion which stabilizes 
the ZF structure. The -helix makes contact with 3 nucleotides of DNA through the -1, +3 
and +6 amino acid residues relative to the start of the -helix.164,206,221 The majority of C2H2 
zinc finger proteins have multiple tandem C2H2 zinc fingers interconnected by highly 
conserved linker peptides159. The canonical linker peptide has the amino acids TGEKP, and 
other C2H2 linkers follow the same sequence with slight variations.159,164,165,169,172 
Initially the linkers were thought to act as spacer elements for the zinc fingers. However, we 
now know they play a significant role in determining the DNA binding affinity of C2H2 
ZFP.163,167,168,170 The canonical linker undergoes a conformational change when the C2H2 ZF 
contacts DNA. This process is known as C-capping, where the linker extends the helix and 
closes the C-terminal fray at the end of the helix.170 Typically the alpha helix is extended 
when the threonine and glycine forms hydrogen bonds with amino acids in the preceding 
helix, and glutamic acid closes the helix by forming hydrogen bonds with the 
threonine.163,164,167,170,171 The lysine forms water mediated contacts with the phosphate 
backbone of the DNA and may likely be the initial conformational change for c-capping to 
occur.164 Thus, disruption of C-capping can potentially reduce the DNA binding affinity of 
C2H2 ZFPs. In fact, DNA binding affinity is reduced when the threonine of the linker is 
phosphorylated by a cell intrinsic mechanism during mitosis.176,178,179,222 The 
phosphorylation of the linker is well documented throughout mitosis with many zinc fingers 
becoming phosphorylated at 1 or more linkers.173,175-177,179,209 Studies have shown that 
mitotic extracts of C2H2 zinc fingers have reduced binding affinity when compared to non-
mitotic extracts and recently it was shown that detection of the phosphorylated linker was 
only observed during mitosis. 173,176,179,209 The kinase responsible for this phosphorylation 
event during mitosis appears to be TOPK although there is some evidence CDK1 can perform 
the same role.174,175  
The Krüppel like factor/specificity protein (KLF/SP) family of proteins all have three 
conserved C2H2 zinc fingers in their DNA binding domain.204,205 There are 17 KLFs and 9 SP 
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transcription factors. Due to the high conservation of the DNA binding domain of these 
proteins, all bind a 9bp DNA element known as a CACCC box (CCN CNC CCN). These CACCC-
box elements are found in many tissue specific gene promoters and enhancers; e.g. globin 
genes.149 In most cases the zinc fingers are interconnected by a canonical linker with a 
second more variant linker. It is likely that all the linkers in the KLF/SP family undergo the C-
capping mechanism except for the second linker in KLF17 and SP7 due to the introduction of 
arginine at the +2 position of the linker.  
KLF1 was the first mammalian KLF discovered. It is only expressed in erythroid 
cells.44,45,108,149 Recent genomic studies of KLF1 have shown it is responsible for nearly all 
aspects of erythropoiesis.65,116,117 It binds CACCC motifs throughout the genome at both 
enhancers and promoters of genes required for erythroid differentiation.43,54,65,92,110,115,116,149 
The KLF1 binding motif was further refined in from ChIPseq studies and found to be CCM 
CRC CCN (M=A/C and R=A/G).65,116  
In the previous chapter I found that the H350R mutation significantly reduced the 
expression of a subset KLF1 target genes. The H350R mutation resides in the middle of the 
second linker of KLF1. It is likely that the mutation could cause reduced DNA binding affinity 
or loss of DNA binding. I hypothesized that the loss of gene expression would correlate with 
the loss of KLF1 binding near these H350R sensitive genes. Our aim was to perform 
chromatin immune precipitation with next generation sequencing (ChIPseq) to interrogate 
the binding dynamics of H350R KLF1 across the mouse genome.  
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4.2 Results 
4.2.1 Chromatin Immunoprecipitation in Klf1+/+ and Klf1H350R/H350R show similar binding 
context 
In order to perform ChIPseq successfully there needs to be a balance between sonicating 
DNA to appropriate sizes and reducing the adverse effects of sonication on the protein of 
interest. I harvested foetal livers at 14.5DPC and crosslinked with fresh PFA. I then isolated 
nuclear pellets and sonicated the chromatin using a Diagenode Bioruptor pico. Our results 
show that DNA fragment size was optimal when sonicated between 4 or 8 cycles of 30s on 
and 30s off (Figure 4.1). The fragmentation of the DNA was analysed by gel electrophoresis 
as well as on the Agilent Bioanalyzer. The ideal DNA fragment size (green) can be observed 
when the chromatin is sonicated for 4 cycles but is proportionally higher in the 8 minute 
sonication (Figure 4.1). I then performed ChIP-qPCR to validate the ChIP DNA to identify 
how the sonication may perturb the levels of enrichment (Figure 4.2). 
KLF1 binds the Ahsp promoter and E2f2 intronic enhancer as indicated by the higher 
enrichment relative to input in comparison to regions 1kb upstream (1kb+) and 1kb 
downstream (1Kb-). I performed ChIP-qPCR on DNA from 4min of sonication and 8 min of 
sonication. I also replicated this for the H350R mutant samples. 
The Ahsp promoter had very little difference in enrichment between the 4 minute and 8 
minute samples. However there was a slight reduction in enrichment between wildtype and 
H350R. The reduction was more noticeable at the E2f2 enhancer where the wildtype had 
enrichment consistently 2 or 3 times more than the H350R. There was also reduced 
enrichment between the 4min and 8min samples for the E2f2 intronic enhancer, however 
the background regions (1Kb up and downstream) were reduced more in comparison. I 
found as expected that when the samples were sonicated for 8min the relative enrichment 
of characterized KLF1 occupied sites (E2f2 intron and Ahsp promoter) was lower. The same 
effect was observed in the Klf1H350R/H350R samples, although the enrichment at the KLF1 
occupied site consistently showed that regardless of 4 or 8min sonication I was able to get 
good enrichment over the background when I normalized to the input samples (Figure 4.2). I 
then used the NEBNext ChIPseq Kit with multiplex primers to synthesize libraries for Paired 
end sequencing (Figure 4.3). I performed the sequencing on the Nextseq500 and reads with 
a PHRED score of less than 30 were removed. I mapped the data to the mm9 genome and 
found across wildtype and H350R samples reads were equally represented across both 
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genotypes. I removed duplicate reads and passed the data through MACS2 to identify 
throughout the genome wildtype (KLF1-WT) and H350R mutant KLF1 (KLF1-H350R) occupied 
sites. MACS2 identified 1144 regions of relative enrichment in the KLF1-WT data set and 490 
in the KLF1-H350R (Figure 4.4). Between the KLF1-WT and KLF1-H350R peak sets there was 
an overlap of 372 peaks. I then used an in-house script (unpublished, KR Gillinder) to find 
the genomic context of these KLF1-WT and KLF1-H350R occupied sites. I found that the 
binding profiles were similar despite the reduction in the number of occupied sites in the 
KLF1-H350R data set (Table 4.1). I found in our dataset contrary to previously published data 
that KLF1-WT and KLF1-H350R bound predominantly to promoters than intronic and distal 
elements. 
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Figure 4.1 Sonication optimization for the Diagenode Bioruptor Pico 
DNA sonication on the Diagenode bioruptor pico for 4 min (4 cycles of 30s on and 30s off) or 
8 min (8 cycles of 30s on and 30s off). There is a higher enrichment of DNA fragments 
between 100-400bp in the 8min sonication which is an ideal size for NGS library prepration. 
There is a broader range of DNA sizes in the 4min sonication however the majority of DNA 
fragments are smaller than 750bp.  
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Figure 4.2 Enrichment of KLF1 bound sites in Ahsp and E2f2 
ChIP-qPCR for the Ahsp promoter and the E2f2 intronic enhancer with regions 1kb up and 
downstream included. The enrichment of ChIP DNA relative to input background is higher at 
the binding site (CACC) when compared to regions 1kb up-stream (1kb+) and down-stream 
(1kb-) from the binding site. This is observed for the Ahsp promoter and E2f2 intronic 
enhancer for both wildtype and H350R variant. There was reduced enrichment of the CACC 
site DNA in the sample sonicated for 8 minutes (8min) when compared to 4 minute 
sonication (4min). 
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Figure 4.3 Sequencing of ChIP libraries show equal representation of reads in each genotype. 
Quality metrics of ChIPseq and Input DNA libraries. Agilent Bioanalyser 2100 tracers of 
ChIPseq and input DNA libraries shows library fragments were all more than 200bp. Library 
sizes ranged between 200 to 1000bp in all samples. Prior to sequencing libraries were size 
selected for fragments between 150-500; to eliminate large library fragments. Sequencing 
of librarires was performed on the NEXTseq500 and there was equal read representation for 
both wildtype and H350R samples for input and chip libraries.  
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Figure 4.4 The H350R mutation has reduced number of peaks but does not alter genomic profile 
MACS2 identified 1144 KLF1 occupied sites from KLF1 ChIPseq in wildtype (WT-Klf1) foetal 
livers and 490 H350R-Klf1 occupied sites from H350R homozygous foetal livers. There was 
an overlap of 372 sites as defined by summits within 100bp of each other. I found that KLF1 
and KLF1-H350R bind similar genome contexts, with promoters taking up 57% and 62% of 
peaks, respectively (651 in wildtype and 302 in H350R). I found approximately 21% and 18% 
peak occupation in introns (235 in Wildtype and 91 in H350R). Binding regions that were 
distal, intergenic, in UTR or in coding regions accounted for approximately 20% of binding 
sites in both wildtype and H350R (258 and 97 respectively).  
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Table 4.1 Genomic context of binding by KLF1 (Wildtype) and H350R KLF1 (H350R) 
 Wildtype H350R 
promoter 651 302 
intron 235 91 
distal 180 63 
intergenic 33 14 
UTR 28 12 
CDS 17 8 
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4.2.2 The H350R mutation does not change DNA binding specificity 
I performed MEME analysis to identify overrepresented motifs in both data sets and found 
that the H350R mutation does not alter the DNA binding specificity of KLF1 (Figure 4.5). I 
further analysed the individual CACCC motifs closest to each binding site to evaluate the 
likely motif bound by KLF1. I did this by finding all CACCC motifs and identifying the closest 
KLF1-WT and KLF1-H350R occupied site. KLF1 occupied sites with 2 or more motifs nearby 
were excluded from analysis. Using this specific method of looking at the DNA binding 
sequence I found further evidence that the H350R mutation does not alter the binding 
specificity (Figure 4.6). For example, wildtype KLF1 and KLF1-H350R both prefer GGGCGGGG 
and GGGCGTGG (40% of all bound sites) over other motifs, but there is quite a broad 
spectrum of potential binding sites. As a measure of quality I then took the binding 
sequence and performed CENTRIMO analysis against our respective data sets and found 
that the MEME motifs found were central to the regions identified as KLF1 occupied sites 
(Figure 4.7). In addition to the CACCC motif I was able to identify over-representation of 
other binding elements.  
I found GATA and NFY DNA motifs in both the wildtype and H350R, suggesting that there is 
no loss of association with GATA bound sites. The NFY sequence is typically over-
represented in promoter sequences which is concordant with our binding profiles for KLF1-
WT and KLF1-H350R. It is possible there is a direct interaction between KLF1 and NFY which 
has not previously been noticed. Interestingly, I found in the KLF1-H350R dataset a loss of 
NRF1 motif as well as a secondary SP/KLF motif (Figure 4.8). Instead these were replaced 
with a repeat element GGAAT. The motif was analysed by TOMTOM and the likely binding 
protein to this motif is ZFP410. However when MEME was performed on a larger window 
and longer sequence of DNA I find that this GGAAT is likely a repetitive element in the 
binding sites of KLF1-H350R. This sequence is reminiscent of satellite repeat elements 
typically found in centromeres.223  
I then wanted to correlate the ChIPseq Data with the RNAseq data from the previous 
chapter. Specifically, I wanted to see whether I could show loss of KLF1-H350R binding at 
the H350R sensitive genes (Figure 4.9). MACS2 found KLF1-WT occupied sites nearby 
Dematin and Slc2a4, whereas the KLF1-H350R data was unable to reach the significance 
threshold of enrichment. This suggests that there is loss of KLF1-H350R binding at these 
genes and thus the inability to activate their expression. However, at Slc1a5 and Slc2a1 
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MACS2 was unable to find significant enrichment in both KLF1-WT and KLF1-H350R 
datasets. Nevertheless, by visual inspection of the UCSC browser it appears that KLF1-WT 
but not KFL1-H350R can bind the promoter elements of these genes. These examples 
establish that the loss of gene expression is likely due to reduced KLF1-H350R binding.  
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Figure 4.5 The H350R mutation does not alter DNA binding specificity 
De novo motif discovery with MEME shows the canonical CACCC motif from both wildtype 
(WT) and H350R data. Shown are the G-rich strands of the motif.  
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Figure 4.6 No change in DNA binding specificity of the H350R variant 
Analysis of KLF1 bound sequences in proportion to bound sites. Specific binding sequence 
was analysed by identifying peaks with only one CACCC site within the peak region. The 
most highly preferred binding sequence is likely to contain a central C at position 5 with 24 
and 26% of identified sites containing the GGGCGGGG motif for wildtype (WT) and H350R, 
respectively.  
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Figure 4.7 CACCC motifs identified in both datasets show central enrichment in peak regions 
CENTRIMO analysis of the motif identified in Figure 4.5 with respect to the position within 
the DNA fragments sequenced from wildtype (WT) and H350R. Using the motif discovered I 
analysed the ‘centrality’ of the motif relative to the region of the peak. I identified that in 
both wildtype and H350R data sets the CACCC site sites centrally in the peak regions.   
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Figure 4.8 Secondary motif analysis reveals H350R loses Nrf1 co-occupancy 
De novo motif discovery for secondary motifs within the peak region identified GATA and 
NFY binding sites in the wildtype data set. These motifs were also found in the H350R 
dataset. (A) In the wildtype dataset I found a Nrf1 binding motif as well as a secondary 
SP/KLF site which were not present in the H350R dataset. (B) Interestingly in our H350R 
dataset I found what appeared to be a motif for ZFP410, further investigation revealed that 
this element was a repetitive DNA element similar to the satellite DNA sequences found in 
centromeres.  
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Figure 4.9 Loss of binding is consistent with reduced gene expression 
Sequencing read histograms (wiggle track) visualized on the UCSC genome bowser of 
ChIPseq data and RNAseq data for the genes Dematin and Slc2a4. Dark blue boxes are the 
exons of the genes and dashed lines in between are the introns. The KLF1 wildtype (Klf1+/+) 
ChIPseq is represented in red wiggle track and the H350R variant (Klf1H350R/H350R) as the blue 
wiggle track. Peak summits are highlighted above each wiggle track in their respective 
colours. RNAseq for all three genotypes sequenced (Klf1+/-, Klf1H350R/- and Klf1-/-) are shown 
as grey wiggle tracks.  
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Figure 4.10 Loss of binding is consistent with reduced gene expression 
Sequencing read histogram visualized on the UCSC genome bowser of ChIPseq data and 
RNAseq data for the genes Slc1a5 and Slc2a1. Dark blue boxes are the exons of the genes 
and dashed lines in between are the introns. The KLF1 wildtype (Klf1+/+) ChIPseq is 
represented in red wiggle track and the H350R variant (Klf1H350R/H350R) as the blue wiggle 
track. RNAseq for all three genotypes sequenced (Klf1+/-, Klf1H350R/- and Klf1-/-) are shown as 
grey wiggle tracks.   
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Figure 4.10 The H350R mutation results in lowered binding affinity across all KLF1 occupied sites 
Heatmap density plots to visualize the read enrichments (central, darker regions) for all 
peaks within a 1kb window identified in both wildtype and H350R datasets. There was 
consistent loss of read enrichment in the H350R dataset when compared to the wildtype. 
Peaks were stratified into three groups according to figure 4.4; wildtype only (WT only 
peaks), common peaks and H350R only peak. Loss of read enrichment was observed in the 
H350R dataset across all three subcategories. However, the WT only peaks appear to have 
the most significant loss of H350R binding.  
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4.2.3 The H350R mutation displays reduced DNA binding affinity across all KLF1 occupied 
sites 
I quantified the sequencing read density in both KLF1-H350R and KLF1-WT across all peak 
regions identified by MACS2 and found significant enrichment of reads from both KLF1-
H350R and KLF1-WT data sets (Figure 4.10). The combined peaks represent the total 
number of sites (1272) from both KLF1-H350R and KLF1-WT. The density plots show the 
darker regions in the wildtype which is representative to the amount of reads in each 
individual occupied site. I found across the combined sites KLF1-H350R had a general 
reduction in the amount of reads in each region suggesting a reduction in binding. I then 
created subsets of regions based on whether they were only found in KLF1-WT, KLF1-H350R 
or shared. The pattern of reduced read density in the KLF1-H350R was consistent across all 
three groups suggesting a global loss of binding affinity in vivo. Thus while some genes may 
exhibit complete loss of binding (e.g. Dematin, Slc2a4, Slc2a1 and Slc1a5) other genes may 
respond in a dosage dependant manner to the levels of binding by KLF1-H350R. 
I then wanted to further evaluate the intrinsic binding affinity of KLF1 and KLF1-H350R. I 
purified GST tagged zinc finger only constructs from bacteria with other linker mutations 
(T348A and G349R) as well as the E339D (NAN) altered specificity mutant (see methods) 
(Figure 4.11). 100,106,213   
4.2.4 There is reduced binding affinity in vitro due to mutations in the linker residues 
I performed electro-mobility shift assays (EMSA) with non-fluorescent probes for E2f2 and 
Ahsp as well as the -globin promoter (Figure 4.12). Where possible, I attempted to quantify 
the bound bands by densitometry analyses and calculated the Kd. Using the Hill curve, I 
found reduced binding of G349R exhibiting the highest Kd, followed by the T348A variant 
and lastly the H350R variant. Visual inspection of each EMSA shows clearly the reduced level 
of binding by any of the 3 linker mutants when compared to the wildtype. In particular the 
G349R and T348A mutations reduced binding affinity much more than the H350R mutation. 
This is consistent with the literature as these residues are directly involved with the c-
capping mechanism163,164,167,170. Our data so far shows that the H350R mutation has a global 
reduction in binding affinity in vivo that is also present when tested in vitro.  
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Figure 4.11 Purification of recombinant zinc finger peptides from E. Coli 
1D gradient-SDS gel of GST-tagged KLF1 zinc fingers and GST only control after purification. 
Lysozyme was used a standard to measure the quantity of protein eluted from the GST 
purification.  
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Figure 4.12 Loss of DNA binding affinity of variants of linker 2 
(A-D) A loss of DNA binding affinity in KLF1 linker mutations is also observed in electro-
mobility shift assays (EMSA). Proteins were titrated by half starting from 12µM protein in 
the very left columns for each probe and probe only controls are in the first lane of each gel. 
EMSA was performed with -globin promoter sequence as well as Alas2 and E2f2 sites. (E-G) 
DNA binding affinity was reduced when comparing the linker mutants relative to the 
wildtype across all sites. 
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4.2.5 The H350R mutation results in gain of function of phosphorylation by TOPK 
I further analysed the phosphorylation potential of the linkers and its mutants to 
understand how regulation by phosphorylation may be affected. In collaboration with the 
Hurt lab, we performed in vitro kinase assays with recombinant TOPK incubated with a 
radioactive phosphorous isotope (P32) and our linker peptides containing the H350R, G349R 
mutations as well as phosphodead controls (T348A), wildtype mouse linker (TGHRP) and 
wildtype human linker (TGQRP) (Figure 4.14). Interestingly we found that the introduction 
of an arginine in either position +2 or +3 from the beginning of the linker results in a gain of 
function with respect to phosphorylation at the threonine residue. Phosphorylation leads to 
reduced DNA-binding. Thus, it is likely that a “gain of biochemical function” 
(phosphorylation) may persist past mitosis and prolong reduced DNA binding affinity in G1 
of the cell cycle. 
We also attempted to use the antibody targeted against phosphorylated linker 1 to detect 
via cold kinase assay the phosphorylated second linker of KLF1 for both human and mouse 
(Figure 4.14). We were able to detect the first linker of KLF1 as expected, due to the high 
conservation of the linker sequence. Surprisingly, we observed reactivity of the antibody 
against the phosphorylated second linkers although at a lower level when compared to the 
canonical linker. This shows the cross reactivity of antibodies against phosphorylated linkers 
and would likely impede detection when both linkers are present in the same protein.  
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Figure 4.13 Arginine substitutions in the second linker of mouse and human KLF1 result in a gain of function of 
phosphorylation by TOPK 
Top: Coumassie stain of purified GST-fusion peptides. Middle: Three exposures of in vitro 
kinase assay after incuation of GST-peptide with 32P-ATP and TOPK. Bottom, Western blot 
with antibodies to TOPK or pTGEKP.176 Lanes: 1, GST alone; 2, GST with finger 1 linker; 3, 
GST-finger 2 linker; 4—8, GST fusion with variants of linker 2 as indicated.   
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4.3 Discussion 
In this chapter I performed ChIPseq on wildtype KLF1 as well as the H350R mutant. Here I 
present the first ChIPseq against KLF1 from pure pool of wildtype foetal livers as well as in 
primary tissue from homozygous H350R embryos.116,117 Our ChIPseq has benefitted from 
better sequencing technology and library preparation compared to previous KLF1 ChIPseq 
experiments.116,117 I found 1144 KLF1 occupied sites in the wildtype samples and 490 in the 
homozygous H350R samples. An overlap of 372 sites was observed between the two data 
sets. It is possible that some regions of enrichment did not make the default significance 
threshold in MACS2 although they may be real KLF1 binding sites (Figure 4.9, Slc1a5 and 
Slc2a1). 
I also analysed the motif within each region of enrichment and found that for both KLF1-WT 
and KLF1-H350R an established motif was the most abundantly bound motif in vivo. I found 
that the CACCC motif is centralized at KLF1-occupied sites. The motif found in the H350R 
data set was the same as the wildtype suggesting that there is no change in the DNA binding 
sequence specificity. I further analysed the binding motif by searching for the closest CACCC 
sequence to peak in both datasets. Peaks with only 1 CACCC sequence nearby were further 
analysed. Using this precise method I found no variance of the binding sequence. Taken 
together our data suggests that while the H350R mutation reduces the number of sites 
bound there is no change in the DNA sequence specificity. This is concordant with the 
literature as the linkers do not play a direct role in contacting the nucleotides.163,167-170 
I was also able to use MEME to find other motifs within the regions of KLF1 binding. In both 
KLF1-WT and KLF1-H350R the next top two motifs are GATA and CCAAT. The GATA motif is 
bound by GATA factors; in this case it would likely be GATA1, as previous studies have 
shown the functional interaction on the genome between KLF1 and GATA1.65,116,129 The 
CCAAT motif is enriched in promoters, and is known to bind the NFY tripartite complex.224-
226 There may be cooperative binding between KLF/SP factors and the NFY complex227. 
However, I also found loss of a Nrf1 motif in the KLF1-H350R data set. This motif is also 
frequently present at promoters and is known to bind the pioneering transcription factor, 
NRF1. This might mean KLF1-H350R is unable to bind promoters cooperatively with NRF1. 
This warrants further exploration. I found a GGAAT element in the KLF1-H350R ChIPseq data 
but not the wildtype data. The significance of this is unclear. It may just be a repeat motif. 
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I then used the ChIPseq data to compare KLF1-DNA binding with gene expression. I found 
some gene promoters had a KLF1-WT peak, suggesting regulation by KLF1. There was no 
signal for the KLF1-H350R ChIP-seq data at these sites. This suggests that loss of binding by 
H350R led to lack of gene activation. However, there were also cases where both KLF1-WT 
and KLF1-H350R did not have a MACS2 called peak although the genes were differentially 
expressed. By visual inspection peaks can be identified in the KLF1-WT data and not the 
KLF1-H350R. This could be due to the stringency of the significance threshold leading to the 
peaks not being identified. 
I found that across all regions KLF1-H350R showed reduced read density suggesting a 
lowered affinity globally. I then broke down the regions into 3 groups to separate out KLF1-
WT regions, Shared regions and KLF1-H350R regions. I found that across these three sub 
groups, KLF1-H350R had consistently lower read depth. Thus, reduced DNA binding affinity 
has variable effects on gene expression where some genes are more affected than others 
depending on the strength of binding. I further investigated the DNA binding affinity directly 
by EMSA. I confirmed that the H350R along with other mutations in the linker resulted in 
lowered DNA binding affinity in vitro. However, I still do not have a good explanation as to 
why some genes are more sensitive than others to the H350R mutation in vivo.  
In collaboration with Myra Hurt, I also interrogated phosphorylation of the H350R variant 
compared to the wildtype second linker. However, as our in vitro binding assays shows, 
irrespective of phosphorylation, the arginine mutation within the second linker of KLF1 can 
disrupt the DNA binding affinity. I show for the first time that the linkers of KLF1 (human 
and mouse) can be phosphorylated by TOPK. I was surprised to find that the introduction of 
arginine at position 2 or 3 in the linker was able to increase the ability of TOPK to 
phosphorylate the threonine in the linker. This could potentially result in a second 
mechanism of DNA binding interference in vivo. Phosphorylation of the linkers normally 
occurs during mitosis and may persist in the case of erythroid cells bearing the H350R 
variant. This could result in delayed or reduced KLF1 binding in G1. Although I observed 
reduced binding affinity in the absence of phosphorylation by in vitro studies, the binding 
affinity of the KLF1-H350R may be exacerbated by the presence of a phosphorylated 
threonine. 
Using ChIPseq I was able to ascertain in vivo the H350R mutation does not alter the binding 
specificity of KLF1; however, it does reduce the binding affinity. I confirmed this in vitro and 
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also observed a gain of function with respects to phosphorylation. All together the H350R 
mutation may result in lowered gene expression or loss of gene expression due to the 
altered DNA binding dynamics. Further analysis of the association and dissociation would be 
required to tease apart the binding affinity and dynamics of the H350R mutation compared 
to the wildtype. 
Furthermore it is likely that in the H350R animals there may be other mechanisms that may 
interfere with gene expression such as different interacting partners as well as changes in 
early erythroid differentiation. 
In the next chapter, I begin to interrogate some of these other possibilities. In particular, I 
tested the possibility of detecting and measuring the phosphorylation of the KLF1 linkers by 
using immunoprecipitation of KLF1 coupled with liquid chromatography assisted tandem 
mass spectrometry. Due to the synergery in the technical approach, I also explored the 
potential interacting protein partners of KLF1.  
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5.1 Introduction 
Krüppel-Like factor 1 (KLF1) also known as Erythroid Krüppel-Like factor (EKLF), is the 
founding member of the Krüppel-Like factor family of C2H2 zinc finger transcription 
factors.228 It is critical for erythropoiesis and its expression is restricted to haematopoietic 
tissues that are destined to become red blood cells44,45,108. KLF1 interacts with a variety of 
proteins to initiate transcriptional changes during erythropoiesis.141 These include 
chromatin modifying proteins, basal transcriptional machinery, other transcription factors 
and proteins that add post-translational modifications (PTMs) to KLF1.130-
135,137,140,145,146,148,157 The majority of these proteins and modifications increase the 
transcriptional output of KLF1 target genes. In this chapter, I explored these protein 
interactions of KLF1. 
KLF1 can be separated into two domains; the N-terminal proline rich transactivation domain 
(TAD) and the c-terminal DNA binding domain (DBD).139,157 In the N-terminal domain there 
are two TADs and within the first TAD there are two PEST (Proline, Glutamic acid, Serine, 
Threonine) sequences.140 The C-terminal DBD contains three C2H2 type zinc fingers 
interconnected by two highly conserved linker peptides.141,156 Proteins can interact with 
both domains of KLF1; primarily through the N-terminal trans-activation domains.132-
134,139,140,142,146,148 However there are some proteins that can interact with the three zinc 
fingers in the C-terminal region of KLF1.130,135,141,143,156 In addition, some protein interactions 
are only observed after KLF1 is modified at the protein level.132,134,142,147,148 The majority of 
known PTMs of KLF1 occur within the two PEST sequences found in TAD1, although some 
are found within close proximity to the DBD. 132-134,140,142,146,156 These PTMs can increase 
association with transcriptional activators and repressors, affect the half-life of KLF1 and 
shuttle KLF1 into the nucleus (Chapter 1.2.2).  
In studies investigating KLF1 interacting partners, investigators used immunoprecipitation 
(IP) pull-down of either the partner protein or KLF1 followed by immunoblotting of either 
KLF1 or the partner protein, respectively to infer interaction. Many studies were performed 
using conditions which enhanced the interaction between the two proteins (i.e expression 
of KLF1 and the protein partner in a neutral cell line) which may have forced the interaction. 
To overcome this issue, I performed native immunoprecipitation of KLF1 from erythroid cell 
lines in order to detect potential interacting partners (Figure 6.1). I employed tandem mass-
spectrometry coupled with nano-flow liquid chromatography (LC-MS/MS) to identify 
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proteins in the IP eluent; thus inferring potential interaction with KLF1. The advantage of LC-
MS/MS is the range of information that can be collected from the IP eluent and the relative 
amount of “user-input” bias is lower than traditional biochemical methodology; i.e. not 
specifically targeting interactions. This pilot experiment can then inform a more targeted LC-
MS/MS approach, such as using the identified proteins and their corresponding peptides to 
narrow the search range of the mass-spectrometer for specific spectral masses. This 
provides more information compared to immunoblotting in traditional biochemistry. 
In this chapter I performed immunoprecipitation of native KLF1 coupled with tandem-mass-
spectrometry to explore the proteins that potentially interact with KLF1. In addition to 
detecting interacting proteins, a secondary aim of this method was to determine, in vitro 
and eventually in vivo, the phosphorylation levels of the two KLF1 linkers (between wildtype 
and the H350R mutation). The data presented in this chapter have been generated from the 
first pilot run of our experimental pipeline which provides the groundwork and structure for 
future studies.  
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Figure 5.1 Experimental design for discovery of KLF1-interacting proteins 
K1 and K1ER cells were incubated with either tamoxifen or ethanol and harvested for KLF1 
immunoprecipitation. Purified proteins from the IP were digested with Trypsin after 
alkylation and reduction. The peptides were then filtered through C18 columns to remove 
salts before running on the easyNLC-Qexactive (ThermoFisher Scientific) for LC-MS/MS 
analysis. 
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5.2 Results 
I performed immunoprecipitation of native KLF1 in 3 clones of the K1ER cell line (clones A, C 
and D) as well as the KLF1 null parental cell line, K1. The K1ER cell lines sequester KLF1 in the 
cytoplasm because KLF1 is fused to the oestrogen receptor (ER). Adding tamoxifen into the 
culture medium releases the KLF1-ER fusion protein from its cytoplasmic chaperones 
allowing translocation into the nucleus.43 Ethanol is employed as a control. In addition, the 
K1 cells were used as a second “background” control due to the lack of any KLF1 protein. 
I immunoprecipitated KLF1 from the K1 (control) and K1ER cells and then analysed the 
samples with LC-MS/MS using the easy-nLC coupled with the Q-exactive orbitrap mass 
spectrometer (Thermofisher). I first tested RIPA and CoIP buffer (methods for recipes) for 
lysis efficiency because the CoIP buffer does not contain SDS (Figure6.2). I found that there 
was no difference between the two in extracting whole cell lysates (WCL). The CoIP buffer 
was chosen to avoid downstream negative effects during mass-spectra analysis. It is known 
that SDS can cause suppression of ions which can result in a lower resolution. SDS can also 
be detected during MS scans which may further suppress signals from other ions. 
I first used proteome discoverer (v2.22) to analyse the samples for their quality and also for 
spectral quality analysis. Each sample had similar amounts of spectra analysed by the 
spectrometer (Figure 6.3). This would suggest that the analysis depth by the mass-
spectrometer is consistent across all samples. I then extracted the data for the number of 
charges of the analysed ions and their amount. I found across all samples, ions with a 2+ or 
3+ charge were most prevalent (Figure 6.4 & 6.5). Samples will primarily have a high number 
of ions with 2+ or 3+ charges after tryptic digest. This is because trypsin digests proteins at 
arginine or lysine which have positively charged side chains. This is consistent with trypsin 
digested peptides as trypsin targets arginine and lysines residues. This would leave a 
peptide with an overall positive charge of 2, each additional positive charge would be due to 
the presence of an amino acid with a positive side chain within the peptide sequence; which 
is likely to be histidines. I then analysed the total spectral intensity of each protein, which is 
established by determining the peptide sequence from the scanned spectra and then 
mapped to the mouse proteome (swissprot June 27 2018 database). All proteins identified 
in each sample were compared for their spectral intensity. I found all samples had a 
R2>0.87, with the K1ERC tamoxifen treated sample having the lowest correlation with 
K1ERD with the same treatment (Figure 6.6). When comparing the K1ERC to the K1ERA an 
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R2>0.89 was calculated. This would suggest that the K1ERC after tamoxifen treatment is 
more variable than K1ERA or K1ERD. When K1ERA and K1ERD was compared an R2>0.96 was 
calculated suggesting they were more similar in terms of their overall spectral intensity. 
I then extracted the data for the peptides identified in the experiment for KLF1 and the 
oestrogen receptor (ESR1) as another measure of quality. I identified 9 unique peptides that 
specifically mapped to KLF1 and 14 peptides for ESR1 (Figure 6.7). No spectra were detected 
in the K1 sample (negative control) that could be mapped to either KLF1 or ESR1 as 
expected. The peptides identified in KLF1 overlap the two linker regions. This suggests that 
with this IP protocol we can enrich for KLF1 and detect the linkers reliably for targeted 
quantification and further work on post-translational modifications. 
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Figure 5.2 CoIP and RIPA buffers generate similar protein lysates 
1D gradient-SDS gel of K1 and K1ER whole cell extracts after lysis with RIPA or CoIP buffers. 
10uL of total lysates and 5ul of Novex prestained protein standards were loaded into a 
precast 4-12% bis-tris SDS gel. The gel was run at 200v for 15min and then stained with 
commassie blue.  
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Figure 5.3. Total number of spectra detected for each sample. 
The number of spectra (primary and secondary) identified from each sample is uniform 
across all samples analysed. This is a measure of consistency of the mass-spectrometer 
scans as well as the MS2 scans between each sample e.g. KLF1 null parental cell line (K1) 
KLF1-ER fusion clones A, C & D (K1ERA, K1ERC, K1ERD) treated with either ethanol (Etoh) or 
tamoxifen.  
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Figure 5.4 Histogram of charged spectra detected in ethanol treated samples. 
The number of charged ions found in spectral analysis for each sample. The number on the 
X-axis indicates the number of positive charges. Consistent spread of charged spectra across 
all samples shows consistency in sample digest.  
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Figure 5.5 Histogram of charged spectra detected in tamoxifen treated samples 
Histogram of number of charged ions in tamoxifen treated samples.  
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Figure 5.6 Pearson correlation of total spectral intensity 
Each spectra generates a spectral intensity which can be used as a relative measure of 
quantification. Pearson correlation of the spectral intensity across all samples shows similar 
level of intensity. All control samples (A&B) had an R2>0.90 and tamoxifen treated samples 
(C) had an R2>0.87. 
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Figure 5.7 Schematic of detected KLF1 and ESR1 peptides 
Sequences highlighted in green were detected with mass-spectrometry after KLF1 
immunoprecipitation. A total of 9 unique peptides were identified which mapped 
specifically to KLF1 and 14 unique peptides were mapped to oestrogen receptor (ESR1). No 
KLF1 or ESR1 peptides were detected in the K1 samples. 
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5.2.1 Protein identification from mass-spectra 
I identified a total of 1636 proteins across all samples using the analysis software Spectrum 
Mill (Agilent). An aspect to note is that the software matches the peptides, which are 
generated from high confidence spectra, to a known database of protein sequences 
(Swissprot June 27 2018) and only does this with unique peptides. Highly homologous 
proteins may not be identified or may have low protein coverage due to the removal of 
similar peptides, as they do not map uniquely. It is possible there may be an under-
representation of peptides due to high homology. Additionally, overly-abundant proteins 
and their peptides may be over-represented in the data.  
The proteins identified in the ethanol-treated and tamoxifen-treated were first compared 
against the KLF1 null parental cell line (K1). All proteins identified were normalized to the K1 
samples. This was done by taking the total number of unique identified peptides for each 
protein in the K1ER samples and subtracting from the total number of unique peptides 
identified in the K1 sample. The number of peptides between the K1ER ethanol and 
tamoxifen treated samples were compared by subtracting the average number of peptides 
identified in the tamoxifen samples from the ethanol samples. I found 606 proteins with 
more unique peptides in the tamoxifen samples, 904 proteins in the ethanol samples and 
126 proteins had no difference in the number of peptides identified. Using STRING I created 
a map of the potential interactome of the proteins identified (Figure 6.8 & 6.9). The map 
was created using experimentally determined evidence of interaction (purple lines) and co-
expression of proteins (black lines). This analysis does not provide an empirically proven 
pathway specific to erythropoiesis because of the broad experimental evidence that is 
available, but generates hypotheses as to how KLF1 may be interacting with these various 
proteins and thus function within erythroid cells. I then further interrogated the data to find 
likely candidates for Klf1 interaction.  
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Figure 5.8 K1ER ethanol treated samples have large and varied protein enrichment after KLF1 CoIP 
STRING analysis of all identified proteins enriched in the K1ER ethanol sample after CoIP 
with KLF1. I found that many of these proteins had experimentally published evidence of 
interaction, which are grouped by their likely functions.  
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Figure 5.9Identified proteins from KLF1 CoIP in K1ER cells treated with tamoxifen 
STRING analysis for proteins enriched in K1ER cells treated with tamoxifen after CoIP with 
KLF1. When compared to ethanol treated samples there were fewer proteins identified.  
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5.2.2 KLF1 may interact with DBHS proteins SFPQ, NONO and PSPC in K1ER cells 
I then subtracted the number of peptides found in the K1 parental cell line from the K1ER 
cell line for each protein in both treatments. This approach provides a better perspective of 
relative enrichment of proteins in the absence of KLF1 compared to when KLF1 is present. 
Generally, I found higher number of peptides in the tamoxifen sample when compared to 
the ethanol sample suggesting that proteins identified in the ethanol sample were likely to 
be background (Figure 6.10).  
I then further focussed on proteins that had negative values in the ethanol treated samples 
(blue); which shows that the peptides numbers were lower than the background, K1. I found 
proteins that had negative values in the ethanol samples were highly enriched in the 
tamoxifen induced samples. RCC2, EIF3L, SFPQ, NONO, MATR3 and PSPC1 are some 
examples of the proteins identified. Further literature searches revealed that SFPQ, NONO, 
MATR3 and PSPC1 all form a complex together within nuclear paraspeckles.229-233 
I then examined the number of peptides found for each enriched protein more specifically 
in the tamoxifen treated samples for the three cell lines (Figure 6.11). I found that across all 
enriched paraspeckle proteins, only NONO was consistently represented in each clone of 
the K1ER cell line (Figure 5.11).  
I then used the K1ERC ChIPseq data generated in the previous chapter to correlate with 
NONO ChIPseq data (GSE73426).234 I processed the data and identified 1208 Peaks in the 
NONO ChIPseq by MACS2.  
However, no correlation could be found to suggest that KLF1 and NONO were co-localizing 
to the same place on DNA (Figure 5.12). This could be because NONO typically localizes to 
DNA where there is nascent RNA.234-238 We would ideally need to replicate the NONO 
ChIPseq in our K1ER cell lines to accurately represent genomic localization.  
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Figure 5.10 Data analysis pipeline 
Schematic of the data analysis performed to determine the number of unique peptides identified in the tamoxifen and ethanol treated K1ER 
co-immunoprecipitation for KLF1.  
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Figure continued on next page  
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Figure 5.11 Identified proteins in KLF1 CoIP after tamoxifen induction normalized to parental KLF1 null cell line 
Proteins identified from KLF1 CoIP in ethanol or tamoxifen treated K1ER cells across 3 
different clones. Unique peptide counts for each protein were first normalised to the Klf1 
null K1 parental cell line. Proteins that were highly enriched in the K1 cells were removed. 
The graph represents the number of peptides remaining after normalizing to the K1 
samples. Positive values indicate enrichment over the K1 background. I found some proteins 
were enriched in the tamoxifen treated samples (red) compared to the ethanol (blue). 
Graphs represent SEM±SD for the number of peptides after normalization to the K1 sample. 
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Figure 5.12 Likely target proteins that may interact with KLF1 in the nucleus 
Peptides from tamoxifen-induced samples for each K1ER clone. These 10 proteins had peptides identified in all three KLF1 CoIP experiments; 
i.e reproducible in 3 independent clones (biological replicates). The exception is PSPC1 with the K1ERC clone not having detected any peptides. 
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Figure 5.13 KLF1 ChIPseq data generated from K1ERC does not correlate with NONO ChIPseq peak regions 
Heat map density plot of ChIPseq data generated from the K1ERC cell line and NONO 
ChIPseq from mESC. There was no clear distinction between overlapping regions in the 
NONO ChIPseq data between input DNA and CHIPseq.  
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5.3 Discussion 
In this chapter I report a preliminary workflow for coupling IP of KLF1 with LC-MS/MS for 
proteomics as a screen to find KLF1 interacting proteins. I immunoprecipitated KLF1 from 
the K1ER (Clones A, C and D) and K1 (KLF1 null) cell lines. The K1ER cells were chosen to 
control the sub-cellular location of KLF1 into the nucleus by addition of ethanol or tamoxifen 
into the culture medium.43 The K1 cells were used as a background and negative control 
because they do not contain KLF1. The IP eluents were then digested with trypsin and 
filtered with C18 filter tips to remove salts and the processed samples were analysed using 
LC-MS/MS. 
In each IP from the K1ER cells I consistently found KLF1 and ESR1 which was not observed in 
the K1 samples. Thus the IP was successful. I identified 9 unique peptides for KLF1 and two 
contained the linker peptide sequences. One aim of this study was to determine whether 
the linkers could be detected reliably so that post translational modifications could be 
observed. Further experimentation is required to determine the best method to enrich KLF1 
for PTM studies using mass-spectrometry. In addition, developing specific targeted methods 
for the peptides during mass-spectrometry scans is crucial to obtaining quantitative data. 
I identified 1636 proteins across all samples, then using the K1 cells as a control for 
background enrichment normalized the K1ER samples. I compared the tamoxifen treated 
against the ethanol treated K1ER cells and found 606 proteins were enriched in tamoxifen 
samples, 904 proteins in the ethanol samples and 126 proteins had no difference between 
the two. I found enrichment of proteins NONO, SFPQ and PSPC1, which are involved in 
paraspeckle formation, were enriched in the tamoxifen treated samples229,239-242. 
It may be possible that KLF1 is co-localizing with these proteins in the nucleus due to the 
upregulation of erythroid transcripts. Further experiments are required to answer whether 
KLF1 recruits NONO and SFPQ to form the paraspeckle and thus act as a hub for 
transcription or whether KLF1 passively enters the paraspeckle due to its involvement of 
massive upregulating erythroid genes. One experiment to begin to understand this would be 
to use immunofluorescence for KLF1 and either NONO or SFPQ and determine visually 
whether there is co-localization of signal in the cell.  
Although our data analyse the proteome that is enriched during IP of KLF1, there is some 
evidence in the literature for oestrogen receptor to interact with paraspeckle proteins as 
well.229 Further to this I identified GSN in our tamoxifen induced samples which primarily 
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interacts with the oestrogen receptor.243,244 The presence of the oestrogen receptor and the 
potential interaction proteins may be a factor confounding the results. Accordingly, I 
attempted to immunoprecipitate KLF1 from the J2E cell line. This is an immortalized mouse 
erythroid cell line which does not contain the K1ER fusion protein; however, the levels of 
KLF1 in these cells are much less compared to the K1ER cell lines. I attempted to 
immunoprecipitate KLF1 from these cells, using the antibody serum as a background control 
. However, only two of the three IP samples recovered KLF1 each with only 1 peptide 
scanned and two KLF1 peptides were detected in a serum control. The J2E cell line proved 
more difficult to work with because of the low KLF1 levels and further work is required to 
refine the protocol to eliminate as much background during the IP. 
Although I was able to identify potential interacting proteins with KLF1 that are novel, I was 
unable to detect interactions with biochemically proven partners. Proteins such as GATA1 or 
even components of the SWI/SNF complex were not consistently identified.129,130,135 In the 
case of GATA1, only 1 peptide was discovered in the K1ERC tamoxifen treated sample. There 
are many reasons that can contribute to this issue, including the sample preparation 
method, the chromatography time and elution of the species, or ion scanning in the mass-
spectrometer.245-247 Alternatively, KLF1 and GATA1 may not physically interact in the 
absence of DNA. Surprislingly, I found none of the reported KLF1-interacting proteins.  
Our data show that there were no issues in preparing tryptic digested peptides for LC-
MS/MS and during LC-MS/MS scans but improvements to eliminating background and non-
specific interactions need to be considered for the immunoprecipitation. To begin, more 
thorough washes before the IP elution would remove background and non-specific proteins. 
As we are using sodium deoxycholate, the ability to dissociate protein-protein interactions is 
not as strong as SDS. Another possible solution is to cross-link the cells prior to IP, however 
this may introduce another layer of variability and complexity but would allow for much 
harsher washes. Alternatively, after IP of KLF1 we can run the eluents on a 1D-PAGE gel and 
perform an in-gel digest method where the band of interest will be extracted from the gel 
and prepared for mass-spectrometry. Another experiment could be to develop a tagged 
version of KLF1 and perform two-step enrichment e.g. IP with the KLF1 specific antibody 
then IP again with an antibody specific to the tag (His, flag, etc). Ideally, future experiments 
with the new methodology would be run with the three K1ER cell lines and would be 
sampled three times for technical replicates for robustness of the data in each cell line. 
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Improvements on the current methodology would still require direct validation of the 
identified proteins and further work would be required to determine where the KLF1 
protein is the exact interaction site. A possible way to validate the interaction is to do CoIP 
with the potential interacting partner. Using this pilot experiment as an example, we would 
Co-IP NONO in the three K1ER and K1 cell lines and see if we could detect KLF1 peptides. 
Future work to validate the interactions could be to create specific deletions in KLF1 and 
attempt IP with these truncated versions.  
The fundamental pipeline of work was established in this chapter for KLF1 IP coupled with 
LC-MS/MS. However, there are many aspects of the workflow that will need to be improved 
in particular the IP of KLF1. Parameters for LC-MS/MS can be tweaked in order to obtain 
specific resolution such as LC gradient time, MS/MS scans and fragmentation. By 
culminating all the necessary changes built on the foundation of work from this chapter, 
future studies are aimed at developing a robust methodology for IPs coupled with LC-
MS/MS in order to broadly identify protein interactions in mammalian cells or tissue.
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6.1 Discussion 
6.1.1 Mutations in the second linker of mouse KLF1 cause nonspherocytic haemolytic 
anaemia  
Our group, in collaboration, identified a novel mutation within the second linker of KLF1.107 
To understand its function I generated a mouse model of non-spherocytic haemolytic 
anaemia (NSHA).96,100 I created this mouse model by breeding heterozygous carriers of the 
H350R mutation (Klf1+/H350R) with heterozygous mice for Klf1 loss of function (Klf1+/-). The 
compound heterozygous (Klf1H350R/-) offspring were pale and jaundiced. Klf1H350R/- mice 
exhibited similar phenotypes to humans with compound heterozygosity for loss-of-function 
and linker 2 mutations in KLF1, and thus presented an opportunity to study the molecular 
mechanisms underpinning this mutation and disease. Using RNA sequencing I was able to 
determine that the Klf1H350R/- erythroid cells had a moderate reduction in expression of 
some but not all KLF1 target genes. Interestingly, -globin expression was normal in the 
Klf1H350R/-. This suggests the H350R mutation exhibits selective hypomorphism with respect 
to some target genes but not others. I then established a complete list of genes that were 
differentially expressed between Klf1+/- and Klf1-/- and overlapped this gene set with genes 
that were sensitive to the H350R mutation. I found that 168 genes were both KLF1 
dependent and sensitive to the H350R mutation. I further analysed these genes by gene 
ontology using DAVID. Interestinglyl, I found most of the genes encode proteins that are 
localized to the cell membrane, and/or function in membrane integrity and structure. This is 
consistent with the abnormal erythroid morphology I observed in the blood films and 
destruction of red cells due to membrane fragility. I confirmed these results with qRT-PCR. I 
found expression level of many membrane genes (e.g. Dematin, Slc1a5, Slc2a4, Slc2a1 and 
Slc43a1) in Klf1H350R/-  cells was similar to the levels of expression in Klf1-/- erythroid cells. 
That is, the H350R allele was essentially functionless with respect to these genes (Figure 
7.1). It is likely that loss of expression of these genes contributes to the morphology 
(poikilocytes, anisocytes) of the red blood cells observed Klf1H350R/- mice (Figure 7.1A). 
Furthermore, the disruption to the membrane may likely inhibit the RBC’s ability to 
continually undergo deformation as they are passed through the capillaries of the 
microvasculature. This would result in fragile RBCs prone to accumulation in the spleen. The 
resulting high turnover of red cells as they are cleared in the spleen would further 
exacerbate the anaemia. In addition the reduced expression of membrane transporters 
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Slc43a1 (Lats3) and Slc1a5 (Asct2) would likely result in the loss of amino acid uptake by the 
red blood cell.216,248 LATS3 coordinates the uptake of L-leucine during erythropoiesis. This is 
critical in maintaining homeostasis in maturing erythrocytes. In the absence of L-leucine 
uptake, translation is reduced in response to mTORC1/4E-BP signalling.248 Similarly, 
knockdown of ASCT2 significantly reduces the uptake of glutamine, which can affect 
nucleotide biosynthesis and red blood cell differentiation.216 These two processes have not 
previously been appreciated as KLF1-depedent processes (Figure 7.1B). Thus, this work 
sheds some new light on the function of KLF1 in some contexts.  
In this chapter, I generated a novel mouse model of NSHA that phenocopies the disease in 
human patients with similar mutations in KLF1. I determined that the underlying cause of 
the disease was likely due to the selective hypomorphism exhibited by the mutation within 
the second linker. The genes that were most affected, according to Gene Ontology and 
Functional Annotation by DAVID, were those involved in membrane function, membrane 
integrity and transport as well as cytoskeletal proteins. The molecular mechanisms 
underpinning the disease can be potentially attributed to the loss of membrane gene 
expression. However, I observed only a small fraction (~10%) of Klf1-dependant genes were 
sensitive to the H350R mutation. This result raises important questions. How does the 
H350R mutation selectively affect KLF1 binding loss of gene expression? Is this dependent 
on DNA binding sequence specificity? Does the H350R mutation alter the way KLF1 interacts 
with other proteins? I attempted to answer these questions in the subsequent chapters. In 
the next section, I looked at in vivo binding of KLF1 across the entire genome using 
chromatin immunoprecipitation with next generation sequencing.  
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Figure 6.1 Selective hypomorphism of the H350R mutation in KLF1 
(A) In combination with a loss-of-function allele in Klf1, the H350R mutation result in a 
marked loss of cytoskeletal and membrane gene expression. (B) As determined by RNAseq, 
it is likely that the loss of critical membrane genes results in haemolysis due to fragile 
membranes or defects in translation or nucleotide biosynthesis.  
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6.1.2 The H350R mutation in the second linker of KLF1 reduces its DNA binding affinity 
but does not change the DNA specificity  
I investigated the binding profile of the H350R mutation using ChIPseq and compared it to 
the binding of wildtype KLF1. I successfully identified 1144 KLF1 binding sites in the wildtype 
ChIPseq dataset and 490 in the H350R dataset. There was no difference in the genomic 
context (e.g. promoter, enhancer) of H350R versus wildtype KLF1 binding sites. I found that 
the majority of binding sites were either at the promoters of the gene or within introns. I 
then performed de novo motif discovery using MEME on both datasets. I found that H350R 
and wildtype KLF1 bound similar motifs in vivo. This means the mutation does not alter DNA 
binding specificity. I further evaluated the binding sequence by identifying the closest 
CACCC sequence to the summit of the peak regions. Again, I found that the H350R bound a 
similar subset of CACCC motifs compared to wildtype KLF1. I then used Centrimo to analyse 
the motif with respect to each binding site in both H350R and wildtype. I found that the 
CACCC motif was central to these regions suggesting these are bonafide KLF1-occupied 
sites. In the H350R dataset, I found loss of two secondary motifs compared with wild type 
ChIP-seq; i.e. loss of Nrf1 and a second SP/KLF motif. It may be that there is a loss of 
functional interaction with Nrf1 and a second nearby KLF1-bound site across the genome. 
The possible loss of interaction with Nrf1 could be tested by performing Nrf1 ChIP-seq in 
wild type and Klf1H350R/- cells.  
I then compared the ChIPseq data with some of the genes that were significantly 
downregulated from Chapter 3. I found where there was a significant loss of expression 
where there was a loss of H350R binding. However, I found no identifying genomic features 
in the regions where KLF1-H350R had reduced binding. For example, there was no 
association with GATA1-binding sites. I analysed our ChIPseq data across all KLF1 occupied 
sites and found that globally the H350R had reduced read enrichment when compared to 
wildtype KLF1. The reduced expression of certain genes was most likely directly due to 
reduced H350R binding and lack of gene activation.  
I then studied the in vitro DNA binding affinity of H350R and various linker mutations 
compared to the wildtype. I found consistent loss of DNA binding affinity for all linker 
mutations including the H350R mutation. I found the loss of DNA binding in fluorescent 
polarization assays which were replicated in EMSA. I cannot tell from these studies whether 
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the reduced affinity of H350R for DNA is due to a slowing ‘on rate’ or faster ‘off rate’ or 
both.  
There are two hypothesized biochemical mechanisms of how the mutation may affect its 
association with DNA. The first is the H350R mutation results in a linker that is unable to 
perform C-capping. This would increase the linker flexibility compared to a linker that has 
undergone the c-cap conformational change upon binding DNA. The rigid c-cap structure is 
required to lock the protein to DNA once bound. This would mean the H350R mutation 
might not be able to ‘lock’ onto the DNA, thus increasing the dissociation rate of the H350R 
protein to DNA. The second is that the linker is now less flexible, i.e the conformation of the 
linker results in rigid structure even when it is not bound to DNA. There are studies that 
show that particular zinc finger proteins slide along the DNA and search for their DNA 
binding motif.249 A rigid linker structure may impair H350R’s ability to scan DNA for a 
suitable binding motif. 
In addition, I asked how the mutation may affect the phosphorylation potential of the 
threonine in the linker.174-176 In collaboration with Myra Hurt, we observed the second linker 
of both mouse and human KLF1 were able to be phosphorylated at much higher levels when 
compared to the canonical linker peptide. Surprisingly, the substitution of the central 
histidine to an arginine in the mouse linker (H350R), or the glycine to an arginine in the 
same relative position in human linker 2, increased the phosphorylation by TOP kinase at 
the preceeding threonine. That is, the linker mutation are gain of function mutations with 
respect to TOPK-dependent phosphorylation. This would need to be tested in vivo to 
determine whether there is hyper-phosphorylation of linker 2 in H350R. Threonine 
phosphorylation of SP family linkers is known to be associated with loss of DNA-binding 
during mitosis. So, the outcome of hyper-phosphorylation could be to delay or impair 
dephosphorylation following mitotic exit and thus result in apparent loss of DNA binding 
affinity. To address this we would require cell cycle synchronisation and sorting for in vivo 
binding assays (e.g. by EMSA). I attempted to synchronise the K1 cell lines using a double 
thymidine block procedure, but was not successful.  
However, neither the hyper-phosphorylation model nor loss of global DNA binding affinity 
model explain why only some KLF1 occupied sites had reduced binding affinity for the 
H350R variant in vivo.   
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Figure 6.2 H350R mutation in KLF1 may cause the linkers to be more flexible 
Schematic of the three C2H2 zinc fingers in KLF1 wildtype and H350R interacting with DNA. 
The model depicts a flexible linker in the H350R unable to form a tight lock on DNA. Thus, 
reduces the DNA binding affinity as the third finger associates and dissociates frequently.  
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6.1.3 Co-immunoprecipitation of KLF1 in the K1ER cell line reveals possible interactions 
with paraspeckle proteins 
I undertook a preliminary study to try to find proteins that can directly interact with KLF1. I 
hypothesized the difference in DNA binding of the H350R compared to the wildtype may be 
due to the change in cofactor/s binding. I used an unbiased proteomics approach to search 
for any proteins that might interact with KLF1 by IP; i.e. IP of KLF1 followed by liquid 
chromatography coupled with tandem mass-spectrometry (LC-MS/MS). This method can be 
used to broadly determine the protein interactome of wildtype KLF1 versus KLF1-H350R, 
which may identify why there is reduced binding by H350R variant at some KLF1 binding 
sites and not all. 
The K1ER cell line was used to test and optimize the protocol for KLF1 IP followed by LC-
MS/MS. These cell lines harbour an oestrogen receptor (ER) fused to KLF1. They were 
derived from K1 cells that were immortalized from Klf1-knockout mouse foetal liver 
erythroid cells. K1 cells do not contain KLF1 protein and thus served as a useful control for 
non-specific interactions.43 Addition of tamoxifen to K1ER cells releases KLF1 from its 
cytoplasmic chaperones which results in translocation of KLF1 into the nucleus. I chose the 
K1ER system because the ability to control the subcellular location of KLF1 and also having 
an equivalent control cell line that does not contain KLF1. 
I performed IP of native KLF1 from the K1ER and K1 cell lines after treatment with ethanol 
(control) and tamoxifen then processed the samples for LC-MS/MS. Following LC-MS/MS 
analysis, I was able to identify KLF1 and ESR1 peptides in the K1ER samples and not in the K1 
sample suggesting the IP of KLF1 was successful. The quality of the sample processing and 
LC-MS/MS run was monitored by analysing the spectral data obtained. The quality metrics 
showed our sample processing generated a significant number of tryptic digested peptides 
and the spectra analysed across all samples were consistent. 
A total of 1636 proteins was identified from all samples; 904 proteins were higher in the 
ethanol treated K1ER cells, 606 proteins were higher in tamoxifen treated K1ER cells and 
126 had no difference when comparing the K1ER cells between ethanol and tamoxifen 
treatment. The high number of proteins could possibly be due to a high level of background 
proteins but these set might contain real interacting proteins, which can be identified by 
surveying the data against the K1 “background” levels. I identified four proteins as potential 
candidates, NONO, SFPQ, PSPC1 and MATR3. However, I noted that these proteins also have 
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the ability to interact with the ER proportion of the KLF1-ER fusion protein. Further 
experiments repeating the IP of KLF1 coupled with LC-MS/MS from the J2E cell line (with no 
ER fusion) would be the first step to resolve this issue. I also would repeat the experiment in 
primary erythroid cells but the level of KLF1 protein may be limiting. 
Interestingly, these four proteins are typically found together in the nucleus and are 
involved in the formation and retention of paraspeckles in the presence of long non-coding 
RNA Neat1.250 However, the roles of NONO, SFPQ and PSPC1 go beyond structural 
organization of paraspeckles and have been implicated in other functions such as RNA 
processing (splicing, adenylation, translation and localization), transcriptional regulation 
(repression, activation, elongation and termination) and even double stranded DNA damage 
repair.229-231,233,239-242,251-256 
NONO, SFPQ and PSPC1 belong to a family of proteins known as drosophila 
behaviour/human splicing (DBHS).230 DBHS proteins are characterized by an N-terminal RNA 
recognition motif, NonA/paraspeckle domain and a C-terminal coiled-coil domain and 
nuclear localization signal.230,231,239,252,253,256 Due to the high homology between these 
proteins they may all perform similar functions and have been shown to partially 
compensate each other.233,255 The coiled-coil domain is exclusively involved in association of 
these proteins and allows for different dimerization states (e.g. NONO/SFPQ, NONO/PSPC1, 
or PSPC1/SFPQ).230,252  
A vast body of work suggests NONO and SFPQ may have many of the functions beyond 
regulation of paraspeckle structure and formation.235,242,243,252-254,257 As a heterodimer 
NONO/SFPQ can sequester transcriptional activators away from their target promoters 
resulting in transcriptional repression.230 They can interact with the carboxyl-terminal 
domain of RNA polymerase II, the 5’ mRNA splice site and U5 snRNAs which together drives 
RNA elongation, termination and splicing.236,258 Individually, NONO has been shown to 
upregulate transcription of genes by recruiting RNAPII to promoters.237,238 Conversely, SFPQ 
can bind promoters and is known to interact with HDAC1 and SIN3A which causes 
transcriptional silencing.242,256,259  
KLF1 has been previously shown to interact with SIN3A in repression of target genes.148 In 
addition, it may be possible that these DBHS proteins are involved in the formation and 
maintenance of “transcription factories”.260 If we explore the idea that KLF1 interacts with 
NONO, SFPQ, PSPC1 and MATR3 it raises a few questions: 
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1. How is KLF1 interacting with these proteins? Specifically, is KLF1 recruiting these 
proteins (whether individually or as a complex) to sites of transcription or is KLF1 
being localized to predetermined sub-nuclear compartments in order to activate 
transcription? 
2. Is KLF1 interacting with proteins in on protein complex or individually? What 
domains in KLF1 and the interactions proteins are required for these interactions? 
What are the functional consequences of these interactions? 
 
It is important that future work determines whether the KLF1 interactions with these 
proteins are localized to paraspeckles in a complex consisting of all four proteins and the 
long noncoding RNA Neat1, or to these proteins independently. We can perform Co-IP 
experiments with tagged versions of these proteins and KLF1 followed by WB to determine 
which bind directly and which bind indirectly. Another ambitions experiment could be use 
FRET to determine co-localization by labelling SFPQ, NONO and PSPC1 with different 
fluorescent acceptors and KLF1 with a fluorescent donor. FRET requires close physical 
proximity in order for the donor fluorophore to excite the secondary fluorophores. By 
observing the fluorescent signal we can infer the association of KLF1 with these proteins as a 
complex or individually within living cells. 
While there have been many KLF1-interacting proteins identified in the past, there has not 
been a broad approach in identifying the interactome of KLF1. Profiling the interactome 
would be invaluable and could be used in association with ChIPseq and RNAseq data to build 
a complete picture of transcriptional regulation by KLF1. Ultimately, in order to understand 
why there is specific loss of genomic binding by the H350R mutation, we will need to build a 
comprehensive foundation of the KLF1 interactome. 
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Figure 6.3 Co-localization of PSPC1, SFPQ, NONO and KLF1 could potentially indicate regions of active transcription 
Model of KLF1 interactions with DBHS proteins may cause different transcriptional 
responses. KLF1 may interact with the paraspeckle complex consisting of SFPQ, PSPC1, and 
NONO which would indicate active transcription. Conversely, KLF1 may be involved in 
transcriptional repression by interacting with the proteins individually such as with SFPQ 
which is known to interact with SIN3A.  
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6.2 Future Directions and Concluding Remarks 
In this thesis I created a novel mouse model of NSHA which harboured compound 
heterozygous KLF1 mutations and elucidated the molecular mechanisms underlying the 
disease. I performed next generation sequencing techniques, RNAseq and ChIPseq, to 
elucidate the changes in KLF1 function due to the H350R KLF1 mutation. I found that there 
is specific loss of binding at regulatory regions of genes involved in red cell membrane 
function and membrane bound transporters, and subsequent loss of expression of these 
genes. The loss of binding and gene expression was selective for these gens and not found 
at other KLF1 target sites suggesting there is undetermined mechanism underpinning this 
result.  
I believe the mutation may have perturbed interaction with protein partners, so I performed 
pilot experiments to identify protein partners of KLF1. I used mass spectrometry to identify 
potential protein partners that interact with KLF1. I immuno-precipitated native KLF1 from 
the K1ER cells after tamoxifen induction. I also performed KLF1 immuno-precipitation in J2E 
cells identifying protein partners from whole cell extract as well as stratifying nuclear and 
cytoplasmic interactors. However, due to the lower intrinsic levels of KLF1 this was 
unsuccessful because no KLF1 peptides were detected in the IP. More work is required to 
optimize the KLF1 Co-IPs and to validate the interacting partners. The discovery of the 
putative interaction partners may help us decipher why some sites are more sensitive to the 
reduced binding affinity to DNA we observe in the H350R variant although it is not 
immediately clear how.  
Another direction of study further is the binding kinetics of KLF1 and H350R-KLF1.  It is 
important to delineate whether association or dissociation is contributing to the lowered 
binding affinity of H350R. The linkers provide a critical role in “locking” the protein to DNA 
by undergoing a conformation change known as c-capping. If c-capping is interrupted due to 
the mutation there may be issues in the protein maintaining binding to DNA (increased 
dissociation rate) although this would not affect the initial stages of binding to DNA 
(association rate).  
In collaboration with Myra Hurt, we found increased phosphorylation by TOPK in the H350R 
mutant linker when compared to wildtype. Phosphorylation of the linker peptides in C2H2 
zinc-fingers lowers DNA binding affinity, likely by interrupting the C-capping mechanism. 
Phosphorylation of C2H2 zinc-fingers is typically observed during mitosis, where proteins 
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are evacuated from the DNA to allow faithful segregation of sister chromatids. The aberrant 
phosphorylation of H350R linker by TOPK could affect the binding affinity of KLF1 in many 
different ways. A simple explanation would be an overall loss of binding affinity across all 
KLF1 bound sites; which is partially supported by the lower quantification of reads in our 
ChIPseq data. However, it is unlikely that phosphorylation persists beyond mitosis due to 
the broad upregulation of many phosphatases at the end of mitosis. Thus, determining 
whether phosphorylation persists beyond mitosis or if there is aberrant phosphorylation 
outside of mitosis is critical to understanding if phosphorylation contributes to the specific 
loss of binding observed. If phosphorylation indeed occurs beyond mitosis, this might 
explain why loss of binding is observed only at some sites and not all. A possible explanation 
could be that different KLF1 bound sites have varying strengths of association with KLF1. To 
test this we would first determine the strength of binding by KLF1 to different KLF1 bound 
sequences. If we quantified association rates, dissociation rates and binding affinity we may 
be able to stratify the strength of binding at the different KLF1 sites; as some sites have 
lower binding strength when compared to others (such as those observed in the EMSA 
when bound by H350R). Phosphorylation of KLF1 could mean these “low-affinity” sites lose 
binding by phosphorylated KLF1 and sites with higher association retain some binding albeit 
at lower affinities. 
The linkers were previously been thought to be as inert peptides separating C2H2 zinc 
fingers. That is, they were simple spacers. This idea is being challenged. The extensive 
conservation of the canonical linker peptide (TGEKP) in nearly all C2H2 zinc fingers, including 
KLF1, suggests functional importance. There are hundreds of zinc finger genes encoded in 
the mammalian genome. Most DNA-binding C2H2 zinc-finger proteins contain linkers with 
the sequence S/T-G-x-R/K-P motif, and potentially behave in similar ways to the canonical 
SP/KLF linkers. There are many studies which have shown the importance of the linkers in 
determining structural organization of C2H2 zinc fingers when bound to DNA. The work in 
this thesis also adds to the existing knowledge suggesting their functional roles beyond 
simple spacer peptides. I present the first ChIPseq data of a linker mutant (H350R in KLF1) 
relative to the wildtype counterpart as well as RNAseq of the H350R mutation in a dosage 
dependant context replicating a human disease in mouse. The results demonstrate that 
linker mutations are not simple loss of function mutations. This study of the function of the 
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linkers of KLF1 is an important step in comprehensively understanding the functions of 
linkers in other C2H2 zinc fingers. 
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Chapter 8  Appendix 
8.1 Additional data 
8.1.1 There is reduced binding affinity in vitro due to mutations in the linker residues 
I first performed fluorescent polarization (FP) assays to compare the binding affinity of the 
mutants (H350R, G349R, T348A and E339D) against the wildtype (Figure 4.12). The G349R 
mutation is a clinically relevant mutation identified in a human patient with NSHA100. I used 
the T348A mutation as a control for phosphorylation and to also test whether changing the 
threonine residue to the phosphodead alanine reside would impact binding affinity. The 
E339D mutation had previously been characterized to have a loss of binding to canonical 
KLF1 target sites95,106. 
I used fluorescently labelled probes designed to replicate the Ahsp and E2f2 KLF1 binding 
sequences. I found for all mutants a loss of binding affinity as calculated by the Hill curve for 
a 1 to 1 binding ratio. The dissociation constant (Kd) is the concentration at which half of the 
protein is bound to the DNA probe when the reaction is at equilibrium. The E339D mutation 
had reduced binding affinity as expected in both Ahsp and E2f2 with a Kd of 11.68µM and 
14.31µM, respectively. I saw in the Ahsp probe that the G349R mutation had the weakest 
binding with a Kd of 30.16µM followed by the phosphodead T348A mutant with a Kd of 
18.07µM and our H350R mutation with a Kd of 11.94 µM. This pattern is replicated for the 
E2f2 binding site where I see the G349R Kd is 285 µM, T348A Kd at 14.97 µM and the H350R 
mutant at 12.21 µM. Our data show that the reduction in binding affinity by the H350R 
mutation is quite minimal and perturbations to other residues in the linker may be more 
detrimental to the binding affinity. 
 
Figure 8.1 Linker mutations result in loss of binding affinity at E2f2 and Alas2 binding sites 
There is a general loss of DNA binding affinity across all mutations (Nan, H350R, G349R and 
T348A) when compared to the wildtype for CACCC sites found in Alas2 and E2f2. All data 
was normalized first to the GST only control. Binding curves were fit with the hill equation 
for 1 binding site and dissociation constants (Kd) were calculated at 50% binding.  
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8.2 Primer Sequences 
Primer Sequence Utility 
Hprt_F GCA GTA CAG CCC CAA AAT GG qRT-PRC 
Hprt_R AAC AAA GTC TGG CCT GTA TCC AA  qRT-PRC 
Ahsp_F CTC AGC ACC ATT AGA CTT GAA qRT-PRC 
Ahsp_R TGC TGA TCC AGC AGA ACA TTA AAC TC qRT-PRC 
E2F2_F CCC CAA ACC CCC CAA GTC T qRT-PRC 
E2F2_R ACT CGC TCA GAA GGT AAA TGA ACT qRT-PRC 
E2F4_F GCAGATGCTTTGCTGGAGAT qRT-PRC 
E2F4_R TCTGGTACTTCTTCTGGCCATTGA qRT-PRC 
Hbb-b1_F CTG ACA GAT GCT CTC TTG GG qRT-PRC 
Hbb-b1_R CAC AAC CCC AGA AAC AGA CA qRT-PRC 
Dusp1_F GTGGTGCTGCTGGACGAG qRT-PRC 
Dusp1_R GACTGTTTGCTGCACAGCTC qRT-PRC 
Slc2a1_F GGCATCCTTATTGCCCAGGTGTTT qRT-PRC 
Slc2a1_R ATACACTGTAGCAGGGCTGGGAT qRT-PRC 
Slc2a4_F GGTCAATACGGTCTTCACGTTGGT qRT-PRC 
Slc2a4_R ATCAAGATGGCACAGCCACACA qRT-PRC 
Fn3k_F AAGAGCCTTAGCAGTCAGGCAT qRT-PRC 
Fn3k_R TGTTCTGCCGAGTCTTGGACTTCT qRT-PRC 
Rgcc_F AGGGACAGCTTCACCTTCAGTGAT qRT-PRC 
Rgcc_R TCGGCAATGAAGTCTTCGAGCTCT qRT-PRC 
Slc1a5_F TCCTGGTCTCCTGGATTATGTGGT qRT-PRC 
Slc1a5_R GCGGACGTCTTTCATCTCCACAAT qRT-PRC 
Slc43a1_F GGATTTGCTGGCATCTGCTTAACG qRT-PRC 
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Slc43a1_R GAGCCAATCATGAGGGCCATGAAA qRT-PRC 
Tspo2_F TGCTTGTGTGGGTGACCATCTACT qRT-PRC 
Tspo2_R TGCCAGGAAGAGCACCAAGAAAGT qRT-PRC 
Gata1_F CTCTCATCCGGCCCAAGAA qRT-PRC 
Gata1_R TTGTAGTGGTCGTTTGACAGTTAGTG qRT-PRC 
Gata2_F AACCGGCCGCTCATCA qRT-PRC 
Gata2_R TCGTCTGACAATTTGCACAACA qRT-PRC 
Fli1_F CTGTTGTCGCACCTCAGTTACC qRT-PRC 
Fli1_R GTCTGTATGGGAGGTTGTGTTATAGG qRT-PRC 
   
Dusp1_5p_F TGGTAATAATGCCCAGCACA ChIP qPCR 
Dusp1_5p_R ATTCCAGAGACCAACGCATC ChIP qPCR 
Dusp1_Cacc_F CCCTCACTGCCACTATGTGA ChIP qPCR 
Dusp1_Cacc_R TTGACAAATGAATGCCGAAA ChIP qPCR 
Dusp1_3p_F GCCAGGAAAAACAGATGAGAA ChIP qPCR 
Dusp1_3p_R GAGCCCCACTCAGCTACATC ChIP qPCR 
Ahsp_5p_F AAT TTA CCC AGG AAA CTT ACA TGA AAC ChIP qPCR 
Ahsp_5p_R CAG AGA AAC AAT TGA CTT TAC CAA GAT C ChIP qPCR 
Ahsp_Cacc_F CCT CAC CGC CCA CCT TCT ChIP qPCR 
Ahsp_Cacc_R CCT GCC TTG TGG TCC TGA A ChIP qPCR 
Ahsp_3p_F GAT AAT GCC AGA ATA AGA TGT ATG TTC AT ChIP qPCR 
Ahsp_3p_R CCC ACC CCC CCG AAT T ChIP qPCR 
   
E2F2_5p_F GGTTGTGAGGTGGGTGAAGAATA ChIP qPCR 
E2F2_5p_R AACACCTCCCCGCTCATCT ChIP qPCR 
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E2F2_cacc_F TGGGCAGGAGGGAGAGTG ChIP qPCR 
E2F2_cacc_R AGTGCCACACCCCAGGG ChIP qPCR 
E2F2_3p_F TTGGGTCAAGGCCCCC ChIP qPCR 
E2F2_3p_R CTGGTGGTCCTAGGTGAGCC ChIP qPCR 
   
-globin_F /5FluorT/TAGAGCCACACCCTGGTAAG FP assay 
-globin_R CTTACCAGGGTGTGGCTCTA FP assay 
Alas2_F /5FluorT/TCTCTCCCACGCCCTGGGCTC FP assay 
Alas2_R GAG CCC AGG GCG TGG GAG AGA FP assay 
   
-globin_F TA GAG CCA CAC CCT GGT AAG EMSA 
-globin_R CTT ACC AGG GTG TGG CTC TA EMSA 
Alas2_F TCT CTC CCA CGC CCT GGG CTC EMSA 
Alas2_R GAG CCC AGG GCG TGG GAG AGA EMSA 
E2f2_F TGCTGGCCCCACCCTGATAAG EMSA 
E2f2_R CTTATCAGGGTGGGGCCAGCA EMSA 
   
pGEX_3_primer CCGGGAGCTGCATGTGTCAGAGG Sequencing 
BamFw TCGGGATCCGGGGCCACTGCGATCGC Cloning 
EcoRv GACGAATTCTCAGAGGTGACGCTTCATGTGCAGAG Cloning 
H350RFw CGGAAGCACACTGGACGTCGTCCC Cloning 
H350RRv GGGACGACGTCCAGTGTGCTTCCG Cloning 
G349RFw CGGAAGCACACTAGACATCGTCCC Cloning 
G349RRv GGGACGATGTCTAGTGTGCTTCCG Cloning 
T348AFw CGGAAGCACGCTGGACATCGTCCC Cloning 
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T348ARv GGGACGATGTCCAGCGTGCTTCCG Cloning 
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8.3 Antibodies 
antibody-conjugate concentration dilution clone supplier 
CD71 – PE 0.2mg/ml 1:800 C2 BD Biosciences 
TER119 – PeCy7 0.2mg/ml 1:400 TER119 BD Biosciences 
B220 – Pacific Blue 0.2mg/ml 1:200 RA3-6B2 BD Biosciences 
CD3e – A647 0.5mg/ml 1:200 145-2c11 Biolegend 
Hoechst 33342 10mg/ml 1:1000  molecular probes 
 
Sample Antibodies 
Spleen CD71, TER119, B220, CD3e 
Blood CD71, TER119 
Bonemarrow CD71, TER119, Hoechst33342 
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8.4 Plasmids 
  
Plasmid name Insert description 
pGEX-6p-1-KLF1-WT wildtype Klf1 zinc fingers (261-376) fused to GST 
pGEX-6p-1-KLF1-D45 H350R second linker mutation mutant Klf1 zinc fingers (261-376) fused to GST 
pGEX-6p-1-KLF1-G349R G349R second linker mutation Klf1 zinc fingers (261-376 fused to GST) 
pGEX-6p-1-KLF1-T348A T348A phosphor-dead second linker mutation Klf1 zinc fingers (261-376) fused to GST 
pGEX-6p-1-KLF1-NAN NAN mutation Klf1 zinc fingers (261-376) fused to GST 
pGEX-4T-1 none (GST control) 
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8.5 Mass-spectrometry Gradients 
90 minute gradient 
Percentage of Acetonitrile Time (min) 
3% 1 
3-25% 61 
25-40% 73 
40-95% 74 
95% 89 
3% 90 
 
28 minute gradient 
Percentage of Acetonitrile Time (min) 
3% 1 
7% 10 
30% 11 
50% 13 
95% 15 
95% 23 
3% 28 
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8.6 Buffers and solutions 
A 
100mg/mL Ampicillin 100mg/mL Ampicillin in pure H2O 
 
C 
50mg/mL Chloramphenicol 50mg of Chloramphenicol in 100% Ethanol 
CoIP buffer Final Concentration 
 25mM Tris pH7.5 
 50mM  NaCls 
 0.2% Triton X-100 
CoIP elution buffer Final Concentration 
 100mM Tris pH8.0 
 10mM TCEP 
 40mM 2-chloroacetamid (2-CAA) 
 1%  Sodium Deoxycholate 
2-Chloracetamide/2-CAA (93.51mw) 
 400mM 
3.2 
ChIP Cell lysis buffer Final Concentration 
 10mM Tris pH8.0 
 10mM NaCl 
 0.2% NP-40 (or equivalent eg igepal 
CA630) 
ChIP Nuclear Lysis buffer Final Concentration 
 50mM Tris pH8.0 
 10mM EDTA pH8.0 
 1%  SDS 
ChIP Dilution Buffer Final Concentration 
 20mM Tris pH8.0 
 2mM EDTA pH8.0 
 150mM NaCL 
 1%  Triton X-100 
 0.01% SDS 
ChIP wash buffer ONE Final Concentration 
 20mM Tris pH8.1 
 50mM NaCl 
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 0.1% SDS 
 1%  Triton X-100 
 2mM  DTA pH8.0 
ChIP wash buffer TWO Final Concentration 
 10mM Tris pH8.1 
 250mM LiCl 
 1%  NP-40 ( or equivalent eg igepal 
CA630) 
 1mM EDTA (pH8.0) 
ChIP High Salt Buffer Final Concentration 
 20mM Tris pH8.1 
 500mM NaCl 
 1%  Triton X-100 
 2mM EDTA pH8.0 
 
ChIP dilution buffer NANOCHIP Final Concentration 
 16.7mM Tris pH8.1 
 167mM NaCl 
 1.2mM EDTA pH8.0 
 1.1% Triton X-100 
 0.01% SDS 
ChIP elution buffer NANOCHIP (for column 
elution) 
Final Concentration 
 0.1M NaHCO3 
 1%  SDS 
 5mM DTT 
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E 
EDTA (372.24mw) 
 0.5M 
 pH8.0 
18.612g in 80mL of milliQ H2O 
adjust pH with sodium hydroxide to pH8.0 
top up to 100mL 
 
F 
Primary Fetal Liver Culture Media final concentration 
 IMDM (500mL) 
 15% FCS (Heat inactivated) 
 2mM L-glutamine/glutamax 
 1x Pen/Strep 
 1uM Dex (in methanol) 
 20ng/mL IGF1 
 2U/mL EPO 
 180ng/mL mouse SCF 
Primary Fetal Liver Differentation Media final concentration 
 IMDM (500mL) 
 15% FCS (Heat inactivated) 
 2mM L-glutamine/glutamax 
 1x Pen/Strep 
 200ng/mL Biotin 
 10ng/mL Hypoxanthine 
 10U/mL EPO 
 4x10-4 U/mL Insulin 
 1uM Mifepristone (RU486) 
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G 
Glycine 
 2.5M 
37.5g Glycine in 200mL of milliQ H2O 
 
K 
DMEM Media (K1, K1ER, J2E, GP+E) Final concentration 
 High glucose DMEM (500mL) 
 10%  Fetal Calf Serum (Heat Inactivated) 
 2mM L-Glutamine/Glutamax 
 100x Pen/Strep 
 
L 
LB Broth  5g Tryptone 
 5g NaCl 
 2.5g Yeast Extract 
 500mL milliQ H2O 
LB Agar 2%  LB Broth (~500mL) 
 10g Agar 
Lithium Chloride (42.4mw) 
 4M 
16.96g lithium chloride in 100mL of milliQ H2O 
 
N 
NaCl Sodium Chloride (58.44mw) 
 5M 
29g sodium chloride in 100mL milliQ H2O 
NaOH Sodium Hydroxide (40mw) 
 5M 
20g sodium hydroxide pellets in 100mL milliQ 
H2O 
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P 
10% Paraformaldehyde (PFA) 10g paraformaldehyde in 85ml PBS 
Mix over 70oC heat 
Buffer to pH8 with sodium hydroxide solution 
top up to 100mL with PBS 
mono-Potassium Phosphate 
 0.2M 
27.2g mono-potassium phosphate in 500mL 
milliQ H2O 
di-Potassium Phosphate 
 0.2M 
34.8g di-potassium phosphate in 500mL milliQ 
H2O 
 
R 
RIPA Final Concentration 
 50mM Tris pH7.6 
 150mM NaCl 
 0.5% Sodium Deoxycholate 
 1% Sodium Dodecyl Sulfate (SDS) 
 1% Triton X-100 
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S 
Sodium Dodecyl Sulfate (SDS) 
 20% 
20g SDS in 100mL milliQ water 
Sodium Deoxycholate 
 10% 
10g Sodium Deoxycholate in 100mL milliQ water 
T 
Tris:EDTA buffer 
 pH8.0 
Final Concentration 
 1mM EDTA pH8.0 
 10mM Tris pH8.0 
 
Z 
Zinc Chloride (136.28mw) 
 1M 
13.628g in 100mL milliQ H20 
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8.7 Scripts 
8.7.1 BASH Scripts 
8.7.1.1 Ion Torrent mapping 
 
#!/bin/bash 
 
# qsub -N tooThug -l ncpus=8 -l walltime=168:00:00 -l mem=32GB -j oe 
IonTorrentRNAseq_complete.sh 
 
# map fastq files with tophat2 
# fastq files should be within unique subfolders (sample name) of parent directory 
# modify parent directory to the experiment directory 
 
parent_dir="/home/tshuang/SeqANALYSIS/D45_RNA-seq/1_BIOREP1/" 
 
dirList=`ls $parent_dir/input` 
 
for i in $dirList 
do 
        filename=`ls $parent_dir/input/$i` 
        mkdir -p $parent_dir/output/$i 
 
        tophat2 \ 
        -g 3 \ 
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        --library-type fr-secondstrand \ 
        -o $parent_dir/output/$i \ 
        -p 32 \ 
        -G 
/home/tkgillin/genomes/iGenomes/Mus_musculus/UCSC/mm9/Annotation/Genes/genes.g
tf \ 
        --transcriptome-index /home/tkgillin/genomes/Tophat2-index/mm9 \ 
        
/home/tkgillin/genomes/iGenomes/Mus_musculus/UCSC/mm9/Sequence/Bowtie2Index/ge
nome \ 
        $parent_dir/input/$i/$filename 
done 
 
# Mapping Ion Torrent RNAseq data 
# first map with Tophat2 followed by re-mapping the unmapped portion with TMAP 
# Initial script assumes Tophat2 has been run 
 
# qsub -N tooThug -l ncpus=8 -l walltime=168:00:00 -l mem=32GB -j oe 
IonTorrentRNAseq.sh 
 
# Parent folder that contains sub-folders with Tophat2 output 
parent="$parent_dir/output" 
list_parent=`ls $parent` 
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# Extract fastq from unmapped BAM file 
for i in $list_parent 
do 
        mkdir -p $parent/$i/fastq 
        bedtools bamtofastq -i $parent/$i/unmapped.bam -fq 
$parent/$i/fastq/unmapped.fastq 
done 
 
# TMAP indices (mm9) 
genome="/home/tgmagor/genomes/TMAP_index_mm9/genome.fa" 
 
# program 
for i in $list_parent 
do 
        mkdir -p $parent/$i/TMAP_mapped 
        tmap map4 -f $genome -r $parent/$i/fastq/unmapped.fastq -s 
$parent/$i/TMAP_mapped/mapped.bam -o 1 
done 
 
# Re-header the BAM files in order to combine 
for i in $list_parent 
do 
        # make directory for combined BAM file 
        mkdir -p $parent/$i/combined 
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        samtools view -H $parent/$i/accepted_hits.bam > $parent/$i/combined/new.header 
        samtools view -H $parent/$i/TMAP_mapped/mapped.bam | grep @PG >> 
$parent/$i/combined/new.header 
 
        # create a new header then add to files 
        samtools reheader $parent/$i/combined/new.header 
$parent/$i/TMAP_mapped/mapped.bam > $parent/$i/combined/combined.tmap.bam 
        samtools reheader $parent/$i/combined/new.header $parent/$i/accepted_hits.bam > 
$parent/$i/combined/combined.tophat.bam 
 
        # sort new bams 
        samtools sort $parent/$i/combined/combined.tmap.bam 
$parent/$i/combined/combined.tmap.sorted 
        samtools sort $parent/$i/combined/combined.tophat.bam 
$parent/$i/combined/combined.tophat.sorted 
 
        # merge new bams 
        samtools merge $parent/$i/combined/combined.bam \ 
        $parent/$i/combined/combined.tmap.sorted.bam \ 
        $parent/$i/combined/combined.tophat.sorted.bam 
 
        # sort and index new combined file 
        samtools sort $parent/$i/combined/combined.bam 
$parent/$i/combined/combined.sorted 
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        samtools index $parent/$i/combined/combined.sorted.bam 
 
        # remove intermediate bam files 
        rm -r $parent/$i/combined/combined.bam 
        rm -r $parent/$i/combined/combined.tmap.bam 
        rm -r $parent/$i/combined/combined.tmap.sorted.bam 
        rm -r $parent/$i/combined/combined.tophat.bam 
        rm -r $parent/$i/combined/combined.tophat.sorted.bam 
        rm -r $parent/$i/combined/new.header 
done 
8.7.1.2 Cuff diff 
#!/bin/bash 
 
# cuffdiff 
 
# qsub -N all_cfdf -l ncpus=8 -l walltime=23:59:59 -l mem=32GB -o 
$HOME/SeqAnalysis/D45_RNA-seq/cuffdiff/nullVd45Vwtv2.qlog -j oe nullvD45vWT_cfdf.sh 
 
transcripts="/home/tkgillin/genomes/iGenomes/Mus_musculus/UCSC/mm9/Annotation/G
enes/genes.gtf" 
 
 
Wildtype1="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/1_BIOREP1/output/Klf1_Het/combined/combined.sorted.bam" 
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Wildtype2="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/2_BIOREP2/output/Klf1_Het_2/combined/combined.sorted.bam" 
Wildtype3="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/3_BIOREP3/output/Klf1_Het/combined/combined.sorted.bam" 
 
Compound1="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/1_BIOREP1/output/D45_compound_het/combined/combined.sorted.bam" 
Compound3="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/3_BIOREP3/output/D45_compound_het/combined/combined.sorted.bam" 
Compound2="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/2_BIOREP2/output/D45_compound_het_2/combined/combined.sorted.bam" 
 
null1="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/1_BIOREP1/output/null/combined/combined.sorted.bam" 
null3="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/3_BIOREP3/output/null/combined/combined.sorted.bam" 
null2="/home/tshuang/SeqANALYSIS/D45_RNA-
seq/2_BIOREP2/output/null_2/combined/combined.sorted.bam" 
 
 
 
mkdir /home/tshuang/SeqANALYSIS/D45_RNA-seq/cuffdiff/all_cfdfv2_label 
output="/home/tshuang/SeqANALYSIS/D45_RNA-seq/cuffdiff/all_cfdfv2_label" 
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# program 
 
cuffdiff -p 32 -l DKO,KO,HET -o $output $transcripts 
$Compound1,$Compound2,$Compound3 $null1,$null2,$null3 
$Wildtype1,$Wildtype2,$Wildtype3 
8.7.1.3 Trailblazer script 
 
8.7.1.4 ChIPseq PE mapping 
 
#!/bin/bash 
#PBS -N bowtie2 
#PBS -l walltime=167:59:59 
#PBS -l mem=128GB 
#PBS -l ncpus=8 
#PBS -j oe 
 
fastqfiles=(`ls $sample_directory`) 
fwd_reads=$sample_directory/${fastqfiles[0]} 
rev_reads=$sample_directory/${fastqfiles[1]} 
 
bowtie2 \ 
-p 8 \ 
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-x 
/home/tkgillin/genomes/iGenomes/Mus_musculus/UCSC/mm9/Sequence/Bowtie2Index/ge
nome \ 
-1 $fwd_reads \ 
-2 $rev_reads \ 
-S $output_dir/bowtie_mapped.sam 
 
samtools view -bS $output_dir/bowtie_mapped.sam > $output_dir/bowtie_mapped.bam 
samtools sort $output_dir/bowtie_mapped.bam $output_dir/bowtie_mapped.sorted 
samtools index $output_dir/bowtie_mapped.sorted.bam 
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8.7.1.6 ChIPseq filtering SAMfilter script 
8.7.1.7 ChIPseq removing duplicates 
#PBS -S /bin/bash 
 
 
I="$HOME/T_DRIVE/RawData/Nextseq/steve_ChIP_seq_nextera_all_files/Bowtie_mapping/
output/WT_pool_chip/bowtie_mapped.sorted.bam" 
O="$HOME/T_DRIVE/RawData/Nextseq/steve_ChIP_seq_nextera_all_files/Bowtie_mapping
/output/WT_pool_chip/bowtie_mapped_nodup.sorted.bam" 
M="$HOME/T_DRIVE/RawData/Nextseq/steve_ChIP_seq_nextera_all_files/Bowtie_mappin
g/output/WT_pool_chip/rmDUP.txt" 
 
module load picard/2.2.1 
 
picard MarkDuplicates REMOVE_DUPLICATES=true INPUT=$I OUTPUT=$O 
METRICS_FILE=$M 
8.7.1.8 MACS2 
 
#PBS -S /bin/bash 
#PBS -N nodup_wt_macs2 
#PBS -l ncpus=32 
#PBS -l mem=128GB 
#PBS -l walltime=23:0:0 
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macs2 callpeak -t 
$HOME/T_DRIVE/RawData/Nextseq/steve_ChIP_seq_nextera_all_files/Bowtie_mapping/ou
tput/WT_pool_chip/SAMfiltered.sam -c 
$HOME/T_DRIVE/RawData/Nextseq/steve_ChIP_seq_nextera_all_files/Bowtie_mapping/ou
tput/WT_pool_input/SAMfiltered.sam\ 
 -f SAM -g mm -n WT2_FL_CHIP -B --call-summits\ 
 --outdir 
$HOME/T_DRIVE/RawData/Nextseq/steve_ChIP_seq_nextera_all_files/Bowtie_mapping/ou
tput/WT_pool_chip/2MACS_output/ 
8.7.1.9 Fell runner script 
 
8.7.1.10 Meme 
 
#PBS -S /bin/bash 
#PBS -N dankeconomy 
#PBS -l walltime=48:0:0 
#PBS -l ncpus=32 
#PBS -l mem=168GB 
 
if [ -z "$genomes_dir" ]; then genomes_dir="/lustre/shared/MMRI_CG"; fi 
if [ -z "$genome_build" ]; then genome_build="mm9"; fi 
if [ -z "$genome_species" ]; then genome_species="Mus_musculus"; fi 
if [ -z "$genome_species_code" ]; then genome_species_code="mm"; fi 
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if [ -z "$genome_fasta" ]; then 
genome_fasta="$genomes_dir/iGenomes/$genome_species/UCSC/$genome_build/Sequen
ce/WholeGenomeFasta/genome.fa"; fi 
if [ -z "$genome_chrominfo" ]; then 
genome_chrominfo="$genomes_dir/iGenomes/$genome_species/UCSC/$genome_build/A
nnotation/Genes/ChromInfo.txt"; fi 
if [ -z "$genome_repeats" ]; then genome_repeats="$genomes_dir/Custom-
Genomes/$genome_species/UCSC/$genome_build/Annotation/RepeatMasker/$genome_b
uild.RepeatMasker.gtf"; fi 
if [ -z "$genome_blacklist" ]; then 
genome_blacklist="$genomes_dir/Blacklisted/$genome_species/${genome_build}-
blacklist.bed"; fi 
if [ -z "$genome_whitelist" ]; then 
genome_whitelist="$genomes_dir/Whitelisted/$genome_species/${genome_build}-
whitelist.bed"; fi 
if [ -z "$genome_annot" ]; then genome_annot="$genomes_dir/Custom-
Genomes/$genome_species/UCSC/$genome_build/Annotation/Genes/genes.gtf"; fi 
if [ -z "$tmap_idx" ]; then tmap_idx="TMAP-index/$genome_build/genome.fa"; fi 
if [ -z "$idx_bowtie" ]; then 
idx_bowtie="$genomes_dir/iGenomes/$genome_species/UCSC/$genome_build/Sequence/
BowtieIndex/genome"; fi 
 
# get path of script directory 
script_dir="$(dirname "${BASH_SOURCE[0]}")" 
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# get path of experiment home 
cd $script_dir/.. 
ParFol=`pwd` 
 
#write $ParFol to test.txt 
#echo "$ParFol" >> $ParFol/test.txt 
#echo "$scrip_dir" >> $ParFol/test.txt 
 
meme 
$HOME/T_DRIVE/rawDATA/Nextseq500_files/steve_ChIP_seq_nextera_all_files/Bowtie_ma
pping/output/WT_pool_chip/2MACS_output/NoDUP_MACS2/MEMErunner_nofastadouble
up/NOdoubleNOdup.101nt.fasta\ 
 -o 
$HOME/T_DRIVE/rawDATA/Nextseq500_files/steve_ChIP_seq_nextera_all_files/Bowtie_ma
pping/output/WT_pool_chip/2MACS_output/NoDUP_MACS2/MEMErunner_nofastadouble
up/MEME5-15/\ 
 -dna -mod zoops -nmotifs 5 -minw 5 -maxw 15 -revcomp -maxsize 3000000 -p 32 
 
#echo start time for MEME 
#echo "Start MEME8-10  `date +%H:%M:%S`" 
#meme 
$HOME/T_DRIVE/rawDATA/Nextseq500_files/steve_ChIP_seq_nextera_all_files/Bowtie_ma
pping/output/WT_pool_chip/2MACS_output/NoDUP_MACS2/MEMErunner_nofastadouble
up/NOdoubleNOdup.101nt.fasta\ 
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# -o 
$HOME/T_DRIVE/rawDATA/Nextseq500_files/steve_ChIP_seq_nextera_all_files/Bowtie_ma
pping/output/WT_pool_chip/2MACS_output/NoDUP_MACS2/MEMErunner_nofastadouble
up/MEME8-10/\ 
# -dna -mod zoops -nmotifs 5 -minw 8  -maxw 10 -revcomp -maxsize 3000000 -p 32 
 
8.7.1.11 ChIPseq Wiggle tracks with MACS2 
 
#!/bin/bash 
#PBS -l mem=128GB 
#PBS -l ncpus=16 
#PBS -l walltime=12:0:0 
#PBS -N ProxyHatch 
 
folder="$HOME/T_DRIVE/rawDATA/Nextseq500_files/steve_ChIP_seq_nextera_all_files/Bo
wtie_mapping/output/wiggle_trackz/MACS2_Subtracted_wiggles/bdg_files" 
macs2 bdgcmp -t ${folder}/WT_FL_ChIP_treat_pileup.bdg -c 
${folder}/WT_FL_INPUT_ctrl_lambda.bdg -o ${folder}/WT_FL_subtract.bdg -m subtract -p 
1.0 --outdir $folder 
bedtools slop -i WT_FL_subtract.bdg -g 
/lustre/shared/MMRI_CG/iGenomes/Mus_musculus/UCSC/mm9/Annotation/Genes/Chrom
Info.txt -b 0 | bedClip -verbose=2 stdin 
/lustre/shared/MMRI_CG/iGenomes/Mus_musculus/UCSC/mm9/Annotation/Genes/Chrom
Info.txt WT_FL_subtract.clipped.bdg 
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bedGraphToBigWig WT_FL_subtract.clipped.bdg 
/lustre/shared/MMRI_CG/iGenomes/Mus_musculus/UCSC/mm9/Annotation/Genes/Chrom
Info.txt WT_FL_subtract.clipped.bigwig 
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8.7.2 R Scripts 
8.7.2.1 DESEQ2 analysis 
# Setting up R environment ------------------------------------------------ 
library(DESeq2) 
library(d3heatmap) 
library(ggplot2) 
library(gplots) 
library(RColorBrewer) 
 
setwd("T:/mater_research/RG04. Cancer Genomics Research Group/Stephen 
Huang/PROJECT mommeD45xKlf1KO/RNA-seq/cuffdiff/HTseq_Deseq2") 
 
 
# Import count files ------------------------------------------------------ 
 
#combined data in excel and imported 
### be aware that excel messes up gene names similar to months "e.g mar-1, sep-08 etc" 
# HTseqall.count <- read.csv (file="all.csv") 
 
  #importing individual count files from HTseq 
DKO1 <- read.csv("DKO1.count", sep="\t", header=FALSE) 
DKO2 <- read.csv("DKO2.count", sep="\t", header=FALSE) 
DKO3 <- read.csv("DKO3.count", sep="\t", header=FALSE) 
KO1 <- read.csv("null1.count", sep="\t", header=FALSE) 
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KO2 <- read.csv("null2.count", sep="\t", header=FALSE) 
KO3 <- read.csv("null3.count", sep="\t", header=FALSE) 
Het1 <- read.csv("Het1.count", sep="\t", header=FALSE) 
Het2 <- read.csv("Het2.count", sep="\t", header=FALSE) 
Het3 <- read.csv("Het3.count", sep="\t", header=FALSE) 
 
  #merge into groups by genotype 
Het_merge <- merge(merge(Het1, Het2, by='V1', all=T), Het3, by='V1', all=T) 
DKO_merge <- merge(merge(DKO1, DKO2, by='V1', all=T), DKO3, by='V1', all=T) 
KO_merge <- merge(merge(KO1, KO2, by='V1', all=T), KO3, by='V1', all=T) 
 
#rename columns 
colnames (Het_merge) <- c("gene_id",'Het1', 'Het2', 'Het3') 
colnames (DKO_merge) <- c("gene_id",'DKO1', 'DKO2', 'DKO3') 
colnames (KO_merge) <- c("gene_id",'KO1', 'KO2', 'KO3') 
 
 
  #merge all together and trim gene_id (as this info is now in rownames) 
merge_all <- merge(merge(Het_merge, DKO_merge, by="gene_id", all=TRUE),KO_merge, 
by="gene_id",all=TRUE) 
rownames(merge_all)<- merge_all$gene_id 
merge_all <- merge_all[,c(2,3,4,5,6,7,8,9,10)] 
 
# write (merge_all, file="all.count", sep="\t") 
Chapter 8 - Appendix 
XLVIII 
 
 
 
# Deseq2 analysis --------------------------------------------------------- 
    # import data as dataframe matrix (not recommended) 
    # coldata <- 
DataFrame(condition=factor(c("dko1","dko2","dko3","het1","het2","het3","ko1","ko2","ko3
"))) 
    # ds <- DESeqDataSetFromMatrix(merge_all, coldata, formula(~condition)) 
 
  # creating DF for "sampleTable" in Deseq from HTseq 
  # (sampleTABLE is a dataframe that contains info on each sample) 
  # each column contains info for each individual count file (in rows) 
sample_name = c("1","2","3","4","5","6","7","8","9") 
file_name = 
c("DKO1.count","DKO2.count","DKO3.count","Het1.count","Het2.count","Het3.count","null
1.count","null2.count","null3.count") 
genotype = c("DKO","DKO","DKO","Het","Het","Het","null","null","null") 
 
sampleTable <- DataFrame(sample_name,file_name,genotype) 
  # import data as htseqcount 
dsh <- DESeqDataSetFromHTSeqCount (sampleTable, 
                                   directory="T:/mater_research/RG04. Cancer Genomics Research 
Group/Stephen Huang/PROJECT mommeD45xKlf1KO/RNA-seq/cuffdiff/HTseq_Deseq2/", 
                                   formula(~genotype) 
Chapter 8 - Appendix 
XLIX 
 
                                   ) 
 
  #begin deseq2 analysis and result output 
dsh1 <- DESeq(dsh) 
resds <- results(dsh1) 
resord <- resds[order(resds$padj),] 
resdiff <- resord[!(is.na(resord$padj)),] 
resdiff <- resdiff[resdiff$padj<0.10,] 
# resdiff <- resdiff[abs(resdiff$log2FoldChange)>=1,] 
plotMA(dsh1) 
selected <- rownames(resdiff) 
 
  # make a dataframe of counts 
sig_counts <- counts(dsh1, normalized=T)[rownames(dsh1) %in% selected,] 
colnames(sig_counts) <- 
c("DKO1","DKO2","DKO3","Het1","Het2","Het3","KO1","KO2","KO3") 
  # make a single column of averages of each genotype 
foldavgdko <- rowMeans(sig_counts[,c("DKO1","DKO2","DKO3")]) 
foldavghet <- rowMeans(sig_counts[,c("Het1","Het2","Het3")]) 
foldavgKO <- rowMeans(sig_counts[,c("KO1","KO2","KO3")]) 
  # combine columns into a dataframe 
sig_counts_avg <- DataFrame(foldavghet,foldavgdko,foldavgKO) 
colnames(sig_counts_avg)<- c("Het","DKO","KO") 
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  # making a barplot of 'total' counts per sequencing run 
barplot(colSums(merge_all), names=colnames(merge_all), ylab="Library Size (counts)") 
 
 
# creating heatmap visualizations of data --------------------------------- 
 
  # setting up colour palette for heatmap 
hmcol <- colorRampPalette(brewer.pal(9, "GnBu"))(100) 
  # heatmap 
heatmap.2(sig_counts, 
          na.color="black", col=hmcol, 
          scale="row", 
          Rowv=TRUE, Colv=FALSE, 
          dendrogram="row", 
          trace="none", 
          na.rm=TRUE) 
  # interactive heatmap widget 
d3heatmap(as.matrix(sig_counts_avg), 
                       na.color="black", col=hmcol, 
                       scale="row", 
                       Rowv=TRUE, Colv=FALSE, 
                       dendrogram="row", 
                       trace="none", 
                       na.rm=TRUE) 
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# GO analysis ------------------------------------------------------------- 
  # load libraries for GO analysis 
library(GOstats) 
library(org.Mm.eg.db) 
 
  # GO analysis in function format for Mus Musculus 
GOanalysis <- function(gene_list, total_list){ 
  # convert gene names to Entrez ID 
  test_entrezIDs <- select(org.Mm.eg.db, gene_list, "ENTREZID", "SYMBOL") 
  total_entrezIDs <- select(org.Mm.eg.db, total_list, "ENTREZID", "SYMBOL") 
  # set up analysis 
  GO_analysis <- new("GOHyperGParams", geneIds = test_entrezIDs , 
                     universeGeneIds=total_entrezIDs, annotation="org.Mm.eg.db", 
                     ontology="BP",pvalueCutoff=0.01, conditional=FALSE, testDirection="over") 
  #run analysis 
  GO_results<-hyperGTest(GO_analysis) 
  #visualize by outputting results 
  return(summary(GO_results)) 
} 
 
 
  # make gene lists 
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total_genes <- rownames(merge_all) 
sig_genes <- rownames(sig_counts) 
 
DEGO <- GOanalysis(sig_genes, total_genes) 
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8.7.3 CuffDiff Analysis 
#download and set up packages----- 
  #installing bioclite and cummerbund packages (don't need to run everytime if already 
installed) 
# source ("http://bioconductor.org/biocLite.R") 
# biocLite ("cummeRbund") 
library(RColorBrewer) 
library(cummeRbund) 
library(d3heatmap) 
library(ggplot2) 
library(gplots) 
library(data.table) 
#install.packages("ggplot2", dependencies = TRUE) 
#install.packages('Rcpp', dependencies = TRUE) 
# install.packages("reshape2", dependencies=TRUE) 
# install.packages("stringi", dependencies=TRUE) 
 
#set up environment and cummeRbund qc------ 
setwd("T:/mater_research/RG04. Cancer Genomics Research Group/Stephen 
Huang/PROJECT mommeD45xKlf1KO/RNA-seq/cuffdiff/all_cfdf") 
cuff =readCufflinks() 
 
  # open cuffdiff differential gene expression file as an object gene_diff 
gene_diff <- read.table("gene_exp.diff", header=TRUE) 
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  # sort siginifcant genes into an object gene_sig 
gene_sig <- subset(gene_diff, significant=="yes") 
 
  # pull out gene matrix containing FPKMs and replicate FPKMs for all genes under all 
conditions 
gene.matrix<-fpkmMatrix(genes(cuff)) 
genereplicate.matrix <-repFpkmMatrix(genes(cuff)) 
setDT(genereplicate.matrix, keep.rownames=T) 
  # Principle component analysis (PCA) 
genes.PCA.rep<-PCAplot(genes(cuff),"PC1","PC2", replicates=T) 
 
  #create a list of unique significant genes and list of genes not containing duplicates 
Sig_unique_gene_list<- unique(gene_sig$gene_id) 
gene_sig_nodups<- gene_sig[duplicated(gene_sig$gene_id),] 
 
  #rename columns for gene.matrix and genreplicate.matrix 
colnames(gene.matrix) <- c("d45","KO", "Het") 
colnames(genereplicate.matrix) <- c("gene_id", "d451", "d452", "d453", "KO1", "KO2", 
"KO3", "Het1", "Het2", "Het3") 
 
  #write out csv files for fpkm 
# write.csv (genereplicate.matrix, file="replicate_fpkm.csv") 
# write.csv (gene.matrix, file="fpkm_all_genes_avg.csv") 
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# subsetting lists based of comparators (KOvHet, d45vHet, d45vKO) --------- 
  #q1,q2,q3 based off cuffdiff labels (in this case [Klf1 genotype] q1=d45/KO, q2=KO/KO, 
q3=WT/KO) 
CvN_sig <- subset(gene_sig, sample_2=="q2") 
CvH_sig <- subset(gene_sig, sample_1=="q1" & sample_2=="q3") 
HvN_sig <- subset(gene_sig, sample_1=="q2") 
 
  #give rownames the gene_id names 
rownames(CvN_sig) <- CvN_sig$gene_id 
rownames(HvN_sig) <- HvN_sig$gene_id 
rownames(HvN_sig) <- HvN_sig$gene_id 
 
  #remove unnecessary columns (using dF[,c()] to select desired columns) 
CvN_sig <- CvN_sig[,c(2,4,5,6,8,9,10)] 
CvH_sig <- CvH_sig[,c(2,4,5,6,8,9,10)] 
HvN_sig <- HvN_sig[,c(2,4,5,6,8,9,10)] 
 
#merge CvH and HvN files----- 
#turn dataframe gene_id into "value lists"Large factors" to subset replicate fpkm matrix 
  #making list 
CvH_list <- CvH_sig$gene_id 
HvN_list <- HvN_sig$gene_id 
 
Chapter 8 - Appendix 
LVI 
 
  #subsetting fpkm matrix 
CvH_fpkm <- genereplicate.matrix[genereplicate.matrix$gene_id %in% CvH_list,] 
HvN_fpkm <- genereplicate.matrix[genereplicate.matrix$gene_id %in% HvN_list,] 
 
  #merge files to produce 3 lists d45 only, Het only, Shared 
shared <- intersect (CvH_list, HvN_list) 
Het_only <- setdiff (HvN_list, CvH_list) 
d45_only <- setdiff (CvH_list, HvN_list) 
 
  #NOTE: double check list of genes for 'double ups' in one variable e.g. "Ear6,Ear7" as seen 
in Het_only 
  #subset replicate fpkm dataframe with shared, Het_only and d45_only lists 
Shared_fpkm <- genereplicate.matrix[genereplicate.matrix$gene_id%in%shared,] 
Het_fpkm <- genereplicate.matrix[genereplicate.matrix$gene_id%in%Het_only,] 
d45_fpkm <- genereplicate.matrix[genereplicate.matrix$gene_id%in%d45_only,] 
 
# Data table manipulation for Graph and Analysis -------------------------- 
  #formatting data tables (some weirdness with data.table packge interfering with normal 
data.frame functions i.e c()) 
row.names(Shared_fpkm) <- Shared_fpkm$gene_id 
Shared_fpkm <- as.data.frame(Shared_fpkm) 
 
row.names(Het_fpkm) <- Het_fpkm$gene_id 
Het_fpkm <- as.data.frame(Het_fpkm) 
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row.names(d45_fpkm) <- d45_fpkm$gene_id 
d45_fpkm <- as.data.frame(d45_fpkm) 
 
  #formatting data tables for heatmap 
  #formatting shared genes (Klf1 dependent and D45 sensitive) HetvKO overlapped with 
HetvD45 
heat_shared <- Shared_fpkm[,c(2,3,4,5,6,7,8,9,10)] 
heat_shared_d45 <- rowMeans(heat_shared[,c(1:3)]) 
heat_shared_het <- rowMeans(heat_shared[,c(7:9)]) 
heat_shared_KO <- rowMeans(heat_shared[,c(4:6)]) 
heat_shared_avg <- data.frame(heat_shared_het, heat_shared_d45, heat_shared_KO) 
 
shared_fc <- data.frame(heat_shared_het, heat_shared_d45, heat_shared_KO) 
fc <- heat_shared_het/heat_shared_d45 
log2fc <- log2(fc) 
shared_fc <- data.frame(log2fc) 
setDT(shared_fc, keep.rownames=T) 
colnames(shared_fc)<- c("gene_id", "fold_change") 
 
#formatting HetvKO Het only 
heat_Het <- Het_fpkm[,c(2,3,4,5,6,7,8,9,10)] 
heat_Het_d45 <- rowMeans(heat_Het[,c(1:3)]) 
heat_Het_het <- rowMeans(heat_Het[,c(7:9)]) 
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heat_Het_KO <- rowMeans(heat_Het[,c(4:6)]) 
heat_Het_avg <- data.frame(heat_Het_het, heat_Het_d45, heat_Het_KO) 
colnames(heat_Het)<-c("Het","D45", "KO") 
 
Het_fc<- data.frame(heat_Het_het, heat_Het_d45, heat_Het_KO) 
fch <- heat_Het_het/heat_Het_KO 
log2fch <- log2(fch) 
Het_fc <- data.frame(log2fch) 
setDT(Het_fc, keep.rownames=T) 
colnames(Het_fc)<- c("gene_id", "fold_change") 
 
 
#formatting HetvD45 D45 only 
heat_d45 <- d45_fpkm[,c(2,3,4,5,6,7,8,9,10)] 
heat_d45_d45 <- rowMeans(heat_d45[,c(1:3)]) 
heat_d45_het <- rowMeans(heat_d45[,c(7:9)]) 
heat_d45_KO <- rowMeans(heat_d45[,c(4:6)]) 
heat_d45_avg <- data.frame(heat_d45_het, heat_d45_d45, heat_d45_KO) 
colnames(heat_d45)<-c("Het","D45", "KO") 
 
D45_fc<- data.frame(heat_d45_het, heat_d45_d45, heat_d45_KO) 
fcd <- heat_d45_het/heat_d45_d45 
log2fcd <- log2(fcd) 
D45_fc <- data.frame(log2fcd) 
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setDT(D45_fc, keep.rownames=T) 
colnames(D45_fc)<- c("gene_id", "fold_change") 
 
 
#writing out DEG tables for fellrunner (HPC script to compare chip peaks vs genes and 
nearest tss) 
write.table(shared_fc, "T:/mater_research/RG04. Cancer Genomics Research 
Group/Stephen Huang/Failrunner.txt", sep="\t", quote=F, row.names=F) 
write.table(Het_fc, "T:/mater_research/RG04. Cancer Genomics Research Group/Stephen 
Huang/Hailrunner.txt", sep="\t", quote=F, row.names=F) 
write.table(D45_fc, "T:/mater_research/RG04. Cancer Genomics Research Group/Stephen 
Huang/Dailrunner.txt", sep="\t", quote=F, row.names=F) 
 
 
#making graphical outputs e.g. heatmaps----- 
 
#   #source gplots for heatmap.2 function 
#source(gplots) 
#   #source d3heatmap for an interactive heatmap widget 
# source(d3heatmap) 
#   #source ggplot2 for more plotting options! 
#source (ggplot2) 
#   #source RColorBrewer for more colours! also wesanderson for wes anderson pallete 
#source(RcolorBrewer) 
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#source(wesanderson) 
  #make heatmap 
  #heatmap.2( 
#       dF,                               the dataframe you want to draw as heatmap - numerical values 
#       trace="none""row"or"col",         draws the trace by indicated value row, col or none 
#       scale="row"or"col",               scale the heatmap by row or column 
#       dendrogram="row""col""both""none" variable to direct what dendrogram to draw 
#       Colv/Rowv=T or F                  variable for column or row clustering 
#       cexRow ="0.5"                     size of row labels 
#       cexCol ="0.5"                     size of column labels) 
 
BlueOrGr <- c("#D8B365","#F5F5F5","#5AB4AC","#253494") 
mycol <- colorRampPalette(BlueOrGr) 
RdylBu <- 
c("#4575B4","#74ADD1","#ABD9E9","#E0F3F8","#FFFFBF","#FEE090","#FDAE61","#F46D43"
,"#D73027") 
mycol2 <- colorRampPalette(RdylBu) 
 
heatmap.2(as.matrix(heat_shared), Colv=T, scale="row", trace="none", cexRow="0.5", 
cexCol="1", main="Shared genes", col="mycol2") 
heatmap.2(as.matrix(heat_Het), Colv=T, scale="row", trace="none", cexRow="0.5", 
cexCol="1", main="Het only", col="mycol2") 
heatmap.2(as.matrix(heat_d45), Colv=T, scale="row", trace="none", cexRow="0.5", 
cexCol="1", main="D45 only", col="mycol2") 
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heatmap.2(as.matrix(heat_shared_avg), Colv=F, scale="row", trace="none", cexRow="0.5", 
cexCol="1", main="Shared genes", col="mycol2") 
heatmap.2(as.matrix(heat_Het_avg), Colv=F, scale="row", trace="none", cexRow="0.5", 
cexCol="1", main="Het only", col="mycol2") 
heatmap.2(as.matrix(heat_d45_avg), Colv=F, scale="row", trace="none", cexRow="0.5", 
cexCol="1", main="D45 only", col="mycol2") 
 
 
# grid.newpage() 
# draw.pairwise.venn(area1=1786, area2=228, cross.area=168, category=c("Het only","d45 
only"),lty=rep("blank",2), fill=c("Red","Yellow"), cat.pos=c(0,0),cat.dist=rep(0.025,2)) 
#making heatmap interactive widget---- 
 
  #make interactive heatmap widget using d3heatmap 
d3heatmap (as.matrix(heat_shared), scale="row") 
 
#   #export heatmap as eps file 
# > setEPS() 
# > postscript("heatmap_test.eps") 
# > d3heatmap(as.matrix(Shared_fpkm), scale="row", yaxis_font_size ="7.5pt", 
show_grid=TRUE) 
# > dev.off() 
 
Chapter 8 - Appendix 
LXII 
 
# GO ontology analysis ---------------------------------------------------- 
 
#use d45_only, Het_only and Shared for gene list 
 
  # load mouse annotation and ID library 
# biocLite("org.Mm.eg.db") 
library(org.Mm.eg.db) 
  # load GO scoring package 
# biocLite("GOstats") 
library(GOstats) 
  
  #gene list for all genes 
selected <- rownames(gene.matrix) 
 
 
  #GO analysis in function format for Mus Musculus 
GOanalysis <- function(gene_list, total_list){ 
  # convert gene names to Entrez ID 
  test_entrezIDs <- select(org.Mm.eg.db, gene_list, "ENTREZID", "SYMBOL") 
  total_entrezIDs <- select(org.Mm.eg.db, total_list, "ENTREZID", "SYMBOL") 
  # set up analysis 
  GO_analysis <- new("GOHyperGParams", geneIds = test_entrezIDs , 
                     universeGeneIds=total_entrezIDs, annotation="org.Mm.eg.db", 
                     ontology="BP",pvalueCutoff=0.01, conditional=FALSE, testDirection="over") 
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  #run analysis 
  GO_results<-hyperGTest(GO_analysis) 
  #visualize by outputting results 
  return(summary(GO_results)) 
} 
 
#running GOanalysis function 
shared_GO <- GOanalysis(shared,selected) 
d45_GO <- GOanalysis (d45_only, selected) 
Het_GO <- GOanalysis(Het_only, selected) 
 
 
 
##################### 
#redundant code for "GOanalysis" function 
#   # convert gene names to Entrez ID 
# d45_only_GO <- select(org.Mm.eg.db, d45_only, "ENTREZID", "SYMBOL") 
# Het_only_GO <- select(org.Mm.eg.db, Het_only, "ENTREZID", "SYMBOL") 
# shared_GO <- select(org.Mm.eg.db, shared, "ENTREZID", "SYMBOL") 
#  
#  
# all_genes_GO <- select(org.Mm.eg.db, selected, "ENTREZID", "SYMBOL") 
#  
#   # set up analysis 
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# shared_GO_analysis<- new("GOHyperGParams", geneIds = shared_GO, 
#                            universeGeneIds=all_genes_GO, annotation="org.Mm.eg.db", 
#                           ontology="BP",pvalueCutoff=0.01, conditional=FALSE, testDirection="over") 
# d45_only_GO_analysis<- new("GOHyperGParams", geneIds = d45_only_GO, 
#                          universeGeneIds=all_genes_GO, annotation="org.Mm.eg.db", 
#                          ontology="BP",pvalueCutoff=0.01, conditional=FALSE, testDirection="over") 
# Het_only_GO_analysis<- new("GOHyperGParams", geneIds = Het_only_GO, 
#                            universeGeneIds=all_genes_GO, annotation="org.Mm.eg.db", 
#                            ontology="BP",pvalueCutoff=0.01, conditional=FALSE, 
testDirection="over") 
#   # run analysis 
# shared_GO_results<-hyperGTest(shared_GO_analysis) 
# d45_only_GO_results<-hyperGTest(d45_only_GO_analysis) 
# Het_only_GO_analysis <- hyperGTest(Het_only_GO_analysis) 
#   # visualize 
# Het_GO <- summary(Het_only_GO_analysis) 
# shared_GO <- summary(shared_GO_results) 
# d45_GO <- summary(d45_only_GO_results) 
 
 
#sample code to write csv---- 
# write.csv (file_df, file="file_name.csv")  
#sample code for duplicated and unique functions----- 
# test_gene_fpkm_nodup$gene_id <- row.names(test_gene_fpkm_nodup) 
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# test_merge_unique_id <- test_merge[!duplicated(test_merge$gene_id),] 
# test_merge_unique_id <- test_merge_unique_id[order(test_merge_unique_id$gene_id),] 
# write.csv (test_merge_unique_id, file="victory_fpkm_all_nodup.csv") 
  #sort alphabetically 
#df <- df[order(df$x),] 
  #remove duplicates and create dataframe 
#duplicated duplicated(df) 
#example code to add or rename columns----- 
  #add or rename columns 
#test_merge <- merge (a, sig_gene_nodup_geneid, by="gene_id") 
#colnames(test_merge) <- c('gene_id','d45', 'KO', 'Het', 'test_id') 
#test_merge <- test_merge[order(test_merge$gene_id),] 
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8.7.4 ChIPseq analysis 
# Functions --------------------------------------------------------------- 
 
convertMACSXLStoGRanges <- function(xlsfile){ 
  xlsf <- read.table(xlsfile, header=T) 
  gr <- with(xlsf, GRanges(chr, IRanges(start, end))) 
  values(gr) <- DataFrame(length=xlsf$length,abs_summit = xlsf$abs_summit,pileup = 
xlsf$pileup, pvalue = xlsf$X.log10.pvalue, fold_enrichment = xlsf$fold_enrichment, qvalue = 
xlsf$X.log10.qvalue) 
   
  return(gr) 
} 
write_mm9_FASTAfileFromGenomicRanges <- function(gr, name_of_file){ 
  seq <- getSeq(Mmusculus, gr) 
  fasta <- convertToFasta(seq) 
  writeLines(fasta, con=paste0(name_of_file,".fasta")) 
} 
convertToFasta <- function(DNAstring){ 
  x <- 1:length(DNAstring) 
  y <- paste0(">",1:length(DNAstring),"\n",DNAstring) 
} 
 
# Environment setup ------------------------------------------------------- 
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setwd("T:/mater_research/RG04. Cancer Genomics Research 
Group/Cancer_Genomics_Raw_Data/Nextseq/steve_ChIP_seq_nextera_all_files/Bowtie_m
apping/output/WT_pool_chip/2MACS_output/HPC_incompatible_files/fellrunner_modified
BED_test/") 
 
source("http://bioconductor.org/biocLite.R") 
 
biocLite("IRanges") 
biocLite("GenomicsRanges") 
biocLite("BSgenome") 
biocLite("BSgenome.Mmusculus.UCSC.mm9") 
biocLite("Biostrings") 
biocLite("ShortRead") 
biocLite("pheatmap") 
biocLite("RColorBrewer") 
biocLite("DESeq2") 
biocLite("TxDb.Mmusculus.UCSC.mm9.knownGene") 
 
library(IRanges) 
library(GenomicRanges) 
library(BSgenome) 
library(BSgenome.Mmusculus.UCSC.mm9) 
library(Biostrings) 
library(ShortRead) 
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library(pheatmap) 
library(RColorBrewer) 
library(DESeq2) 
library(TxDb.Mmusculus.UCSC.mm9.knownGene) 
 
# Analysis ---------------------------------------------------------------- 
 
setMethod("nchar", "ANY", base::nchar) # fix for version incompatibilty 
 
wt_unique <- convertMACSXLStoGRanges("./WT2_FL_CHIP_peaks.xls") 
d45_unique <- convertMACSXLStoGRanges("./D45_pool_CHIP_nodup_peaks.xls") 
 
overlap <- d45_unique[d45_unique %over% wt_unique] 
overlap2 <- wt_unique[wt_unique%over%d45_unique] 
d45_only <- d45_unique[!d45_unique %over% wt_unique] 
wt_only <- wt_unique[!wt_unique %over% d45_unique] 
 
 
wt_unique500 <- 
flank(GRanges(seqnames(wt_unique),IRanges((wt_unique$abs_summit),(wt_unique$abs_s
ummit+1))),250, both=TRUE) 
d45_unique500 <- 
flank(GRanges(seqnames(d45_unique),IRanges((d45_unique$abs_summit),(d45_unique$ab
s_summit+1))),250, both=TRUE) 
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overlap500 <- 
flank(GRanges(seqnames(overlap),IRanges((overlap$abs_summit),(overlap$abs_summit+1))
),250, both=TRUE) 
wt_only500 <- 
flank(GRanges(seqnames(wt_only),IRanges((wt_only$abs_summit),(wt_only$abs_summit+1
))),250, both=TRUE) 
d45_only500 <- 
flank(GRanges(seqnames(d45_only),IRanges((d45_only$abs_summit),(d45_only$abs_summ
it+1))),250, both=TRUE) 
 
#trouble shooting for less than 0 values for chrom length. 
#seqlengths(K1ER_common500bp) <- mm9_seqlengths 
#K1_common500bp <- trim(K1_common500bp) 
 
# writing fasta files ----------------------------------------------------- 
 
write_mm9_FASTAfileFromGenomicRanges(overlap, "overlap") 
write_mm9_FASTAfileFromGenomicRanges(d45_only, "d45_only") 
write_mm9_FASTAfileFromGenomicRanges(wt_only, "wt_only") 
 
write_mm9_FASTAfileFromGenomicRanges(wt_unique500, "WT500") 
write_mm9_FASTAfileFromGenomicRanges(d45_unique500, "D45500") 
write_mm9_FASTAfileFromGenomicRanges(overlap500, "overlap500") 
write_mm9_FASTAfileFromGenomicRanges(d45_only500, "d45_only500") 
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write_mm9_FASTAfileFromGenomicRanges(wt_only500, "wt_only500") 
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8.7.5 ATAC seq analysis 
# Functions --------------------------------------------------------------- 
 
convertMACSXLStoGRanges <- function(xlsfile){ 
  xlsf <- read.table(xlsfile, header=T) 
  gr <- with(xlsf, GRanges(chr, IRanges(start, end))) 
  values(gr) <- DataFrame(length=xlsf$length,abs_summit = xlsf$abs_summit,pileup = 
xlsf$pileup, pvalue = xlsf$X.log10.pvalue, fold_enrichment = xlsf$fold_enrichment, qvalue = 
xlsf$X.log10.qvalue) 
   
  return(gr) 
} 
write_mm9_FASTAfileFromGenomicRanges <- function(gr, name_of_file){ 
  seq <- getSeq(Mmusculus, gr) 
  fasta <- convertToFasta(seq) 
  writeLines(fasta, con=paste0(name_of_file,".fasta")) 
} 
convertToFasta <- function(DNAstring){ 
  x <- 1:length(DNAstring) 
  y <- paste0(">",1:length(DNAstring),"\n",DNAstring) 
} 
 
# Environment setup ------------------------------------------------------- 
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setwd("T:/mater_research/RG04. Cancer Genomics Research Group/Stephen 
Huang/PROJECT MEP/ATAC_MACS2") 
 
source("http://bioconductor.org/biocLite.R") 
 
# biocLite("IRanges") 
# biocLite("GenomicsRanges") 
# biocLite("BSgenome") 
# biocLite("BSgenome.Mmusculus.UCSC.mm9") 
# biocLite("Biostrings") 
# biocLite("ShortRead") 
# biocLite("pheatmap") 
# biocLite("RColorBrewer") 
# biocLite("DESeq2") 
# biocLite("TxDb.Mmusculus.UCSC.mm9.knownGene") 
 
library(IRanges) 
library(GenomicRanges) 
library(BSgenome) 
library(BSgenome.Mmusculus.UCSC.mm9) 
library(Biostrings) 
library(ShortRead) 
library(pheatmap) 
library(RColorBrewer) 
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library(DESeq2) 
library(TxDb.Mmusculus.UCSC.mm9.knownGene) 
 
# Analysis ---------------------------------------------------------------- 
 
setMethod("nchar", "ANY", base::nchar) # fix for version incompatibilty 
 
B_ATAC <- convertMACSXLStoGRanges("./B_ATAC/ATACseq_peaks.xls") 
CD4_ATAC <- convertMACSXLStoGRanges("./CD4_ATAC/ATACseq_peaks.xls") 
CD8_ATAC <- convertMACSXLStoGRanges("./CD8_ATAC/ATACseq_peaks.xls") 
CMP_ATAC <- convertMACSXLStoGRanges("./CMP_ATAC/ATACseq_peaks.xls") 
EryA_ATAC <- convertMACSXLStoGRanges("./EryA_ATAC/ATACseq_peaks.xls") 
GMP_ATAC <- convertMACSXLStoGRanges("./GMP_ATAC/ATACseq_peaks.xls") 
Granulocytes_ATAC <- 
convertMACSXLStoGRanges("./Granulocytes_ATAC/ATACseq_peaks.xls") 
LSK_ATAC <- convertMACSXLStoGRanges("./LSK_ATAC/ATACseq_peaks.xls") 
MEP_ATAC <- convertMACSXLStoGRanges("./MEP_ATAC/ATACseq_peaks.xls") 
Monocytes_ATAC <- convertMACSXLStoGRanges("./Monocytes_ATAC/ATACseq_peaks.xls") 
NK_ATAC <- convertMACSXLStoGRanges("./NK_ATAC/ATACseq_peaks.xls") 
 
# overlap in erythroid differentiation lineage 
LSKoCMP <- CMP_ATAC[CMP_ATAC %over% LSK_ATAC] 
LSKoCMPoMEP <- MEP_ATAC[MEP_ATAC %over% LSKoCMP] 
LSKoCMPoMEPoERYA <- EryA_ATAC[ EryA_ATAC %over% LSKoCMPoMEP] 
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#individual overlaps 
CMPoMEP <- MEP_ATAC[MEP_ATAC %over% CMP_ATAC] 
MEPoERYA <- EryA_ATAC[EryA_ATAC %over% MEP_ATAC] 
 
# unique in erythroid differentiation lineage 
LSKuCMP <- CMP_ATAC[!CMP_ATAC %over% LSK_ATAC] 
LSKuCMPuMEP <- MEP_ATAC[!MEP_ATAC %over% LSKuCMP] 
LSKuCMPuMEPuERYA <- EryA_ATAC[!EryA_ATAC %over% LSKuCMPuMEP] 
 
#individual overlaps 
CMPuMEP <- MEP_ATAC[!MEP_ATAC %over% CMP_ATAC] 
MEPuERYA <- EryA_ATAC[!EryA_ATAC %over% MEP_ATAC] 
 
#making Granges elements 
#EryFROMLSK500 <- 
flank(GRanges(seqnames(LSKoCMPoMEPoERYA),IRanges((LSKoCMPoMEPoERYA$abs_summ
it),(LSKoCMPoMEPoERYA$abs_summit+1))),250, both=TRUE) 
 
EryFROMLSK100 <- 
flank(GRanges(seqnames(LSKoCMPoMEPoERYA),IRanges((LSKoCMPoMEPoERYA$abs_summ
it),(LSKoCMPoMEPoERYA$abs_summit+1))),50, both=TRUE) 
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LSKoCMP100  <- 
flank(GRanges(seqnames(LSKoCMP),IRanges((LSKoCMP$abs_summit),(LSKoCMP$abs_sum
mit+1))),50, both=TRUE) 
CMPoMEP100 <- 
flank(GRanges(seqnames(CMPoMEP),IRanges((CMPoMEP$abs_summit),(CMPoMEP$abs_su
mmit+1))),50, both=TRUE) 
MEPoERYA100 <- 
flank(GRanges(seqnames(MEPoERYA),IRanges((MEPoERYA$abs_summit),(MEPoERYA$abs_s
ummit+1))),50, both=TRUE) 
 
EryFROMLSKu100 <- 
flank(GRanges(seqnames(LSKuCMPuMEPuERYA),IRanges((LSKuCMPuMEPuERYA$abs_summ
it),(LSKuCMPuMEPuERYA$abs_summit+1))),50, both=TRUE) 
LSKuCMP100 <- 
flank(GRanges(seqnames(LSKuCMP),IRanges((LSKuCMP$abs_summit),(LSKuCMP$abs_summ
it+1))),50, both=TRUE) 
MEPuERYA100 <- 
flank(GRanges(seqnames(MEPuERYA),IRanges((MEPuERYA$abs_summit),(MEPuERYA$abs_s
ummit+1))),50, both=TRUE) 
CMPuMEP100  <- 
flank(GRanges(seqnames(CMPuMEP),IRanges((CMPuMEP$abs_summit),(CMPuMEP$abs_su
mmit+1))),50, both=TRUE) 
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# wt_unique500 <- 
flank(GRanges(seqnames(wt_unique),IRanges((wt_unique$abs_summit),(wt_unique$abs_s
ummit+1))),250, both=TRUE) 
# d45_unique500 <- 
flank(GRanges(seqnames(d45_unique),IRanges((d45_unique$abs_summit),(d45_unique$ab
s_summit+1))),250, both=TRUE) 
# overlap500 <- 
flank(GRanges(seqnames(overlap),IRanges((overlap$abs_summit),(overlap$abs_summit+1))
),250, both=TRUE) 
# wt_only500 <- 
flank(GRanges(seqnames(wt_only),IRanges((wt_only$abs_summit),(wt_only$abs_summit+1
))),250, both=TRUE) 
# d45_only500 <- 
flank(GRanges(seqnames(d45_only),IRanges((d45_only$abs_summit),(d45_only$abs_summ
it+1))),250, both=TRUE) 
 
#trouble shooting for less than 0 values for chrom length. 
#seqlengths(K1ER_common500bp) <- mm9_seqlengths 
#K1_common500bp <- trim(K1_common500bp) 
 
# writing fasta files ----------------------------------------------------- 
 
#write_mm9_FASTAfileFromGenomicRanges(EryFROMLSK500, "ALLopen500") 
write_mm9_FASTAfileFromGenomicRanges(EryFROMLSK100, "ALLopen100") 
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write_mm9_FASTAfileFromGenomicRanges(EryFROMLSKu100, "UNIQUEopen100") 
write_mm9_FASTAfileFromGenomicRanges(LSKuCMP100, "LSKvCMP100") 
write_mm9_FASTAfileFromGenomicRanges(CMPuMEP100, "CMPuMEP100") 
write_mm9_FASTAfileFromGenomicRanges(CMPoMEP100, "CMPoMEP100") 
write_mm9_FASTAfileFromGenomicRanges(LSKoCMP100, "LSKoCMP100") 
# write_mm9_FASTAfileFromGenomicRanges(overlap, "overlap") 
# write_mm9_FASTAfileFromGenomicRanges(d45_only, "d45_only") 
# write_mm9_FASTAfileFromGenomicRanges(wt_only, "wt_only") 
#  
# write_mm9_FASTAfileFromGenomicRanges(wt_unique500, "WT500") 
# write_mm9_FASTAfileFromGenomicRanges(d45_unique500, "D45500") 
# write_mm9_FASTAfileFromGenomicRanges(overlap500, "overlap500") 
# write_mm9_FASTAfileFromGenomicRanges(d45_only500, "d45_only500") 
# write_mm9_FASTAfileFromGenomicRanges(wt_only500, "wt_only500")
 
 
 
